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Abstract
SRC homology 2 domain-containing phosphatase 2 (SHP2) is a ubiquitously expressed cytosolic protein
tyrosine phosphatase. Downstream of epidermal growth factor receptor (EGFR) and other receptors,
SHP2 is activated by binding to phosphotyrosine-containing receptors and adapter proteins, is required
for complete extracellular regulated kinase 1/2 (ERK) pathway activity, which promotes cellular
proliferation and survival, and regulates other signaling processes. In this thesis, we explored the
signaling functions of SHP2 in lung and brain cancer cell systems with or without clinically relevant
mutations that render EGFR constitutively active and developed computational models of EGFR-mediated
SHP2 activation. In non-small cell lung cancer cells, SHP2 promoted ERK-dependent resistance to EGFR
inhibition, but in cells with EGFR kinase-activating mutations this SHP2 functional role was impaired
through sequestration of biochemically active SHP2 with internalization-impaired EGFR mutants. In
glioblastoma multiforme cells, SHP2 simultaneously promoted ERK activity and antagonized STAT3
phosphorylation such that SHP2 drove proliferation while also promoting sensitivity to EGFR and c-MET
co-inhibition. These SHP2 functions were perturbed by sufficiently high expression of the EGFR variant III
mutant. Furthermore, SHP2 was found to regulate EGFRvIII and c-MET phosphorylation and control
hypoxia-inducible factor expression in a way that may regulate tumorigenesis. We next developed
computational models and associated quantitative experimental data sets to gain quantitative
understanding of the regulation of protein complexes containing SHP2 and GRB2-associated binder 1
(GAB1), the primary phosphorylated adapter with which SHP2 associates following EGFR activation. Our
analysis revealed that in some cell settings EGFR activity is amplified by intermediary SRC family kinases
(SFKs) which drive GAB1 phosphorylation and enable GAB1-SHP2 complexes to persist in the cytosol
distal from EGFR. A reaction-diffusion model further predicted that EGFR-initiated GAB1-SHP2 complexes
persist over the entire cell length scale, which could permit membrane-localized EGFR to regulate
signaling events through SHP2 at subcellular locations where EGFR itself is not present. Overall, these
results motivate the continued search for specific SHP2 inhibitors, while providing a contextual basis for
predicting when such interventions may be particularly effective, and establish a quantitative framework
for understanding EGFR's ability to activate SHP2 and how this might be perturbed in different
pathological contexts.
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ABSTRACT

THE PROTEIN TYROSINE PHOSPHATASE SHP2 AS A MEDIATOR OF
DIFFERENTIAL CELLULAR SENSITIVITY TO EGFR KINASE INHIBITORS

Christopher Mark Furcht
Matthew J. Lazzara

SRC homology 2 domain-containing phosphatase 2 (SHP2) is a ubiquitously
expressed cytosolic protein tyrosine phosphatase. Downstream of epidermal growth
factor receptor (EGFR) and other receptors, SHP2 is activated by binding to
phosphotyrosine-containing receptors and adapter proteins, is required for complete
extracellular regulated kinase 1/2 (ERK) pathway activity, which promotes cellular
proliferation and survival, and regulates other signaling processes. In this thesis, we
explored the signaling functions of SHP2 in lung and brain cancer cell systems with or
without clinically relevant mutations that render EGFR constitutively active and
developed computational models of EGFR-mediated SHP2 activation. In non-small cell
lung cancer cells, SHP2 promoted ERK-dependent resistance to EGFR inhibition, but in
cells with EGFR kinase-activating mutations this SHP2 functional role was impaired
through sequestration of biochemically active SHP2 with internalization-impaired EGFR
mutants. In glioblastoma multiforme cells, SHP2 simultaneously promoted ERK activity
and antagonized STAT3 phosphorylation such that SHP2 drove proliferation while also
promoting sensitivity to EGFR and c-MET co-inhibition. These SHP2 functions were
iv

perturbed by sufficiently high expression of the EGFR variant III mutant. Furthermore,
SHP2 was found to regulate EGFRvIII and c-MET phosphorylation and control hypoxiainducible factor expression in a way that may regulate tumorigenesis. We next developed
computational models and associated quantitative experimental data sets to gain
quantitative understanding of the regulation of protein complexes containing SHP2 and
GRB2-associated binder 1 (GAB1), the primary phosphorylated adapter with which
SHP2 associates following EGFR activation. Our analysis revealed that in some cell
settings EGFR activity is amplified by intermediary SRC family kinases (SFKs) which
drive GAB1 phosphorylation and enable GAB1-SHP2 complexes to persist in the cytosol
distal from EGFR. A reaction-diffusion model further predicted that EGFR-initiated
GAB1-SHP2 complexes persist over the entire cell length scale, which could permit
membrane-localized EGFR to regulate signaling events through SHP2 at subcellular
locations where EGFR itself is not present. Overall, these results motivate the continued
search for specific SHP2 inhibitors, while providing a contextual basis for predicting
when such interventions may be particularly effective, and establish a quantitative
framework for understanding EGFR’s ability to activate SHP2 and how this might be
perturbed in different pathological contexts.

v

TABLE OF CONTENTS

ACKNOWLEDGEMENT .............................................................................................. III
ABSTRACT ..................................................................................................................... IV
TABLE OF CONTENTS ............................................................................................... VI
LIST OF TABLES ............................................................................................................X
LIST OF FIGURES ........................................................................................................ XI
CHAPTER 1: INTRODUCTION .....................................................................................1
1-1 RECEPTOR TYROSINE KINASE-MEDIATED CELL SIGNALING...................... 1
1-2 EPIDERMAL GROWTH FACTOR RECEPTOR AND CANCER ............................ 2
1-3 SHP2 ACTIVATION AND FUNCTION .................................................................... 5
1-4 GAB1-SHP2 ASSOCIATION DYNAMICS AND LOCALIZATION ....................... 7
1-5 IMPLICATIONS OF SHP2 IN CANCER AND DISEASE ...................................... 10
1-6 THESIS SUMMARY ................................................................................................. 11

CHAPTER 2: DIMINISHED FUNCTIONAL ROLE AND ALTERED
LOCALIZATION OF SHP2 IN NON-SMALL CELL LUNG CANCER CELLS
WITH EGFR-ACTIVATING MUTATIONS ...............................................................15
2-1 ABSTRACT ............................................................................................................... 15
2-2 INTRODUCTION ...................................................................................................... 17
2-3 MATERIALS AND METHODS ............................................................................... 20
Cell culture........................................................................................................... 20
Cell proliferation assay ........................................................................................ 20
shRNA and expression constructs ....................................................................... 20
Immunoblotting ................................................................................................... 21
Immunoprecipitation............................................................................................ 21
SHP2 activity assay ............................................................................................. 22
Immunofluorescence ............................................................................................ 22
Subcellular fractionation ...................................................................................... 23
Quantitative polymerase chain reaction (qPCR).................................................. 23
Antibodies and other reagents.............................................................................. 24
Statistics ............................................................................................................... 24
IC50 calculations ................................................................................................. 24
2-4 RESULTS ................................................................................................................... 25
Effects of SHP2 knockdown on ERK phosphorylation ....................................... 25
Effects of SHP2 knockdown on cellular response to gefitinib ............................ 27
SHP2 association with GAB1 and EGFR and subcellular compartmentalization31
Intracellular distribution of SHP2 ........................................................................ 33
Role of GAB1 in SHP2 localization and EGF-mediated effects ......................... 35
SHP2 activity ....................................................................................................... 37
Effects of SHP2 mutation .................................................................................... 39

vi

Importance of SHP2-mediated effects downstream of MET ............................... 41
2-5 DISCUSSION............................................................................................................. 42
2-6 ACKNOWLEDGEMENTS ...................................................................................... 48
2-7 SUPPLEMENTAL MATERIAL ............................................................................... 49

CHAPTER 3: MULTIVARIATE SIGNALING REGULATION BY SHP2
DIFFERENTIALLY CONTROLS PROLIFERATION AND THERAPEUTIC
RESPONSE IN GLIOMA CELLS .................................................................................63
3-1 ABSTRACT ............................................................................................................... 63
3-2 INTRODUCTION ...................................................................................................... 64
3-3 MATERIALS AND METHODS ............................................................................... 67
Cell culture........................................................................................................... 67
shRNA and stable expression constructs ............................................................. 67
Transient expression of wild-type or substrate-trapping SHP2 ........................... 68
Inhibitors .............................................................................................................. 68
Cell death quantification ...................................................................................... 69
Proliferation measurements ................................................................................. 69
XTT viability assay .............................................................................................. 69
Tumor xenografts................................................................................................. 69
Subcellular fractionation ...................................................................................... 70
EGF internalization assay .................................................................................... 71
Western blotting................................................................................................... 71
Immunofluorescence............................................................................................ 71
Immunoprecipitation............................................................................................ 72
Antibodies ............................................................................................................ 72
Statistics ............................................................................................................... 73
3-4 RESULTS ................................................................................................................... 74
SHP2 depletion differentially impacts key GBM cell phenotypes and
associated signaling pathways ............................................................................. 74
ERK and STAT3 pathways control cellular proliferation and survival in GBM
cells ...................................................................................................................... 77
SHP2’s ability to regulate signaling and phenotypes is modulated by elevated
EGFRvIII expression ........................................................................................... 80
SHP2 can be sequestered with EGFRvIII at high receptor expression levels...... 84
SHP2 negatively regulates EGFRvIII and c-MET phosphorylation .................... 87
SHP2 knockdown impedes tumor xenograft growth and expression of
hypoxia-inducible factors .................................................................................... 90
3-5 DISCUSSION............................................................................................................. 93
3-6 ACKNOWLEDGEMENTS...................................................................................... 100
3-7 SUPPLEMENTAL MATERIAL ............................................................................. 101

CHAPTER 4: EGFR-ACTIVATED KINASES COUNTERACT GAB1
DEPHOSPHORYLATION TO MAINTAIN GAB1-SHP2 COMPLEXES DISTAL
FROM EGFR .................................................................................................................108
4-1 ABSTRACT ............................................................................................................. 108
4-2 INTRODUCTION .................................................................................................... 109
4-3 MATERIALS AND METHODS ............................................................................. 112
Cell culture......................................................................................................... 112
Immunoblotting ................................................................................................. 112
Immunoprecipitation.......................................................................................... 112

vii

Stable shRNA and expression constructs .......................................................... 112
Transient expression constructs ......................................................................... 113
Antibodies and other reagents............................................................................ 113
Subcellular fractionation .................................................................................... 114
Statistics ............................................................................................................. 114
General model considerations and topology ...................................................... 114
EGF binding and concentration ......................................................................... 115
ATP and inhibitor binding ................................................................................. 115
EGFR dimerization ............................................................................................ 115
EGFR phosphorylation ...................................................................................... 115
GAB1 phosphorylation ...................................................................................... 115
PTP activity ....................................................................................................... 116
EGFR degradation ............................................................................................. 116
GRB2, GAB1, and SHP2 binding...................................................................... 116
SFK activation ................................................................................................... 116
Parameter fitting ................................................................................................ 117
Sensitivity analysis ............................................................................................ 117
Representative H1666 cell ................................................................................. 117
Model implementation ....................................................................................... 118
Process timescale calculations ........................................................................... 118
4-4 RESULTS ................................................................................................................. 119
In response to EGF, SHP2 remains in complex with GAB1 longer than with
EGFR, and GAB1-SHP2 maintenance requires kinase activity to counteract
multiple rounds of GAB1 dephosphorylation .................................................... 119
Src family kinases are required for EGFR-initiated GAB1
phosphorylation and maintenance of GAB1-SHP2 association ........................ 122
GAB1-SHP2 complexes exist mainly in the cytosol ......................................... 124
EGF and HGF promote different dynamics of GAB1-SHP2 complex
persistence.......................................................................................................... 126
A computational model reveals that SFKs amplify EGFR activity to maintain
GAB1-SHP2 complexes distal from EGFR ....................................................... 128
Robustness and sensitivity analyses confirm the need for an SFK-mediated
amplification mechanism and reveal key process controlling system
behavior ............................................................................................................. 133
4-5 DISCUSSION........................................................................................................... 138
4-6 ACKNOWLEDGEMENTS...................................................................................... 143
4-7 SUPPLEMENTAL MATERIAL ............................................................................. 144

CHAPTER 5: A REACTION-DIFFUSION MODEL PREDICTS THE
INTRACELLULAR LENGTH SCALE OVER WHICH EGFR-INITIATED GAB1SHP2 COMPLEXES PERSIST ....................................................................................153
5-1 ABSTRACT ............................................................................................................. 153
5-2 INTRODUCTION .................................................................................................... 155
5-3 MATERIALS AND METHODS ............................................................................. 159
General model considerations and topology ...................................................... 159
Boundary conditions .......................................................................................... 161
Example equations ............................................................................................. 161
EGFR phosphorylation ...................................................................................... 162
GAB1 phosphorylation ...................................................................................... 163
SFK activation ................................................................................................... 163

viii

GRB2, GAB1, and SHP2 binding...................................................................... 163
Phosphatase activity........................................................................................... 163
EGFR inhibition................................................................................................. 163
Protein diffusivity .............................................................................................. 163
Parameter fitting ................................................................................................ 164
Sensitivity analysis ............................................................................................ 164
Representative cell ............................................................................................. 164
Model implementation ....................................................................................... 164
5-4 RESULTS ................................................................................................................. 167
Model predictions with baseline parameterization ............................................ 167
Model parameter sensitivity............................................................................... 169
EGFR pulse-chase dynamics ............................................................................. 173
Model extensions ............................................................................................... 175
5-5 DISCUSSION........................................................................................................... 178
5-6 ACKNOWLEDGEMENTS...................................................................................... 183
5-7 SUPPLEMENTAL MODEL DEVELOPMENT ..................................................... 184
Reaction-diffusion equations and initial and boundary conditions .................... 184
Discretization scheme using finite difference methods ..................................... 189

CHAPTER 6: IMPLICATIONS AND FUTURE WORK .........................................193
6-1 SUMMARY ............................................................................................................. 193
6-2 DEVELOPMENT AND APPLICATION OF SHP2 INHIBITORS ........................ 194
6-3 INVOLVEMENT OF SHP2 IN
EPITHELIAL-TO-MESENCHYMAL TRANSITION .................................................. 197
6-4 INDUCIBLE KNOCKDOWN OF SHP2 IN GLIOBLASTOMA
XENOGRAFTS .............................................................................................................. 199
6-5 ROLE OF SHP2 PHOSPHORYLATION ................................................................ 200
6-6 LOCALIZATION OF SHP2 COMPLEXES IN MUTANT EGFR-EXPRESSING
CELLS ............................................................................................................................ 201
6-7 CYTOSOLIC DISTRIBUTION OF GAB1-SHP2 COMPLEXES .......................... 204

BIBLIOGRAPHY ..........................................................................................................207

ix

LIST OF TABLES
Table S4-1: Model parameters .........................................................................................152
Table 5-1: Model parameters ...........................................................................................166

x

LIST OF FIGURES
Figure 1-1: Activation of SHP2 ...........................................................................................6
Figure 1-2: Function of SHP2 downstream of EGFR ..........................................................7
Figure 1-3: Example for the importance of SHP2 activity distal from EGFR.....................9
Figure 2-1: SHP2 knockdown reduces ERK phosphorylation more in NSCLC cells
expressing wild-type EGFR than in those expressing EGFR mutants ..............................26
Figure 2-2: Knockdown of SHP2 enhances cellular sensitivity to gefitinib in subsets of
NSCLC cells ......................................................................................................................28
Figure 2-3: Observed effects of SHP2 knockdown on ERK phosphorylation and gefitinib
response are specific to SHP2 ............................................................................................30
Figure 2-4: GAB1 and EGFR are basally associated with SHP2 in NSCLC cells
expressing EGFR mutants and are induced to associate with SHP2 by EGF in NSCLC
cells expressing wild-type EGFR.......................................................................................32
Figure 2-5: Intracellular redistribution of SHP2 in response to EGF is observed in H1666
cells, but not in H3255 cells ...............................................................................................34
Figure 2-6: GAB1 knockdown alters EGF-mediated ERK phosphorylation and response
to gefitinib in H1666 cells..................................................................................................36
Figure 2-7: SHP2 is active in H1666 and H3255 cells, and EGF increases SHP2 activity
in H1666 cells ....................................................................................................................38
Figure 2-8: Ectopic expression of SHP2 mutants alters cellular response to gefitinib in
H1666 and H3255 cells ......................................................................................................40
Figure 2-9: Sequestration of SHP2 at the plasma membrane may enhance gefitinib
response in cells expressing EGFR mutants by reducing ERK activity ............................45
Figure S2-10: SHP2 knockdown reduces ERK phosphorylation more in NSCLC cells
expressing wild-type, versus mutant, EGFR......................................................................49
Figure S2-11: EGF-mediated phosphorylation of SHP2 at Y542 is impaired in H3255 and
HCC827 cells relative to H1666 cells ................................................................................51
Figure S2-12: SHP2 knockdown more strongly influences the phosphorylation of ERK
than phosphorylation of AKT or STAT3 in NSCLC cells expressing wild-type EGFR ...52

xi

Figure S2-13: H292 cells are significantly growth inhibited by SHP2 knockdown, while
HCC827 cells are not .........................................................................................................54
Figure S2-14: EGF promotes membrane localization of SHP2 in H1666 cells, but not in
H3255 cells ........................................................................................................................55
Figure S2-15: EGF promotes the formation of EGFR-positive endocytic vesicles in
H1666 cells, but not in H3255 cells ...................................................................................56
Figure S2-16: GAB1 does not influence the localization of SHP2 in H1666 or H3255
cells, but does alter EGF-mediated ERK phosphorylation and response to gefitinib in
H1666 cells ........................................................................................................................58
Figure S2-17: SHP2 is not required for HGF-mediated rescue of ERK phosphorylation in
NSCLC cells treated with gefitinib ....................................................................................61
Figure S2-18: SHP2 is basally associated with GAB1 and pEGFR in H1781 cells ..........62
Figure 3-1: SHP2 knockdown differentially impacts GBM cell proliferation and
survival ...............................................................................................................................76
Figure 3-2: ERK and STAT3 pathways both control proliferation and survival of GBM
cells ....................................................................................................................................79
Figure 3-3: Sufficiently high EGFRvIII expression diminishes the ability of SHP2 to
promote ERK activity and to reduce STAT3 phosphorylation in the presence of EGFR
and c-MET inhibitors .........................................................................................................83
Figure 3-4: Sufficiently high EGFRvIII expression suppresses EGF-mediated ERK
phosphorylation by SHP2 sequestration ............................................................................86
Figure 3-5: SHP2 mutant expression reveals negative regulation of EGFRvIII, c-MET,
and STAT3 phosphorylation ..............................................................................................89
Figure 3-6: Gefitinib and PHA665752 co-treatment or SHP2 knockdown impairs U87MG
tumor xenograft growth .....................................................................................................91
Figure 3-7: Summary of SHP2’s oncogenic and anti-survival functions in GBM cells ....94
Figure S3-8: ERK and STAT3 inhibition differentially regulate GBM cell phenotype ..101
Figure S3-9: SHP2’s abilities to promote ERK phosphorylation in resting cells and to
antagonize STAT3 phosphorylation in drug-treated cells are diminished with sufficiently
high EGFRvIII expression ...............................................................................................102

xii

Figure S3-10: With high levels of EGFRvIII expression, SHP2 becomes increasingly
basally associated with EGFRvIII, SHP2 intracellular distribution is perturbed, and EGFmediated ERK induction becomes impaired....................................................................104
Figure S3-11: SHP2 regulatory roles identified by SHP2 knockdown are confirmed by
ectopic expression of SHP2 mutants................................................................................106
Figure 4-1: Timescales of protein dephosphorylation and signaling complex
disassembly ......................................................................................................................120
Figure 4-2: Requirement of SFKs for EGF-initiated GAB1 phosphorylation and GAB1SHP2 binding ...................................................................................................................123
Figure 4-3: Subcellular localization of GAB1-SHP2 complexes ....................................125
Figure 4-4: Sustained association of GAB1 and SHP2 downstream of c-MET ..............127
Figure 4-5: Model topology and validation .....................................................................129
Figure 4-6: Model requirement for SFK-mediated amplification of EGFR and model
sensitivity .........................................................................................................................134
Figure 4-7: Schematic of EGFR-mediated GAB1-SHP2 complex maintenance ............138
Figure S4-8: Differential rates of EGFR-SHP2 and GAB1-SHP2 complex
disassemblies....................................................................................................................144
Figure S4-9: SFK-mediated GAB1 phosphorylation and GAB1-SHP2 binding ............146
Figure S4-10: Sustained HGF-mediated association of GAB1 and SHP2 ......................148
Figure S4-11: Model fitting to experimental data............................................................149
Figure

S4-12:

Effect

of

variations

in

GAB1

phosphorylation

(kG1p)

and

dephosphorylation (kG1dp) rate constants on model error .................................................151
Figure 5-1: Base model predictions and fits ....................................................................168
Figure 5-2: Model sensitivity analysis .............................................................................171
Figure 5-3: EGF-pulse EGFR inhibition-chase predictions ............................................174
Figure 5-4: Model predictions for SFKs only existing at the cell surface .......................176
Figure 5-5: Cytosolic SRC family kinases (SFKs) extend the intracellular GAB1-SHP2
length scale by rephosphorylating GAB1. .......................................................................179

xiii

Chapter 1: Introduction

1-1 RECEPTOR TYROSINE KINASE-MEDIATED CELL SIGNALING
The process of cell signaling enables the coordination of complex cellular
decision-making, both within an individual cell and among several cells, through the
sequential transfer of information between cellular proteins by processes such as protein
modification and protein-protein binding, which ultimately influence cellular outcomes
by altering gene transcription [1]. One key protein modification process involved in
many aspects of cell signaling is phosphorylation, which is the covalent addition of a
phosphate to a serine, threonine, or tyrosine residue on a substrate protein by enzymes
known as kinases [2]. These phosphorylated residues can either alter the intrinsic activity
of a phosphorylated protein, or activate other proteins by serving as binding sites for
proteins containing phosphotyrosine binding (PTB) or Src-homology 2 (SH2) domains
[3]. Both protein phosphorylation and binding are reversible processes, however, as
bound proteins can dissociate from one another and phosphorylated proteins can have a
phosphate removed through the process of dephosphorylation, which is catalyzed by
enzymes known as phosphatases [4, 5].
Some of the major cellular components that initiate phosphorylation-dependent
cell signaling pathways are receptor tyrosine kinases (RTKs), a family of transmembrane
proteins that can translate extracellular cues into intracellular responses such as growth,
differentiation, migration, and apoptosis [6].

RTKs typically function by binding

extracellular ligands, which subsequently promotes the intrinsic kinase activity of these
receptors. These activated RTKs are then able to phosphorylate various tyrosine residues
1

on their cytoplasmic tails, which serve as binding sites for cytosolic adapter proteins that
ultimately promote the activity of numerous downstream signaling pathways such as the
extracellular signal-regulated kinase (ERK), phosphoinositide 3-kinase (PI3K)/AKT, and
signal transducer and activator of transcription (STAT) pathways [6].

This thesis

specifically focuses on the epidermal growth factor receptor (EGFR), which binds ligands
such as epidermal growth factor (EGF). For the case of EGFR, ligand binding promotes
dimerization of two receptors, which activates the kinase activity of each receptor by
relieving kinase domain auto-inhibition and subsequently permits trans-autophosphorylation of EGFR’s C-terminal tyrosine residues [6].

1-2 EPIDERMAL GROWTH FACTOR RECEPTOR AND CANCER
While EGFR plays an important role in normal physiology, because signaling
initiated by EGFR is typically associated with promoting cellular growth and survival,
EGFR-mediated signaling is also frequently dysregulated in cancer as a result of EGFR
overexpression or EGFR mutation [7]. Examples of cancers where EGFR is frequently
overexpressed or mutated include non-small cell lung carcinoma (NSCLC), where 7080% of tumors display elevated EGFR expression and 10-20% of tumors possess EGFRactivating mutations [8, 9], and glioblastoma multiforme (GBM), a common and
aggressive form of brain cancer where EGFR is overexpressed in ~50% of cases and
mutated in 30-40% of cases [10, 11].
As a way of combating EGFR-driven cancers, pharmaceutical companies have
developed several classes of therapeutics targeted against EGFR [7].

One class of

therapeutics is monoclonal antibodies that bind EGFR extracellular epitopes.

2

For

example, cetuximab inhibits EGFR activity by preventing EGFR from binding ligands
[12]. Another class of therapeutics is EGFR tyrosine kinase inhibitors such as gefitinib,
which function as ATP analogues and block the intrinsic kinase activity of EGFR by
competing with ATP for binding [13]. Although these therapeutics have had remarkable
success in certain NSCLC patients, generally response is limited to 10% of patients, who
are typically those with EGFR-activating mutations [9, 14, 15].

Conversely, GBM

patients generally do not respond at all to EGFR-targeted therapeutics except in rare
cases [16, 17]. Furthermore, cancers from patients who initially respond well to these
therapeutics often become resistant to therapy over time [18], which can result from
secondary mutations in EGFR which inhibit the binding of tyrosine kinase inhibitors to
EGFR, such as the T790M point mutation [19, 20], or overexpression of other RTKs
including c-MET, which can compensate for reduced EGFR function [21].
The aforementioned NSCLC-associated EGFR mutants display enhanced kinase
activity relative to wild-type EGFR [22], and are also endocytosis-impaired [23, 24],
suggesting they remain in a hyper-active state at the plasma membrane with the inability
to be efficiently degraded through internalization.

Consistent with these findings,

NSCLC cells harboring EGFR mutations often display elevated phosphorylation of
EGFR itself, as well as AKT, STAT3/5, ERBB3, and c-MET [15, 25, 26]. However, it
was recently shown that these EGFR mutations surprisingly impair the phosphorylation
of ERK, an important regulator of cell proliferation and survival whose activity can
dampen cellular response to EGFR inhibition [24, 27]. These mutations were also shown
to impair the phosphorylation of the protein tyrosine phosphatase SHP2, which is
required for complete ERK activation downstream of EGFR and other RTKs [24, 28].

3

As phosphorylation of SHP2 is suggested to positively regulate its activity, these results
imply that impaired function of SHP2 could potentially enhance sensitivity to EGFRtargeted therapies by rendering cells in a less survival-prone state due to diminished
SHP2-mediated ERK activity [28, 29]. Conversely, the normal function of SHP2 in
promoting ERK activity in wild-type EGFR-expressing cells may be at least partially
responsible for the resistance of these cells to EGFR-targeted therapies.
The most frequent EGFR mutation in GBM is the in-frame deletion of exons 2-7,
which encode a large portion of the extracellular domain, leading to expression of the
EGFR variant III mutant (EGFRvIII) [11, 30-32]. EGFRvIII is found in ~50% of GBM
with EGFR amplification [10, 11], and in other cancers, but not in normal tissues [33,
34], making it an ideal therapeutic target. In patients who have undergone major tumor
resection followed by radiation, EGFRvIII expression is a negative indicator of ≥1 year
survival [35]. The current standard of care for GBM involves tumor resection, followed
by radiotherapy and subsequent temozolomide adjuvant chemotherapy [36-38]. Though
EGFR amplification and EGFRvIII expression are observed in subsets of GBM, current
clinical strategies are the same across GBM tumor sub-types because targeted therapeutic
approaches have not produced substantial benefits.

Since c-MET amplification and

pathway activation promote resistance to therapy, c-MET pathway-targeted therapeutics
are being evaluated in clinical trials in glioma patients [39], but initial results do not
suggest great promise [40].

In contrast, the VEGF-targeted monoclonal antibody,

bevacizumab, was approved in 2009 for use in GBM following primary therapy [41].
In intracranial murine xenograft models, EGFRvIII expression promotes
enhanced tumorigenicity compared to cells expressing wild-type EGFR [42, 43].

4

EGFRvIII does not bind EGF with high affinity [44] but displays low constitutive
phosphorylation compared to wild-type EGFR phosphorylation induced by EGF in
PTEN-deficient U87MG glioblastoma cells [45]. EGFRvIII also potentiates downstream
signaling differently than wild-type EGFR in ways that promote tumor aggressiveness.
Similar to NSCLC-associated EGFR mutants, EGFRvIII expression impairs EGFmediated receptor internalization [45, 46]. In murine xenografts, EGFRvIII expression
dampens response to erlotinib and sustains ERK and AKT activity in the presence of
erlotinib or a monoclonal antibody against hepatocyte growth factor [43], compared to
wild-type EGFR. The STAT3 pathway may be over-activated in GBM cells, including
those expressing EGFRvIII, and STAT3 inhibition can sensitize these cells to EGFR
inhibition [47].

Such signaling perturbations may depend on EGFRvIII expression

levels, as in U87MG cells where sufficiently high EGFRvIII expression drives AKT
activation preferentially over the ERK and STAT3 pathways and results in c-MET
phosphorylation [48]. When GBM cells from EGFRvIII transgenic mice are cultured ex
vivo, EGFRvIII promotes AKT phosphorylation but impairs EGF-mediated ERK
activation compared to wild-type EGFR [49], but the underlying mechanism remains
unknown.

ERK impairment has also been observed in NIH3T3 cells expressing

EGFRvIII versus wild-type EGFR [50, 51], which may be related to the phenomenon of
impaired phosphorylation of ERK and SHP2 observed in the context of NSCLCassociated EGFR mutants.

1-3 SHP2 ACTIVATION AND FUNCTION
The protein tyrosine phosphatase (PTP) SHP2 is an important signaling
intermediate downstream of most RTKs, including EGFR [28]. Receptor activation
5

results in recruitment of SHP2 to receptors, either by direct binding to the receptor or
through adapter proteins, which activates SHP2 through relief of auto-inhibitory
interactions between its N-terminal SH2 domain and its catalytic PTP domain (Figure 1-1
; [28]). A primary route of SHP2 recruitment to EGFR is through binding to GRB2associated binder 1 (GAB1) phosphorylated at Y627 and Y659 [52], an adapter protein
whose association with EGFR is mediated by GRB2 upon EGFR phosphorylation at
either Y1068 and Y1086 [7]. RTK activation also results in phosphorylation of SHP2 at
Y542 and Y580, which is required for full function of SHP2 downstream of some but not
all RTKs [29].

Figure 1-1: Activation of SHP2.
Basally, SHP2 is stabilized in an inactive state through binding of its N-terminal SH2
domain to its catalytic PTP domain.

Upon activation of receptor tyrosine kinases

including EGFR, SHP2 binding partners such as receptors or cytosolic adapter proteins
become tyrosine phosphorylated. These tyrosines serve as binding sites for SHP2’s Nand C-terminal SH2 domains, which when bound relieve basal auto-inhibition of SHP2
and allow access of SHP2’s PTP domain to substrates.

SHP2’s most well-studied functional role downstream of EGFR is to activate
ERK by positively regulating RAS [53], via dephosphorylation of a RAS GTPaseactivating protein (RASGAP) binding site on GAB1 (Figure 1-2 ; [54]) and c-SRC
tyrosine kinase (CSK) binding sites on both paxillin [55] and phosphoprotein associated
with glycolipid-enriched membranes (PAG), also known as CSK-binding protein (CBP)
6

[56]. Additionally, SHP2 is in some cases a regulator of the PI3K/AKT, c-Jun Nterminal kinase (JNK), and STAT signaling pathways [57-59].

Figure 1-2: Function of SHP2 Downstream of EGFR.
Phosphorylation of EGFR at a representative tyrosine (Y) results in recruitment of the
adapter protein GRB2, which binds GAB1. Following GAB1 phosphorylation, SHP2 is
recruited to this EGFR-GRB2-GAB1 complex through interactions between GAB1
phosphotyrosines and SHP2 SH2 domains. Activated SHP2 is then able to promote the
activation of RAS and subsequently ERK by several mechanisms including
dephosphorylating RASGAP binding sites on GAB1.

1-4 GAB1-SHP2 ASSOCIATION DYNAMICS AND LOCALIZATION
As previously noted, SHP2 is stabilized in an active state when it is bound with
adapter proteins such as GAB1 [28]. Because cell phenotype can be determined by both
the duration of a signaling protein’s activity as well as the specific cellular localization of
that protein [60], it is important to appreciate the dynamics and cellular distribution of
7

GAB1-SHP2 complexes to fully understand SHP2-mediated signaling. While GAB1SHP2 complexes can be detected for at least 30 min following activation of growth factor
receptors such as EGFR [55], these complexes are unlikely to remain statically associated
for this period of time due to rate constants which suggest that phosphotyrosine-SH2
domain interactions fall apart on the order of seconds [61, 62]. This apparent discrepancy
is resolved by similarly rapid rates of binding between phosphotyrosines and SH2
domains, which also occur on the order of seconds [61, 62]. Thus, while SHP2 may
generally exist in an active, GAB1-bound state on a time scale of ~1 hr, it rapidly cycles
between GAB1-bound and –unbound states on a time scale of ~1 sec. This notion is
analogous to previous reports that suggest that protein post-translational modifications
such as phosphorylation also frequently cycle between an “on” state (i.e. phosphorylated)
and an “off” state (i.e. dephosphorylated) [63, 64].
While GAB1 and SHP2 are both cytosolic proteins, RTKs including EGFR have
been reported to phosphorylate GAB1 and promote GAB1-SHP2 association [65]. Other
possibilities may exist, however, as it has also been found that cytosolic Src family
kinases (SFK) members can phosphorylate GAB1 [52, 66], although it has not been
determined whether SFKs phosphorylate GAB1 on the specific tyrosines responsible for
binding SHP2. Given that GAB1 and SHP2 rapidly dissociate, cytosolic kinases could
play an important role in maintaining SHP2’s association with GAB1 distal from the
plasma membrane due to the potential for cytosolic GAB1 to be quickly
dephosphorylated. This could be an important mechanism for allowing EGFR to regulate
SHP2 activity at sites distal from EGFR, such as focal adhesions (Figure 1-3; [55]).
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Figure 1-3: Example for the importance of SHP2 activity distal from EGFR.
A study from Ren et al. showed that downstream of EGFR, SHP2 is required to function
at focal adhesions, where SHP2 dephosphorylates a tyrosine residue on the adapter
protein paxillin. This tyrosine serves as a binding site for c-Src kinase (CSK), which
negatively regulates the activity of Src family kinases (SFKs) by phosphorylating them
on an inhibitory tyrosine. As focal adhesions could be far from EGFR if EGFR were
localized to the apical rather than the basolateral membrane, EGFR itself might not be
able to maintain the association of GAB1 and SHP2 over the entire cellular length scale.
Conversely, if EGFR were able to activate intermediary cytosolic kinases such as SFKs,
EGFR could distally maintain SHP2 activity by allowing SFKs to phosphorylate GAB1
within the cytosol. This example also illustrates a potential mechanism by which SHP2
and SFKs can act in a positive feedback loop.

In addition to the possibility for cytosolic kinases to extend the length scale over
which GAB1 and SHP2 remain associated throughout the cytosol, the internalization of
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RTKs may also permit GAB1-SHP2 complex nucleation to occur further from the plasma
membrane. EGFR has recently been shown to remain phosphorylated and associated
with GRB2 in endosomes following EGF stimulation [67], suggesting that RTKs can
remain active and signaling-competent inside the cell. Indeed, recent evidence suggests
that EGFR internalization is important for promoting SHP2-mediated signaling, as HeLa
cells with a defect in clathrin-mediated endocytosis display impaired phosphorylation of
both SHP2 and ERK in response to EGFR activation [24].

1-5 IMPLICATIONS OF SHP2 IN CANCER AND DISEASE
Based on the important role SHP2 has in regulating pro-survival signaling
pathways such as ERK/MAPK, it is not surprising that SHP2 has been implicated in
tumorigenesis. In fact, PTPN11, the gene encoding SHP2, was the first identified protooncogene encoding a tyrosine phosphatase [68]. Expression of SHP2 has been found to
be elevated in several different cancers, including lung cancer and breast cancer [69, 70].
Additionally, SHP2 has been shown to be required for transformation downstream of
oncoproteins such as CagA, Bcr-Abl, and EGFRvIII [71-73]. SHP2 has also recently
been implicated in promoting epithelial-to-mesenchymal transition (EMT) in breast
cancer cells [74], a process that is associated with cancer progression and metastasis [75,
76].
SHP2-activating mutations have been identified in several cancers including lung
cancer, neuroblastoma, juvenile myelomonocytic leukemias, and acute myelogenous
leukemias [77]. These mutations, which typically occur within the N-SH2 domain of
SHP2, disrupt the basal auto-inhibition of SHP2 and render it constitutively active even
in the absence of SHP2 binding partners [78]. Active SHP2 mutants also contribute to
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other diseases such as Noonan syndrome, an autosomal dominant disorder, which is
caused by SHP2-activating mutations in approximately 50% of diagnosed cases [78, 79].
Despite SHP2’s well-defined role as an oncogene, in some cancer contexts SHP2
serves as a tumor suppressor.

Hepatocyte-specific deletion of SHP2 can promote

spontaneous tumor growth due to SHP2’s negative regulatory role in IL-6-mediated
STAT3 activation [59]. In GBM cells, SHP2 was also found to negatively regulate
STAT3 [80], an important pro-survival signaling intermediate in GBM [47, 81], although
the implications of this negative regulation were not explored.

SHP2-inactivating

mutations, which typically occur within the PTP domain of SHP2 and diminish the
phosphatase activity of SHP2, can also promote diseases associated with diminished ERK
activity such as LEOPARD syndrome [82].

1-6 THESIS SUMMARY
In this thesis, we explore the role of SHP2 in determining response to EGFRtargeted therapeutics using experimental techniques, and build upon these findings by
analyzing the spatiotemporal activation of SHP2 downstream of EGFR using
experimental methods paired with computational modeling techniques. In Chapter 2, we
study the role of SHP2 in NSCLC cells with or without EGFR mutation. We find that
SHP2 depletion in wild-type EGFR-expressing cells reduces ERK phosphorylation and
enhances cellular response to the EGFR inhibitor gefitinib, confirming that SHP2mediated ERK activity promotes resistance to EGFR inhibition. We also find that the
functional role of SHP2 in mediating ERK phosphorylation is impaired in NSCLC cells
expressing EGFR mutants compared to cells expressing wild-type EGFR, and that
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impaired function of SHP2 at least partially contributes to the enhanced sensitivity of
EGFR mutant-expressing cells to gefitinib. Our findings also reveal that the mechanism
by which SHP2’s function is impaired in the context of EGFR mutation is through
apparent sequestration of biochemically active SHP2 at the plasma membrane with
endocytosis-impaired EGFR mutants.
Based on these findings from Chapter 2, we sought to determine whether SHP2
function could also mediate resistance to targeted therapeutics in another cancer. In
Chapter 3, we study the role of SHP2 in glioblastoma cells with or without expression of
the constitutively active EGFRvIII mutant.

While SHP2 is required for ERK

phosphorylation and proliferation, consistent with our findings in NSCLC cells, SHP2
also simultaneously antagonizes STAT3 phosphorylation and promotes cell death
response to gefitinib in combination with the c-MET inhibitor PHA665752.

These

regulatory roles of SHP2 are diminished with sufficiently high expression of EGFRvIII,
analogous to our finding of an impaired functional role of SHP2 in NSCLC cells
expressing EGFR mutants. SHP2 also antagonizes the phosphorylation of EGFRvIII and
c-MET but concurrently promotes the expression of hypoxia inducible factors, thus
providing further insight into SHP2’s capacity to serve as both an oncogene and a tumor
suppressor in glioblastoma cells.
In Chapter 4, we explore the dynamic regulation of SHP2’s association with
GAB1 downstream of EGFR. Experimental studies show that constant kinase activity is
required to maintain the association of GAB1 and SHP2, due to the rapid rate at which
SHP2 dissociates from GAB1, which itself is rapidly dephosphorylated when not bound
with SHP2. Despite the rapid dephosphorylation of GAB1 following EGFR inactivation,
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we find that GAB1 dephosphorylates more slowly relative to EGFR and can remain
associated with SHP2 in the absence of EGFR’s presence within the complex. To
explain this apparent discrepancy, we go on to identify cytosolic SFKs as the primary
kinases responsible for phosphorylating GAB1 and promoting GAB1-SHP2 association
downstream of EGFR. To interpret our experimental data we construct a computational
model trained against our experimental data. In order to best explain our data, the model
requires that SFKs effectively amplify EGFR activity to buffer GAB1 phosphorylation,
and thus GAB1-SHP2 association, when EGFR activity levels are diminished. This
amplification is required even with perturbations to the model parameters and topology,
confirming the robustness of this finding.
In Chapter 5, we expand upon the findings of Chapter 4 by developing a
computational reaction-diffusion model that includes the reactions contained in the
mechanistic model from Chapter 4 but also accounts for the process of protein diffusion
in order to predict where GAB1-bound SHP2 is distributed throughout a representative
lung cancer cell. While the concentration of active SFKs is predicted to quickly diminish
distal from the plasma membrane, the concentration of phospho-GAB1 and GAB1-SHP2
complexes are predicted to remain essentially constant throughout the entire cell volume.
This finding is dependent on the capacity for SFKs to phosphorylate GAB1 throughout
the cytosol, as changing the model topology to permit SFKs to only be active at the
plasma membrane results in steep declines in the predicted concentrations of phosphoGAB1 and GAB1-SHP2 complexes away from the plasma membrane. A parameter
sensitivity analysis identifies protein diffusion as the most important model process for
dictating the length scale of GAB1-SHP2 association distal from the plasma membrane.
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The relationships between model processes on determining the GAB1-SHP2 complex
length scale are also explored, which identifies that SFK overexpression can compensate
for a faster rate of GAB1 dephosphorylation throughout the cytosol to maintain GAB1SHP2 complexes distal from the plasma membrane, while SFK overexpression cannot
compensate for a faster rate of SFK inactivation.
In Chapter 6, we discuss the implications of our findings, which offer support for
both furthering the current understanding of SHP2 function in cancer as well as
developing and testing SHP2-specific inhibitors for clinical applications. Our findings,
of specific importance to SHP2-containing protein complexes, also highlight the broad
need to better understand the dynamics and spatial regulation of phospho-protein
complex assemblies initiated downstream of RTKs.
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Chapter 2: Diminished Functional Role and Altered
Localization of SHP2 in Non-small Cell Lung Cancer Cells
with EGFR-activating Mutations1

2-1 ABSTRACT
Non-small cell lung cancer (NSCLC) cells harboring activating mutations of the
epidermal growth factor receptor (EGFR) tend to display elevated activity of several
survival signaling pathways. Surprisingly, these mutations also correlate with reduced
phosphorylation of ERK and SHP2, a protein tyrosine phosphatase required for complete
ERK activation downstream of most receptor tyrosine kinases.

Since ERK activity

influences cellular response to EGFR inhibition, altered SHP2 function could play a role
in the striking response to gefitinib witnessed with EGFR mutation.

Here, we

demonstrate that impaired SHP2 phosphorylation correlates with diminished SHP2
function in NSCLC cells expressing mutant, versus wild-type, EGFR. In NSCLC cells
expressing wild-type EGFR, SHP2 knockdown decreased ERK phosphorylation, basally
and in response to gefitinib, and increased cellular sensitivity to gefitinib.

In cells

expressing EGFR mutants, these effects of SHP2 knockdown were less substantial, but
expression of constitutively active SHP2 reduced cellular sensitivity to gefitinib. In cells
expressing EGFR mutants, which do not undergo efficient ligand-mediated endocytosis,
SHP2 was basally associated with GAB1 and EGFR, and SHP2’s presence in membrane
fractions was dependent on EGFR activity. Whereas EGF promoted a more uniform
intracellular distribution of initially centrally localized SHP2 in cells expressing wild15
1

A version of Chapter 2 was published as: Furcht, C. M., Muñoz Rojas, A. M., Nihalani, D., & Lazzara, M. J. (2013).
Diminished Functional Role and Altered Localization of SHP2 in Non-Small Cell Lung Cancer Cells with EGFRactivating Mutations. Oncogene, 32(18), 2346-2356. (PMID: 22777356)

type EGFR, SHP2 was basally evenly distributed and did not redistribute in response to
EGF in cells with EGFR mutation. Thus, EGFR mutation may promote association of a
fraction of SHP2 at the plasma membrane with adapters which promote SHP2 activity.
Consistent with this, SHP2 immunoprecipitated from cells with EGFR mutation was
active, and EGF treatment did not change this activity. Overall, our data suggest that a
fraction of SHP2 is sequestered at the plasma membrane in cells with EGFR mutation in
a way that impedes SHP2’s ability to promote ERK activity and identify SHP2 as a
potential target for co-inhibition with EGFR in NSCLC.

16

2-2 INTRODUCTION
In non-small cell lung cancer (NSCLC), tumor response to the EGFR inhibitors
gefitinib and erlotinib is generally limited to the 10-20% of NSCLCs carrying kinaseactivating EGFR mutations [9, 14, 15]. NSCLC cells harboring these mutations often
display elevated phosphorylation of EGFR, AKT, signal transducer and activator of
transcription 3/5 (STAT3/5), ERBB3, and MET [15, 25, 26, 83]. Recently, it was shown
that these EGFR mutations also surprisingly result in impaired EGFR-mediated
phosphorylation of both ERK, an important determinant of cell response to gefitinib, and
the protein tyrosine phosphatase SHP2 [24], which is required for complete ERK
activation by most receptor tyrosine kinases [28]. Thus, the striking responsiveness of
tumors with EGFR mutation to EGFR inhibition may result from an imbalance in EGFR
oncogenic signaling wherein activating mutations promote some signaling pathways
while simultaneously impairing others.
Activation of receptor tyrosine kinases, including EGFR, results in SHP2
phosphorylation at Y542, which is required for normal SHP2-mediated ERK activation in
response to many growth factors [29]. Receptor activation and phosphorylation also
results in SHP2 recruitment to receptors via direct binding or through adapters, which
activates SHP2 through relief of auto-inhibitory intramolecular interactions [28]. SHP2
is recruited to EGFR through binding to phosphorylated adapter proteins including
GRB2-associated binder 1 (GAB1) [52], whose association with EGFR is mediated by
GRB2 upon EGFR phosphorylation at Y1068 and Y1086 [7]. Downstream of EGFR,
SHP2 is primarily associated with promoting ERK activity by regulating RAS [53].
SHP2-activating mutations have been identified in Noonan syndrome, juvenile
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myelomonocytic leukemia, and acute myelogenous leukemia [82, 84]. SHP2-activating
mutations have also been found in lung cancer, although the consequences of these
mutations are not fully understood [77].
The aforementioned differences in SHP2 and ERK phosphorylation in NSCLC
cells with EGFR mutation suggest SHP2 function may be perturbed in this setting.
However, the role of SHP2 in NSCLC has not been thoroughly evaluated. In previous
studies, HeLa cells expressing dominant-negative dynamin [85], a GTPase required for
clathrin-mediated

EGFR

endocytosis,

displayed

diminished

EGF-mediated

phosphorylation of SHP2 and ERK.[24] Since the EGFR-activating mutations observed
in NSCLC result in impaired EGFR endocytosis [23, 24], differential EGFR trafficking
may explain the defects in SHP2 and ERK phosphorylation in NSCLC cells expressing
EGFR mutants. SHP2 localization could also be altered in the context of EGFR mutation
via association with internalization-impaired EGFR.
In this study, we find diminished SHP2 function in NSCLC cells expressing
mutant versus wild-type EGFR. In cells expressing wild-type EGFR, SHP2 knockdown
reduced ERK phosphorylation and increased cellular sensitivity to gefitinib. In cells
expressing EGFR mutants, the effects of SHP2 knockdown were less pronounced, but
expression of constitutively active SHP2 reduced cellular sensitivity to gefitinib. In cells
expressing EGFR mutants, SHP2 was basally associated with GAB1 and EGFR, and the
presence of SHP2 in membrane fractions was dependent on EGFR activity. In cells
expressing wild-type EGFR, EGF promoted redistribution of initially centrally localized
SHP2, but SHP2 was basally evenly distributed and did not redistribute in response to
EGF in cells expressing EGFR mutants.
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SHP2 was catalytically active in cells

expressing EGFR mutants, consistent with the finding that SHP2 association with
adapters was not impaired, but rather basally elevated, in these cells. Overall, our data
suggest that a fraction of SHP2 is sequestered at the plasma membrane in cells with
EGFR mutation in a way that interferes with SHP2-mediated ERK activation and
promotes cellular sensitivity to EGFR inhibition.
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2-3 MATERIALS AND METHODS
Cell culture. H1666 and H3255 cells were maintained in ACL4 [24]. All others
were maintained in RPMI 1640 supplemented with 100 units/mL penicillin, 100 μg/mL
streptomycin, 1 mM L-glutamine, and 10% fetal bovine serum (FBS). H1666 cells were
obtained from the American Type Culture Collection. H3255, H322, and H1781 cells
were provided by Dr. Pasi Jänne (Dana-Farber Cancer Institute). H292 and HCC827
cells were provided by Dr. Eric Haura (Moffitt Cancer Center). For serum starvation,
cells were switched to media containing 0.1% FBS for 16-18 hrs.
Cell proliferation assay. Proliferative response to gefitinib was measured by XTT
assay according to manufacturer’s specifications (Roche, Indianapolis, IN, USA). Cells
seeded in 96-well plates were treated with up to 10 M gefitinib for 4 days.
Subsequently, fresh media and XTT reagent were added to wells, and plates were
incubated for 2-4 hrs at 37°C to maximize signal-to-background. Wells containing only
media were used for background correction. Each experiment was performed at least
three times with each condition plated in three replicate wells on each day.
shRNA and expression constructs. Sequences encoding short hairpins targeting
human SHP2 and GAB1 were cloned in the pSicoR vector (Tyler Jacks, MIT; [86]). The
SHP2

shRNA

targeted

(GGACGTTCATTGTGATTGA)

nucleotides
or,

for

1780-1798
reconstitution

of

SHP2

experiments,

mRNA
5890-5908

(GTATTGTACCAGAGTATTA). The GAB1 shRNA targeted nucleotides 987-1005 of
GAB1 mRNA (GAAACAGACTGCAATGATA). Lentivirus was produced by calcium
phosphate-mediated transfection of 293FT cells (Invitrogen, Carlsbad, CA, USA) with
vector and the packaging plasmids pCMV-VSVG, pMDL-gp-RRE, and pRSV-Rev
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(Marilyn Farquhar, UCSD). Virus was harvested 48 and 72 hrs post-transfection and
used to infect target cells, which were selected in puromycin.
SHP2 cDNAs encoding wild-type, D61A, E76A, Y542F, and C459S SHP2 (Ben
Neel, Ontario Cancer Institute) were inserted at the EcoRI site of the pBabe vector.
Retrovirus was produced by calcium phosphate-mediated transfection of amphotropic
Phoenix cells (Gary Nolan, Stanford University) with vector. Virus was harvested 24,
30, and 48 hrs post-transfection and used to infect target cells, which were selected in
puromycin or hygromycin.
Constructs were validated by sequencing. SHP2 and GAB1 knockdowns were
validated by Western blot and qPCR, respectively.
Immunoblotting. Cell lysates were prepared using cell extraction buffer
(Invitrogen; #FNN0011) supplemented with 1 mM PMSF, additional protease inhibitors
(Sigma, St. Louis, MO, USA), and phosphatase inhibitors (Sigma).

Proteins were

resolved by SDS-PAGE and transferred to nitrocellulose membranes, which were
blocked in Odyssey Blocking Buffer (OBB; LI-COR, Lincoln, NE, USA) and stripped
with 0.2 M NaOH as needed. Images were obtained using a LI-COR Odyssey Infrared
Imaging System.
Immunoprecipitation. Cell lysates were prepared with immunoprecipitation lysis
buffer (Cell Signaling Technology, Danvers, MA, USA; #9803) supplemented with 1
mM PMSF, additional protease inhibitors, and phosphatase inhibitors. 500 μg of total
protein was precleared with Dynabeads (Invitrogen) for 4 hrs and subsequently incubated
with Dynabeads conjugated to SHP2 or control antibody at 4°C overnight. Beads were
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washed with lysis buffer, re-suspended in LDS sample buffer (Invitrogen), and boiled
before SDS-PAGE.
SHP2 activity assay. 500 μg of total protein from cell lysates was incubated
overnight with agarose beads conjugated to an SHP2 antibody. Beads were washed with
lysis buffer and split into two equal fractions.
immunoblotting.

One fraction was reserved for

Beads from the other fraction were washed with assay buffer

(Millipore, Billerica, MA, USA; #20-180) and resuspended in assay buffer containing
100 μM 6,8-difluoro-4-methylumbelliferyl phosphate (Invitrogen). The reaction was
performed at 37°C for 30 min with occasional mixing, and reaction product fluorescence
was measured at excitation and emission wavelengths of 360 nm and 460 nm,
respectively. Linearity of signal with respect to time and protein concentration was
validated for both cell lines.
Immunofluorescence. Serum starved cells on coverslips were treated with EGF,
fixed in 4% paraformaldehyde in PBS for 20 min, and permeabilized with 0.25% Triton
X-100 for 5 min. Coverslips were incubated with primary antibodies diluted in OBB
(EGFR, SHP2) or 1% BSA/0.3% Triton X-100 in PBS (RAB5) for 3 hrs at 37°C.
Coverslips were washed with 0.1% Tween-20 in PBS and incubated with Alexa Fluor
488- and 594-conjugated secondary antibodies and Hoechst (Invitrogen) in the same
diluents used for primary antibodies for 1 hr at 37°C. Coverslips were washed again,
mounted on glass slides, and treated with Prolong Gold antifade (Invitrogen). Specificity
of the SHP2 antibody was confirmed by comparison with SHP2 knockdown cells.
Epifluorescence images were obtained with a Zeiss Axiovert 40 CFL microscope (100X
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objective). Confocal images were obtained with a Nikon Eclipse TE-300 microscope
(60X objective).
To analyze individual cells from these images, MATLAB was used to determine
pixel intensities as a function of distance from the cell center. This was done by outlining
individual cells, locating cell centers, and generating lines from the center to the cell
periphery in all angular directions, along which pixel intensities were quantified. Data
were averaged and normalized to obtain a vector of intensities versus normalized
distances from the cell center.
Subcellular fractionation. Serum starved cells were treated with 0 or 5 M
gefitinib, washed, and collected in hypotonic buffer (10 mM Tris-HCl, pH 7.4, 1 mM
MgCl2, 1 mM EDTA) supplemented with 1 mM PMSF, additional protease inhibitors,
and phosphatase inhibitors. Crude lysates were generated with a Dounce homogenizer
and centrifuged at 3000 and 9300 rpm, for 5 min at each speed, to remove nuclei and
mitochondria, respectively. Cleared lysates were centrifuged at 100 000 g for 60 min to
separate membrane and cytosol fractions. Membrane pellets were washed with PBS,
resuspended in hypotonic buffer, and centrifuged again at 100 000 g. After additional
washes, membrane pellets were resuspended in immunoprecipitation lysis buffer to
solubilize proteins before SDS-PAGE.
Quantitative polymerase chain reaction (qPCR). Cellular RNA was isolated
using an RNEasy kit (Qiagen, Valencia, CA, USA), and cDNA was transcribed using a
High-Capacity cDNA Reverse Transcription Kit (Applied Biosciences, Foster City, CA,
USA). Using the cDNA as a template, qPCR was performed with previously developed
primers for GAB1 mRNA using SYBR Green Master Mix (Applied Biosciences).[87]
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Reactions were monitored on a Model 7300 Real Time PCR System (Applied
Biosciences). RNA polymerase II mRNA was quantified as a normalization control
using

5’-GCACCACGTCCAATGACAT-3’

as

the

forward

primer

and

5’-

GTGCGGCTGCTTCCATAA-3’ as the reverse primer.
Antibodies and other reagents. EGFR (immunoblotting; #2232), pAKT S473
(#9271), AKT (#9272), pERK T202/Y204 (#4377), ERK (#4695), RAB5 (#3547),
pSTAT3 Y705 (#9138), and pGAB1 Y627 (#3233) antibodies were from Cell Signaling
Technology. SHP2 (sc-280) and EGFR (immunofluorescence; sc-81449) antibodies were
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Actin (MAB 1501) and GAB1
(#06-579) antibodies were from Millipore. pEGFR Y1068 (#1727) and pSHP2 Y542
(#2184) antibodies were from Epitomics (Burlingame, CA, USA), unless otherwise
noted.

Infrared dye- and Alexa Fluor-conjugated secondary antibodies were from

Rockland Immunochemicals (Gilbertsville, PA, USA) and Invitrogen, respectively.
Gefitinib (LC Laboratories, Woburn, MA, USA) was diluted in DMSO.
Recombinant human EGF was from Peprotech (Rocky Hill, NJ, USA). Recombinant
human HGF (R&D Systems, Minneapolis, MN, USA) was generously provided by Dr.
Anil Rustgi (University of Pennsylvania).
Statistics. Statistical analyses were performed using a paired two-tailed student’s
t-test.
IC50 calculations.

Gefitinib IC50 values were determined by fitting a four

parameter logistic function to normalized data.
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2-4 RESULTS
Effects of SHP2 knockdown on ERK phosphorylation. To assess the signaling
role of SHP2 in NSCLC cells, we examined the effects of SHP2 knockdown on ERK
phosphorylation in response to gefitinib in a panel of cell lines (Figures 2-1 and S2-10).
In H322 and H292 cells (EGFRWT), SHP2 knockdown reduced ERK phosphorylation in
untreated cells by more than 90%.

In H1666 and H1781 cells (EGFRWT), SHP2

knockdown resulted in notable, but more modest, reductions in baseline ERK
phosphorylation of ~60% and 20%, respectively, as well as reductions in the gefitinib
IC50 values for ERK phosphorylation.

In H3255 cells (EGFRL858R), which display

impaired EGF-mediated SHP2 phosphorylation relative to cells expressing wild-type
EGFR (Figure S2-11; [24]), SHP2 knockdown had no substantial effect on ERK
phosphorylation at any concentration of gefitinib. In HCC827 cells (EGFRdelE746-A750),
which also display impaired SHP2 phosphorylation (Figure S2-11; [24]), there was a
reduction in baseline ERK phosphorylation with SHP2 knockdown compared to controls,
but the effect was less substantial than that observed in cells expressing wild-type EGFR,
other than H1781. There was also no enhancement in gefitinib’s ability to inhibit ERK
phosphorylation in SHP2-depleted HCC827 cells relative to controls. Relative to ERK
phosphorylation, SHP2 knockdown produced smaller changes in AKT and STAT3
phosphorylation in H1666 and H292 cells (Figure S2-12).
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Figure 2-1: SHP2 knockdown reduces ERK phosphorylation more in NSCLC cells
expressing wild-type EGFR than in those expressing EGFR mutants.
SHP2 knockdown reduces ERK phosphorylation more in NSCLC cells expressing wildtype EGFR than in those expressing EGFR mutants. H322 (A), H1666 (B), H292 (C),
H1781 (D), H3255 (E), and HCC827 (F) cells expressing SHP2-targeting or nontargeting control shRNA were treated with 0-10 μM gefitinib for 48 hrs, and lysates were
analyzed by Western blotting with antibodies against phosphorylated and total ERK.
Densitometry data are represented as mean ± s.e.m. (n = 3); * denotes p < 0.05 relative to
controls.
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Effects of SHP2 knockdown on cellular response to gefitinib. In H322 and
H1666 cells, SHP2 knockdown reduced gefitinib IC50 values for cell proliferation by 15and 3-fold, respectively (Figure 2-2). In H1781 cells, a gefitinib-resistant cell line, the
IC50 was reduced from > 10 μM to 2.55 μM. SHP2-depleted H292 cells were only
modestly sensitized to gefitinib but were significantly growth inhibited in the absence of
gefitinib (Figure S2-13A). Thus, gefitinib may have been unable to enhance the already
striking effects of SHP2 knockdown on H292 proliferation. In contrast, H3255 cells
showed virtually no effect of SHP2 knockdown on sensitivity to gefitinib (Figure 2-2E).
HCC827 cells displayed a small shift in sensitivity to gefitinib in response to SHP2
knockdown (Figure 2-2F), but we measured no proliferative effect in the absence of
gefitinib (Figure S2-13B).
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Figure 2-2: Knockdown of SHP2 enhances cellular sensitivity to gefitinib in subsets
of NSCLC cells.
H322 (A), H1666 (B), H292 (C), H1781 (D), H3255 (E), and HCC827 (F) cells
expressing SHP2-targeting or non-targeting control shRNA were treated with 0-10 μM
gefitinib for four days, and cell proliferation was measured by XTT assay. Normalized
28

XTT signal values (y-axis) were computed at a given gefitinib concentration by dividing
absorbances by those measured for cells treated with DMSO as a control. Data are
represented as mean ± s.e.m. for three experiments with three replicate wells in each
experiment (n = 3).

To ensure the measured effects were specific for SHP2, we knocked down SHP2
in a representative cell line expressing wild-type EGFR using an independent hairpin
targeting the 3’ untranslated region of SHP2 and reconstituted cells with SHP2WT or
SHP2Y542F (Figure 2-3).

As before, SHP2-depleted cells displayed impaired ERK

phosphorylation and enhanced sensitivity to gefitinib.
rescued by reconstitution with SHP2WT or SHP2Y542F.
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These effects were partially

Figure 2-3: Observed effects of SHP2 knockdown on ERK phosphorylation and
gefitinib response are specific to SHP2.
H1666 cells expressing SHP2-targeting shRNA or an empty pSicoR vector were
transduced with SHP2WT, SHP2Y542F, or an empty pBabe vector. (A) Cells were treated
with 0-10 μM gefitinib for 48 hrs, and lysates were analyzed by Western blotting with
antibodies against indicated proteins. Images are representative of three sets of biological
replicates. Densitometry data for ERK are represented as mean ± s.e.m. (n = 3); *
denotes p < 0.05 relative to pSicoR and pBabe controls. (B) Cells were treated with 0-10
μM gefitinib for four days, and cell proliferation was measured by XTT assay.
Normalized XTT signal values (y-axis) were computed at a given gefitinib concentration
by dividing absorbances by those measured for cells treated with DMSO as a control.
Data points are represented as mean ± s.e.m. for three replicate wells from at least three
experiments.
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SHP2

association

with

GAB1

and

EGFR

and

subcellular

compartmentalization. To investigate the mechanism underlying apparent differential
SHP2 function in cells with or without EGFR mutation, we examined SHP2 association
with GAB1 and EGFR. In H3255 and HCC827 cells, SHP2 was basally associated with
GAB1 and phosphorylated EGFR to a significantly greater degree than in either H322 or
H1666 cells (Figure 2-4A).

In H3255 cells, these associations were diminished by

gefitinib (Figure 2-4B). EGF enhanced SHP2 association with GAB1 and EGFR in all
cell lines, but the fold increases in association were generally smaller in H3255 and
HCC827 cells (Figure 2-4A).

Since EGFR mutants fail to undergo efficient EGF-

mediated endocytosis [23, 24], we interpreted these findings as indicating that a fraction
of SHP2 was sequestered at the plasma membrane in cells with EGFR mutation. To
further substantiate this, we analyzed SHP2’s distribution in a subset of these cells by
subcellular fractionation. In H1666 and H3255 cells, the majority of SHP2 was cytosolic.
Only in H3255 cells, however, did gefitinib reduce SHP2 levels in crude membrane
fractions, suggesting that SHP2 was membrane-localized in an EGFR-dependent manner
(Figure 2-4C). The EGFR activity-independent presence of SHP2 in H1666 membrane
fractions could be explained by SHP2 localization to membrane compartments which
settle with plasma membrane in the crude membrane fraction generated by our protocol.
This possibility is suggested by previous studies [88].
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Figure 2-4: GAB1 and EGFR are basally associated with SHP2 in NSCLC cells
expressing EGFR mutants and are induced to associate with SHP2 by EGF in
NSCLC cells expressing wild-type EGFR.
Serum-starved cells treated with or without 10 ng/mL EGF for 5 min (A), or serumstarved H3255 cells treated with or without 5 μM gefitinib for 15 min (B), were lysed.
Lysates were immunoprecipitated with either an SHP2 or control antibody, and
immunoprecipitates were analyzed by Western blotting using antibodies against the
indicated proteins.

Images are representative of three sets of biological replicates.

Densitometry data in (A) are represented as mean ± s.e.m. (n = 3); * denotes p < 0.05
relative to wild-type EGFR-expressing cells not stimulated with EGF. (C) Subcellular
fractions were prepared from H1666 and H3255 cells treated with or without gefitinib, as
described in Materials and Methods (Section 2-3), and equivalent relative amounts of the
fractions for both cell lines were analyzed by Western blotting using antibodies against
indicated proteins. To improve signals, membrane fractions were 10× more concentrated
than cytosolic fractions in terms of the relative amount of total lysate loaded. Images are
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representative of three sets of biological replicates. Blots were quantified to determine
the relative difference in membrane-localized SHP2 in H1666 versus H3255 cells. For
each condition, SHP2 signal from the membrane fraction was divided by the SHP2 signal
from the cytosol fraction to determine a membrane/cytosol SHP2 signal.

Data are

represented as mean ± s.e.m. (n = 4); * denotes p < 0.05 relative to untreated cells.

Intracellular distribution of SHP2. We further examined EGF’s ability to alter
the intracellular distribution of SHP2 in H1666 and H3255 cells by immunofluorescence.
In H1666 cells, the distribution shifted from one where SHP2 was concentrated around
the cell center to one where some SHP2 moved toward the cell periphery and SHP2 was
distributed more uniformly (Figure 2-5).

Similar changes were noted by confocal

microscopy, including movement of SHP2 to membrane ruffles (Figure S2-14). EGF
also caused the formation of EGFR- and RAB5-positive endocytic vesicles in H1666
cells (Figure S2-15). In H3255 cells, SHP2 was basally uniformly distributed. EGF did
not alter this distribution or generate endocytic vesicles (Figures 2-5, S2-14, and S2-15),
consistent with previous reports of impaired EGFR internalization in these cells.
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Figure 2-5: Intracellular redistribution of SHP2 in response to EGF is observed in
H1666 cells, but not in H3255 cells.
(A) Serum-starved H1666 and H3225 cells were treated with 10 ng/mL EGF for up to 15
min, fixed, and stained with Hoechst (nucleus) and antibodies against EGFR and SHP2.
Images are representative of three biological replicates. (B) As described in Materials
and Methods (Section 2-3), intracellular SHP2 pixel intensities were quantified as a
function of normalized radial distance from cell centers (x = 0) to the cell periphery (x =
1). Three images for each condition were used for this analysis, in which all cells entirely
contained with the image were analyzed. Data are represented as mean (solid line) ±
s.e.m. (shaded area; n ≥ 7 cells).
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Role of GAB1 in SHP2 localization and EGF-mediated effects.

GAB1

knockdown (Figure S2-16A) did not alter basal association of SHP2 with Y1068phosphorylated EGFR in H3255 cells (Figure 2-6A), nor did it alter SHP2’s intracellular
distribution in either H1666 or H3255 cells (Figure S2-16B), suggesting that recruitment
of SHP2 to EGFR and the cell periphery can be accomplished independent of GAB1
binding, potentially through GAB2. GAB1 knockdown did, however, diminish EGFmediated ERK and SHP2 phosphorylation, reduce ERK and AKT phosphorylation in
response to gefitinib, and increase cellular sensitivity to gefitinib in H1666 cells (Figures
2-6B-D and S2-16C-D).

Although GAB1-depleted H3255 cells displayed a modest

reduction in SHP2 phosphorylation, there was no effect on ERK phosphorylation (Figure
2-6B), suggesting that the mechanism by which SHP2 function is impaired in these cells
may simultaneously perturb GAB1 function.
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Figure 2-6: GAB1 knockdown alters EGF-mediated ERK phosphorylation and
response to gefitinib in H1666 cells.
In H1666 and H3255 cells expressing GAB1-targeting or non-targeting control shRNA:
(A) Serum-starved H3255 cells were lysed, and lysates were immunoprecipitated with
either an SHP2 or control antibody. Immunoprecipitates were analyzed by Western
blotting using antibodies against indicated proteins. Images are representative of three
sets of biological replicates, and densitometry data are represented as mean ± s.e.m. (n =
3). (B) Serum-starved cells were treated with or without 10 ng/mL EGF for up to 15 min,
and lysates were analyzed by Western blotting using antibodies against phosphorylated
and total ERK and SHP2. Densitometry data are represented as mean ± s.e.m. (n = 3).
(C) H1666 cells were treated with 0-10 μM gefitinib for 48 hrs, and lysates were
analyzed by Western blotting with antibodies against phosphorylated and total ERK and
AKT. Densitometry data are represented as mean ± s.e.m. (n = 3); * denotes p < 0.05
relative to controls. (D) H1666 cells were treated with 0-10 μM gefitinib for four days,
and cell proliferation was measured by XTT assay. Normalized XTT signal (y-axis)
represents the normalization of values obtained from cells at a given gefitinib
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concentration by dividing these values by those obtained from cells treated with DMSO
as a control. Data are represented as mean ± s.e.m. for three experiments with three
replicate wells in each experiment (n = 3).

SHP2 activity. SHP2 knockdown in H1666 and H3255 cells resulted in fractional
reductions of measured phosphatase activities comparable to the reductions in
immunoprecipitated SHP2 levels (Figure 2-7A), indicating that SHP2 was active in both
cell lines. In response to EGF, SHP2 activity increased in H1666 cells, with p = 0.08 for
this comparison (Figure 2-7B). EGF elicited no change in SHP2 activity in H3255 cells
(p = 0.50). Note that comparison of activity between cell lines is not straightforward
because more SHP2 was immunoprecipitated from H3255 lysates, lysates were not
controlled for cell numbers due to proliferation differences, and only a fraction of SHP2
was adapter-bound in each cell line. Thus, the lower apparent normalized SHP2 activity
in H3255 versus H1666 cells may not necessarily reflect a lower total SHP2 activity level
on a per cell basis.
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Figure 2-7: SHP2 is active in H1666 and H3255 cells, and EGF increases SHP2
activity in H1666 cells.
H1666 and H3255 cells expressing SHP2-targeting or non-targeting control shRNA (A),
and serum-starved H1666 and H3255 cells treated with or without 10 ng/mL EGF for 5
min (B) were lysed, and SHP2 was immunoprecipitated from whole cell lysates. Half of
each immunoprecipitate was used to determine phosphatase activity, as described in
Materials and Methods (Section 2-3), while the remainder was used to determine SHP2
levels by immunoblot. Data are represented as mean ± s.e.m. (n = 3); AU, arbitrary units.
Blot images in (A) are representative of three sets of biological replicates. Values
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reported in (B) were determined by dividing AU values from the phosphatase activity
assay by the quantified SHP2 levels obtained from immunoblots.

Effects of SHP2 mutation. In H1666 cells, expression of constitutively active
SHP2D61A or SHP2E76A mitigated gefitinib-mediated reductions in ERK phosphorylation,
and expression of catalytically-inactive SHP2C459S reduced ERK phosphorylation basally
and in response to gefitinib (Figure 2-8A). Despite increased ERK phosphorylation in
H1666 cells expressing SHP2D61A or SHP2E76A, there was no change in gefitinib
sensitivity in these cells (Figure 2-8B), suggesting that the parental cell line’s capacity to
activate ERK was at a threshold level for maintaining cell survival. However, H1666
cells expressing SHP2C459S were more responsive to gefitinib, mirroring the effects of
SHP2 knockdown.

In H3255 cells, expression of SHP2E76A augmented ERK

phosphorylation in the presence of gefitinib and substantially decreased cellular
sensitivity to gefitinib (Figure 2-8C-D). As expected, SHP2C459S expression had little
effect on ERK phosphorylation or gefitinib response in H3255 cells.
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Figure 2-8: Ectopic expression of SHP2 mutants alters cellular response to gefitinib
in H1666 and H3255 cells.
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The following experiments were carried out with H1666 and H3255 cells transduced with
SHP2D61A (H1666 only), SHP2E76A, SHP2C459S, or an empty pBabe vector: (A and C)
H1666 and H3255 cells were treated with the indicated concentrations of gefitinib for 48
hrs, and lysates were analyzed by Western blotting with antibodies against indicated
proteins. Images for (A) and (C) are representative of three sets of biological replicates.
Densitometry data for ERK are represented as mean ± s.e.m. (n = 3); * denotes p < 0.05
relative to controls. (B and D) H1666 and H3255 cells were treated with up to 2.5 μM
gefitinib for four days, and cellular proliferation was measured by XTT assay.
Normalized XTT signal values (y-axis) were computed at a given gefitinib concentration
by dividing absorbances by those measured for cells treated with DMSO as a control.
Data are represented as mean ± s.e.m. for three experiments with three replicate wells in
each experiment (n = 3).

Importance of SHP2-mediated effects downstream of MET. Since SHP2-GAB1
association is required for sustained ERK activation downstream of MET [89], we
hypothesized that SHP2 could play a role in hepatocyte growth factor (HGF)-mediated
resistance to EGFR inhibition in NSCLC cells by maintaining GAB1-mediated signaling
in the presence of gefitinib [90, 91]. To explore this idea, we treated SHP2-depleted
H1666 and HCC827 cells with gefitinib in the presence or absence of HGF. Although
HGF sustained phosphorylated GAB1 Y627, a SHP2 binding site, in the presence of
gefitinib, SHP2 knockdown did not affect HGF-mediated rescue of ERK phosphorylation
in either cell line (Figure S2-17).
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2-5 DISCUSSION
Other than in H292 cells, where SHP2 knockdown substantially inhibited cell
growth, SHP2 depletion in cells expressing wild-type EGFR increased sensitivity to
gefitinib by 3- to 15-fold, as measured by XTT assay. Gefitinib IC50 values for cells
expressing wild-type or mutant EGFR typically differ by a factor of ten or more [92].
Thus, SHP2 depletion in cells expressing wild-type EGFR generally produced an effect
consistent with differences on the lower end of what is observed among NSCLC cells
with or without EGFR mutation. Of course, other factors contribute to differences in
NSCLC

cellular

sensitivity to

gefitinib,

including

differential

regulation

of

phosphatidylinositol 3-kinase (PI3K)/AKT and STAT3/5 [15, 25, 83]. Our study appears
to be the first, however, to identify a mechanism wherein a survival signaling pathway is
impaired by EGFR-activating mutations in a way which impacts cellular response to
EGFR inhibition.
We also found that SHP2 depletion most strongly impaired ERK phosphorylation
in cells expressing wild-type versus mutant EGFR. However, H1781 (EGFRWT) cells
were an outlier in terms of the relatively modest effect of SHP2 knockdown on ERK
phosphorylation. Despite this, there was a substantial effect of SHP2 knockdown on
cellular response to gefitinib. H1781 cells express a constitutively active HER2 mutant
(VC insertion at G776) and are dependent on HER2 for ERK and AKT phosphorylation
[93]. Since HER2 can sequester EGFR at the plasma membrane [94, 95], the possibility
exists for SHP2 to be sequestered with EGFR in these cells as well. Indeed, this appeared
to occur (Figure S2-18). However, as SHP2 promotes RAS activity downstream of
HER2 [96], HER2-mediated SHP2 function may contribute to the modest effect of SHP2
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knockdown on ERK phosphorylation in these cells. Further studies are needed to parse
the effects of SHP2 downstream of EGFR and HER2 in these cells.
A previous study demonstrated impaired SHP2 phosphorylation in NSCLC cells
expressing EGFR mutants [24], but the phenotypic implications of SHP2 phosphorylation
status were not directly evaluated. Our finding that reconstitution of SHP2Y542F in SHP2depleted H1666 cells rescued ERK phosphorylation as efficiently as SHP2WT suggests
that SHP2 Y542 phosphorylation is dispensable for SHP2-mediated activation of ERK,
consistent with previous findings regarding EGF-mediated ERK activation in 3T3
fibroblasts [29]. Thus, impaired SHP2 phosphorylation with EGFR mutation may not be
the cause, but rather a result, of a mechanism whereby SHP2 function (but not activity) is
diminished by SHP2 sequestration. We also note that despite the lack of an effect of
SHP2 knockdown in H3255 cells (EGFRL858R), there were small effects of SHP2
knockdown in HCC827 cells (EGFRE746_A750del). This difference between H3255 and
HCC827 cells could reflect a functional difference between the two EGFR mutants or a
differential role of receptors such as MET, which is basally phosphorylated to a higher
degree in HCC827 cells [26].
Based on our studies of GAB1 knockdown, GAB1 function may also be perturbed
by EGFR mutation. GAB1 also appears to be an important determinant of cellular
response to gefitinib in an NSCLC cell line expressing wild-type EGFR. This could be
due to the function of GAB1 upstream of SHP2 in regulating ERK phosphorylation, the
function of GAB1 in promoting AKT phosphorylation by recruiting PI3K, or both.
Additional work is needed to clarify the role and regulation of GAB1.
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Our data suggest that EGFR mutation promotes constitutive binding of a fraction
of SHP2 to EGFR through GAB1 and other adapters. Since adapter engagement of
SHP2’s SH2 domains promotes SHP2 activity, it is perhaps not surprising that SHP2 was
biochemically active in cells with EGFR mutation.

Given these findings, our

immunofluorescence microscopy and subcellular fractionation results, and previous
findings that EGFR mutants are endocytosis-impaired, EGFR mutation appears to result
in sequestration of at least some SHP2 at the plasma membrane in a state where it should
be biochemically active. The finding that not all SHP2 was sequestered at the plasma
membrane in cells with EGFR mutation (as observed by immunofluorescence and
fractionation) could be a stoichiometric effect. Indeed, in A431 cells, with over 3 × 106
EGFR/cell, a more complete redistribution of SHP2 to the cell periphery was observed in
response to EGF than we observed [97]. Moreover, in EGFR mutant cells, the SHP2
which is not sequestered, and less likely to be adapter-bound, should be at a lower
activity and therefore less functionally relevant.

This model is consistent with our

findings that in EGFR mutant cells, where only a fraction of SHP2 was sequestered,
SHP2 depletion had relatively small effects, but expression of constitutively active SHP2
rescued ERK phosphorylation and sensitivity to gefitinib.

The reason why SHP2

sequestration may impede SHP2’s ability to promote ERK phosphorylation could be
related to previous findings that normal EGFR endocytosis is required for complete ERK
activation in some cellular contexts [85]. This coupling between endocytosis and ERK
could involve a role for SHP2 localization wherein normal trafficking of SHP2containing complexes promotes ERK activity by allowing complex access to substrates in
the cell interior (Figure 2-9).
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Figure 2-9: Sequestration of SHP2 at the plasma membrane may enhance gefitinib
response in cells expressing EGFR mutants by reducing ERK activity.
In the proposed mechanism, EGFR activation and phosphorylation leads to recruitment of
GRB2, which is constitutively bound with GAB1 via an SH3 domain-mediated
interaction. Phosphorylated GAB1 (and possibly other adapters) recruits SHP2, whose
activity leads to ERK activation through dephosphorylation of a RASGAP binding site on
GAB1 (as shown) or through other mechanisms (as depicted by dotted arrow), such as
dephosphorylation of CSK binding sites on PAG/CBP and paxillin. The function of
SHP2 in this complex at both the plasma membrane and the cell interior leads to
complete ERK phosphorylation. When SHP2 is sequestered at the plasma membrane in
complex

with

internalization-impaired mutant

phosphorylation is impaired.

EGFR

(e.g. EGFRL858R), ERK

Due in part to impaired ERK activity resulting from

sequestration of SHP2, cells with EGFR mutants display increased sensitivity to EGFR
inhibition.

SHP2 knockdown in an NSCLC cell line was previously shown to slow xenograft
growth in mice [98]. In addition, SHP2-activating mutations have been found in solid
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tumors, including NSCLC [77]. As far as we are aware, however, the effects of SHP2
expression and mutation on cellular response to EGFR inhibition have not previously
been evaluated. Our finding that SHP2 knockdown in NSCLC cells expressing wild-type
EGFR enhanced cellular response to gefitinib suggests that combined inhibition of EGFR
and SHP2 may improve response in tumors that are unresponsive to EGFR inhibition
alone.

The largest effects of SHP2 knockdown on enhancing response to EGFR

inhibition in cells with wild-type EGFR tended to occur at or below 1 μM gefitinib, the
maximum achievable plasma concentration at a clinically relevant dose [99]. Thus, it is
conceivable that such a co-inhibition strategy could have clinical impact. Our finding
that expression of constitutively active SHP2 mutants mitigated the effects of gefitinib on
ERK phosphorylation in H1666 and H3255 cells suggests that SHP2 activity can
maintain the activity of ERK in the presence of EGFR inhibitors. Although we noted no
major effect of ectopic expression of these mutants on sensitivity to gefitinib in H1666
cells, H3255 cells expressing SHP2E76A displayed decreased sensitivity to gefitinib. It
would therefore be interesting to explore the implications for drug resistance in cells with
SHP2 mutation.
Our findings point to SHP2 as a potential target to be co-inhibited with EGFR in
the treatment of NSCLC cells expressing wild-type EGFR. Expanding these studies to an
in vivo model would be helpful in determining if a clinical benefit for combined
SHP2/EGFR inhibition exists, although such studies would be hampered by the present
lack of effective and specific SHP2 inhibitors. Our findings also highlight the nonintuitive possibility for activating mutations of receptors such as EGFR to impair the
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function of specific signaling pathways in ways which promote cellular response to
receptor-targeting therapeutics.
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2-7 SUPPLEMENTAL MATERIAL

Figure S2-10: SHP2 knockdown reduces ERK phosphorylation more in NSCLC
cells expressing wild-type, versus mutant, EGFR.
H322 (A), H1666 (B), H292 (C), H1781 (D), H3255 (E), and HCC827 (F) cells
expressing control or SHP2-targeting shRNA were treated with up to 10 μM gefitinib for
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48 hrs. Lysates were analyzed by Western blotting with antibodies against indicated
proteins. Images are representative of three sets of biological replicates. EGFR was
probed to ensure there was no significant change in its expression due to SHP2
knockdown.
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Figure S2-11: EGF-mediated phosphorylation of SHP2 at Y542 is impaired in
H3255 and HCC827 cells relative to H1666 cells.
Serum-starved cells were treated with 10 ng/mL EGF for up to 15 min and lysed. Whole
cell lysates (A) or SHP2 immunoprecipates from whole cell lysates (B) were then
analyzed by Western blotting using antibodies against the indicated proteins. For each
panel, images for different cell lines were obtained from the same membrane; the
cropping is due to removal of irrelevant lanes. The pSHP2 Y542 antibody was from Cell
Signaling Technology for the analysis in (A) and from Epitomics for the analysis in (B).
The specificity of both antibodies for SHP2 was validated by comparisons with lysates
from cells with SHP2 knockdown.
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Figure S2-12: SHP2 knockdown more strongly influences the phosphorylation of
ERK than phosphorylation of AKT or STAT3 in NSCLC cells expressing wild-type
EGFR.
(A) H292 and H1666 cells expressing control or SHP2-targeting shRNA were treated
with the indicated concentrations of gefitinib for 48 hrs, and lysates were analyzed by
Western blotting with antibodies against indicated proteins. Images are representative of
three sets of biological replicates. Densitometry data for H292 (B) and H1666 (C) blots
from (A) are represented as mean ± s.e.m. (n = 3); * denotes p < 0.05 relative to controls.
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Figure S2-13: H292 cells are significantly growth inhibited by SHP2 knockdown,
while HCC827 cells are not.
H292 (A) and HCC827 (B) cells expressing control or SHP2-targeting shRNA were
plated in 6-well plates at 75 000 and 100 000 cells per well, respectively. Cells were
counted by hemocytometer one day after plating to ensure similar numbers of adherent
cells had been plated. Cells were also counted three days after plating to determine the
difference in proliferation between cells with or without knockdown of SHP2. Data are
represented as mean ± s.e.m. of two replicate wells from two distinct experiments (n = 4).
* denotes p < 0.05 relative to controls.
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Figure S2-14: EGF promotes membrane localization of SHP2 in H1666 cells, but not
in H3255 cells.
Serum-starved H1666 and H3255 cells were treated with or without 10 ng/mL EGF for 5
min (H1666) or 15 min (H3255), and subsequently fixed and stained with antibodies
against EGFR (red) and SHP2 (green). Images represent single frames from z-stacks
obtained on a confocal microscope.

Red arrows denote localization of SHP2 at

membrane ruffles.
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Figure S2-15: EGF promotes the formation of EGFR-positive endocytic vesicles in
H1666 cells, but not in H3255 cells.
Serum-starved H1666 and H3255 cells were treated with or without 10 ng/mL EGF for
up to 15 min, fixed, and stained with antibodies against EGFR (red) and RAB5 (green), a
marker for early endosomes.

Sections of merged images (white rectangles) were

magnified to show co-localization of EGFR and RAB5 (yellow vesicles), which were
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present in EGF-treated H1666 cells. Images are representative of three separate pictures
taken from three biological replicates.
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Figure S2-16: GAB1 does not influence the localization of SHP2 in H1666 or H3255
cells, but does alter EGF-mediated ERK phosphorylation and response to gefitinib
in H1666 cells.
In H1666 and H3255 cells expressing GAB1-targeting or non-targeting control shRNA:
(A) RNA was isolated from cells, and relative levels of GAB1 mRNA were determined
by qPCR as described in Materials and Methods (Section 2-3). (B) Serum-starved cells
were treated with or without 10 ng/mL EGF for 5 min, and subsequently fixed and
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stained with Hoescht nuclear stain (blue) and antibodies against EGFR (red) and SHP2
(green). Images are representative of three separate pictures taken from three biological
replicates. (C) Cells were treated with 10 ng/mL EGF for up to 15 min, and lysates were
analyzed by Western blotting with antibodies against the indicated proteins. Images are
representative of three biological replicates. (D) H1666 cells were treated with up to 010 μM gefitinib for 48 hrs, and lysates were analyzed by Western blotting with antibodies
against indicated proteins. Images are representative of three biological triplicates.
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Figure S2-17: SHP2 is not required for HGF-mediated rescue of ERK
phosphorylation in NSCLC cells treated with gefitinib.
H1666 and HCC827 cells expressing SHP2-targeting or control shRNA were treated with
1 μM gefitinib, with or without 50 ng/mL HGF, for 6 hrs. Lysates were analyzed by
Western blotting with antibodies against indicated proteins.
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Figure S2-18: SHP2 is basally associated with GAB1 and pEGFR in H1781 cells.
Serum-starved H1781 cells were treated with or without 10 ng/mL EGF for 5 min and
lysed. SHP2 was immunoprecipated from whole cell lysates, and immunoprecipitates
were analyzed by Western blotting using antibodies against the indicated proteins.
Images are representative of three biological replicates.
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Chapter 3: Multivariate Signaling Regulation by SHP2
Differentially Controls Proliferation and Therapeutic
Response in Glioma Cells2

3-1 ABSTRACT
Information from multiple signaling axes is integrated in the determination of
cellular phenotypes. Here, we demonstrate this aspect of cellular decision making in
glioblastoma multiforme (GBM) cells by investigating the multivariate signaling
regulatory functions of the protein tyrosine phosphatase SHP2.

Specifically, we

demonstrate that SHP2’s ability to simultaneously drive ERK and antagonize STAT3
pathway activities produces qualitatively different effects on the phenotypes of
proliferation and resistance to EGFR and c-MET co-inhibition. While the ERK and
STAT3 pathways independently promote proliferation and resistance to EGFR and cMET co-inhibition, SHP2-driven ERK activity is dominant in driving cellular
proliferation, and SHP2’s antagonism of STAT3 phosphorylation prevails in promoting
GBM cell death in response to EGFR and c-MET co-inhibition. Interestingly, the extent
of these SHP2 signaling regulatory functions is diminished in glioblastoma cells
expressing sufficiently high levels of the EGFR variant III (EGFRvIII) mutant, which is
commonly expressed in GBM. In cells and tumors expressing EGFRvIII, SHP2 also
antagonizes EGFRvIII and c-MET phosphorylation and drives expression of HIF-1/2α,
adding complexity to the evolving understanding of SHP2’s regulatory functions in
GBM.
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3-2 INTRODUCTION
Cells integrate information from multiple signaling pathways to execute decisionmaking processes [100-103].

While some signaling pathway intermediates act

predominantly in one pathway, others exert substantial effects in multiple pathways, thus
expanding their ability to control cell fate determination. One such protein is SH2
domain-containing phosphatase-2 (SHP2), which plays key roles in development,
homeostatic maintenance, and disease.

Here, we investigate SHP2’s ability to

simultaneously regulate the extracellular signal-regulated kinase (ERK) and signal
transducer and activator of transcription-3 (STAT3) pathways, as well as other signaling
events that we identify as SHP2-regulated for the first time, and the net effect of this
regulation on cellular proliferation and response to co-inhibition of EGFR and the HGF
receptor c-MET.
SHP2 was the first phosphatase to be identified as a proto-oncogene [68, 84], and
it is primarily regarded as a mediator of pro-survival signaling. Indeed, SHP2’s most
well-studied signaling role is to promote ERK activity [28]. SHP2’s catalytic activity,
which is required for this function, is promoted through engagement of its N-terminal
SH2 domains by phosphotyrosines on various receptor tyrosine kinases or adapter
proteins such as GRB2 associated binding protein-1 (GAB1) [28, 52]. SHP2 can also
negatively regulate STAT3 activation downstream of the interleukin-6 receptor [104],
and one recent study even described a “tumor-suppressor” role for SHP2 in
hepatocellular carcinoma through its regulation of STAT3 [105].

SHP2 can also

positively or negatively impact AKT pathway activity [58, 106]. Through these signaling
regulatory functions, the magnitude of which may depend on cell type or disease context,

64

SHP2 is able to control cellular phenotypes including proliferation [107, 108], oncogenic
transformation [73], tumor progression [109], response to therapeutics [108], and
senescence [80].
A specific setting of interest where SHP2 influences multiple complex phenotypes
is glioblastoma multiforme (GBM), the most common and lethal form of adult brain
cancer [36]. One study described SHP2’s ability to suppress cellular senescence in the
GBM cell lines U87MG and A172 and reported simultaneous SHP2-mediated ERK
activation and STAT3 inhibition, though no causal relationships between ERK or STAT3
signaling and the senescence phenotype were established [80]. SHP2 function has also
been linked to tumorigenicity of GBM cells expressing EGFR variant III (EGFRvIII), a
mutant prevalent in GBM [73]. Of course, ERK and STAT3 are both well-described as
promoting proliferation and survival across cancer types [110, 111]. For example, in
GBM cells, ERK activity promotes resistance to cisplatin [112], and STAT3 is an
important regulator of proliferation that has been recognized as a potential therapeutic
target [47, 81]. Since SHP2 regulates the ERK and STAT3 pathways in qualitatively
different ways, and since the ERK and STAT3 signaling pathways promote qualitatively
similar effects across multiple phenotypes, how SHP2’s multivariate signaling roles are
integrated to determine phenotype in GBM cells remains unclear. A more complete
understanding of this could help address a number of outstanding issues, including the
identification of ways to overcome GBM resistance to targeted inhibitors [37, 113, 114]
and the potential efficacy of targeting SHP2 in glioblastoma.
Here, we evaluate the effects of SHP2’s signaling roles on GBM cell proliferation
and resistance to inhibitors of EGFR and c-MET, oncogenic receptors that drive GBM
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progression and chemoresistance. In a panel of GBM cells, SHP2 depletion reduced
cellular proliferation but surprisingly also promoted resistance to EGFR and c-MET coinhibition.

These results appear to derive from SHP2’s ability to drive ERK and

antagonize STAT3 pathway activities in the panel of cell lines and the differential
abilities of those pathways to control different phenotypes. That is, even though ERK
and STAT3 both promote proliferation and survival, SHP2-mediated ERK activity is
dominant in determining cellular proliferation rates, while SHP2 suppression of STAT3
phosphorylation exerts the dominant effect in determining response to EGFR and c-MET
co-inhibition.

Interestingly, SHP2’s ability to regulate these pathways was greatly

diminished in cells with sufficiently high EGFRvIII expression, where SHP2 became
basally sequestered with the receptor. We further found that SHP2 negatively regulates
EGFRvIII and c-MET phosphorylation and drives expression of hypoxia-inducible
factors 1 and 2 alpha (HIF-1/2α in cultured cells and tumor xenografts. These results
expand our understanding of SHP2 as a multivariate regulator of signaling and GBM cell
phenotype and raise additional questions about how SHP2 function may be perturbed in
different GBM contexts.

66

3-3 MATERIALS AND METHODS
Cell culture. LN18, T98G, and U118MG cells were obtained from the American
Type Culture Collection (Manassas, VA, USA).

U87MG parental cells and cells

expressing low (1×106 receptors/cell), medium (1.5×106 receptors/cell), or high (2×106
receptors/cell) levels of EGFRvIII (U87MG-L, -M, and -H, respectively) or a dead kinase
mutant of EGFRvIII (U87MG-DK, 2×106 receptors/cell) were a generous gift from Dr.
Frank Furnari (University of California San Diego). All cells were maintained in DMEM
supplemented with 10% FBS, 1 mM L-glutamine, 100 units/mL penicillin, and 100
μg/mL streptomycin. U87MG cells expressing EGFRvIII were cultured with 400 μg/mL
G418. Where indicated, cells were treated with EGF (Peprotech, Rocky Hill, NJ, USA)
following 8-16 hrs starvation in media containing 0.1% FBS. All cell culture reagents
were from Life Technologies (Carlsbad, CA, USA).

For experiments in hypoxic

conditions, cells were cultured for 24 hrs in 0.5% O2 using an Invivo2 400 hypoxia
workstation (Ruskinn Technology, Grandview, MO, USA) prior to lysis.
shRNA and stable expression constructs. DNA oligonucleotides encoding short
hairpins targeting human SHP2 (Integrated DNA Technologies, San Jose, CA, USA)
were cloned into the pSicoR vector (Tyler Jacks, MIT; [86]). The main shRNA targeted
nucleotides 1780-1798 of SHP2 mRNA (5’-GGACGTTCATTGTGATTGA-3’). Control
vectors were created using shRNA sequences that do not target a known human mRNA.
We also used an alternative, non-overlapping SHP2 shRNA targeting nucleotides 58905908 (5’-GTATTGTACCAGAGTATTA-3’) of human SHP2 in a cell proliferation
experiment in the presence of drugs (Figure S3-9A). Combined with the data showing
the effects of SHP2E76A expression, the data in Figure S3-9A help to demonstrate the
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SHP2 specificity of effects observed using the primary SHP2-targeting hairpin. To
engineer cells with shRNA expression, lentivirus was produced by calcium phosphatemediated transfection of 293FT cells (Life Technologies) with pSicoR plasmids along
with the packaging plasmids pCMV-VSV-G, pMDL-gp-RRE, and pRSV-Rev (Dr.
Marilyn Farquhar, University of California San Diego). Virus was collected 48 and 72
hrs post-transfection and filtered using 0.45 µm syringe filters prior to infecting target
cells.
SHP2 cDNA encoding SHP2E76A (Ben Neel, Ontario Cancer Institute) was
inserted at the EcoRI site of the pBabe vector. Retrovirus was produced by calcium
phosphate-mediated transfection of amphotropic Phoenix cells (Dr. Gary Nolan, Stanford
University) with vector. Virus was harvested 24, 30, and 48 hrs post-transfection and
used to infect target cells, which were selected in 2 μg/mL puromycin (Sigma-Aldrich,
St. Louis, MO, USA).

All expression and shRNA constructs were validated by

sequencing, and protein knockdown was validated by western blot.
Transient expression of wild-type or substrate-trapping SHP2. Expression
constructs for wild-type and substrate-trapping double mutant (DM; D425A/C459S)
SHP2 in the pMT2 vector backbone were provided by Dr. Yehenew Agazie (West
Virginia University). U87MG cells were transfected with pMT2 plasmids using calcium
phosphate.

Cells were lysed in immunoprecipitation lysis buffer (Cell Signaling

Technology, Danvers, MA, USA; #9803) 48 hrs after transfection.
Inhibitors. Stocks of gefitinib (LC Laboratories, Woburn, MA, USA), U0126 (LC
Laboratories), CI-1040 (LC Laboratories), PHA665752 (Santa Cruz Biotechnologies,
Dallas, TX, USA), and Stattic (Sigma-Aldrich) were prepared in DMSO.
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Cell death quantification. Cells were seeded at a density of 75,000-100,000
cells/well in six-well dishes and treated 24 hrs later with different combinations of
gefitinib, PHA665752, CI-1040, and Stattic or DMSO (control). After 72-96 hrs, floating
and adherent cells were pooled and stained for permeability to TO-PRO-3 (Life
Technologies). Cells were analyzed by flow cytometry within 1 hr of resuspension.
Flow cytometry was performed on a Becton Dickinson Biosciences FACSCalibur
cytometer, and data were analyzed using FlowJo.
Proliferation measurements. Cells were seeded at an initial density of 75,000 or
100,000 cells/well in six-well dishes. After growing for 72 hrs, cells were trypsinized,
suspended in complete media, and counted using a hemocytometer.
XTT viability assay. Cell proliferation in the presence of inhibitors was assessed
using the XTT Cell Proliferation Assay (Roche, Indianapolis, IN, USA).

Cells were

seeded in 96-well plates, grown for 16-24 hrs, and switched to complete media
containing up to 20 µM gefitinib and/or 1 μM PHA665752 for an additional 3 days.
Subsequently, fresh media and XTT reagent were added to wells, and plates were
incubated for 2-4 hrs at 37°C to maximize signal-to-background. Absorbance was
measured at 450 nm with a reference wavelength at 660 nm. The percentage of viable
cells was determined by normalizing absorbance to that of cells treated with DMSO.
Each experiment was performed on at least three separate days with each condition
plated in three replicate wells on each day, except where noted.
Tumor xenografts. Female Nu/Nu mice (Charles River, Wilmington, MA, USA)
were subcutaneously injected in both flanks with control or SHP2-depleted U87MG-M
cells (control shRNA: 750,000 cells; SHP2 shRNA: 2,500,000 cells). The difference in
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injected cell numbers was based upon observations of different rates of proliferation in
vivo and in vitro with or without SHP2 knockdown. When tumors reached an average
size of 50 mm3 (achieved by control tumors only), 7 day treatment with gefitinib and
PHA665752 (Selleck Chemicals, Houston, TX, USA) began. Gefitinib was resuspended
in an aqueous solution containing 0.5% hydroxypropylmethylcellulose (Sigma-Aldrich)
and 0.1% Tween-80 (Sigma-Aldrich), and was delivered at 100 mg/kg/day daily by oral
gavage. PHA665752 was resuspended in an aqueous solution containing 1% dimethyl
acetamide (Sigma-Aldrich), 10% propylene glycol (Sigma-Aldrich), and 1.05 moles Llactic acid (Sigma-Aldrich) per mole of PHA665752, and was delivered at 30 mg/kg/day
daily by intraperitoneal injection. Tumors were measured with a caliper before and
throughout treatment, and tumor volume was calculated as π/6 × A × 2B, where A and B
are the larger and smaller tumor diameters, respectively.

Excised tumors were

homogenized in immunoprecipitation lysis buffer before proceeding with western
blotting. All experiments were approved by the University of Pennsylvania Institutional
Animal Care and Use Committee and performed in accordance with NIH guidelines.
Subcellular fractionation. Serum-starved cells were washed with PBS and
collected in hypotonic buffer (10 mM Tris-HCl, pH 7.4, 1 mM MgCl2, 1 mM EDTA)
supplemented with 1 mM PMSF, additional protease inhibitors, and phosphatase
inhibitors. Crude lysates were generated with a Dounce homogenizer and centrifuged at
3,000 and 9,300 rpm, for 5 min at each speed, to remove nuclei and mitochondria,
respectively. Cleared lysates were centrifuged at 100,000 g for 60 min to separate
membrane and cytosol fractions. Membrane pellets were washed with PBS, resuspended
in hypotonic buffer, and centrifuged again at 100,000 g.

70

After additional washes,

membrane pellets were resuspended in immunoprecipitation lysis buffer to solubilize
proteins. To improve signals, membrane fractions were 10× more concentrated than
cytosolic fractions in terms of the relative amount of total lysate loaded.
EGF internalization assay. EGF-mediated EGFR endocytosis rate constants (ke)
were measured using 125I-EGF as described previously [115, 116].
Western blotting. Whole cell lysates were prepared in a standard cell extraction
buffer (Life Technologies; FNN0011) prepared with protease inhibitors and phosphatase
inhibitors (Sigma-Aldrich). Lysates were cleared by centrifugation at 13,200 rpm for 10
min, and total protein concentrations were determined by micro-bicinchoninic acid
(BCA) assay (Thermo Fisher Scientific, Waltham, MA, USA). Proteins were resolved on
4-12% gradient polyacrylamide gels (Life Technologies) under denaturing and reducing
conditions and transferred to 0.2 μm nitrocellulose membranes (Bio-Rad Laboratories,
Hercules, CA, USA).

Membranes were imaged using a LI-COR Odyssey Imaging

System. As needed, membranes were stripped with 0.2 M NaOH.
Immunofluorescence. Cells were seeded at 150,000 cells/well on 18 mm glass
coverslips in six-well culture dishes. After serum starvation for 16 hrs, cells were treated
with 10 ng/mL EGF for up to 30 min. Cells were then washed and fixed for 20 min in
4% paraformaldehyde and permeabilized with 0.25% Triton X-100 in PBS for 5 min.
Coverslips were again washed and incubated with the SHP2 antibody in a humidified
chamber for 3 hrs at 37ºC. Washed coverslips were incubated with Alexa Fluor 488conjugated secondary antibody (Life Technologies) and Hoescht DNA stain (SigmaAldrich) for 1 hr at 37ºC. Coverslips were mounted on microscope slides using Prolong
Gold Antifade mounting media (Life Technologies) and dried overnight. Fixed slides
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were imaged on a Zeiss Axiovert 40 CFL microscope using an A-Plan 100X oil objective
and a SPOT Insight CCD camera.

Specificity of the SHP2 antibody for

immunofluorescence was verified using U87MG-M cells with or without SHP2
knockdown (supplementary material Fig. S3C).
Immunoprecipitation. Cells were lysed in immunoprecipitation lysis buffer, with
1 mM PMSF, protease inhibitors, and phosphatase inhibitors. After lysate centrifugation
at 13,200 rpm and 4°C for 10 min and determination of protein concentrations by BCA
assay, 400-500 μg of protein was incubated with agarose beads conjugated to SHP2 or
STAT3 antibodies at 4°C overnight. Beads were washed three times with cold lysis
buffer, re-suspended in LDS sample buffer (Life Technologies) and boiled before western
blotting. Immunoprecipitation specificity was validated with comparisons to a rabbit
control antibody (IgG; Santa Cruz Biotechnology) (supplementary material Fig. S2D,
S3A, S4C).
Antibodies. EGFR (#2232), c-MET pY1234/1235 (#3126), STAT3 pY705
(#9145), ERK (#4695), and ERK pT202/Y204 (#4377) antibodies were from Cell
Signaling Technology. SHP2 (sc-280) and STAT3 (sc-482) antibodies were from Santa
Cruz Biotechnology.

Actin (MAB1501) and GAB1 (#06-579) were from Millipore

(Billerica, MA, USA). EGFR pY1068 (#1727) was from Epitomics (Burlingame, CA,
USA). Antibodies against HIF-1α (#10006421) and HIF-2α (NB100-122) were from
Cayman Chemical (Ann Arbor, MI, USA) and Novus Biologicals (Littleton, CO, USA),
respectively.

Infrared dye-conjugated secondary antibodies were from Rockland

Immunochemicals (Gilbertsville, PA, USA).
manufacturers’ recommendations.

72

All antibodies were used according to

Statistics. Statistical analyses were performed using a paired two-tailed student’s
t-test.
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3-4 RESULTS
SHP2 depletion differentially impacts key GBM cell phenotypes and associated
signaling pathways. In the GBM cell lines U87MG, LN18, T98G, and U118MG, we first
evaluated the effect of shRNA-mediated SHP2 knockdown on cellular proliferation. As
expected based on reports in other glioblastoma cells [73] and numerous other cell
settings, SHP2 knockdown reduced cellular proliferation rates in all four cell lines
(Figure 3-1A). Interestingly, SHP2 knockdown also promoted cell survival in response
to co-inhibition of EGFR and c-MET using the inhibitors gefitinib and PHA665752
(Figure 3-1B).

Thus, in response to SHP2 knockdown, cells were generally less

proliferative, but significantly more resistant to EGFR and c-MET co-inhibition. The
latter effect was unexpected given previous findings that SHP2 knockdown enhances
death response to EGFR inhibition in non-small cell lung cancer (NSCLC) cells [108]
and that SHP2 antagonizes p73-dependent apoptosis [117].

Western blot analysis

revealed that SHP2 knockdown was accompanied by decreases in ERK phosphorylation
and simultaneous increases in STAT3 phosphorylation (Figure 3-1C), which could
explain how proliferation was impeded while survival in response to EGFR and c-MET
co-inhibition could be enhanced.

That is, ERK activity could contribute more

significantly to determining proliferation rates, and STAT3 activity could contribute
more significantly to survival response to EGFR and c-MET co-inhibition.
To explore that idea further, we used the data from Figures 3-1A-C to assign
quantitative values to the individual contributions of SHP2-controlled ERK and STAT3
activation toward cellular proliferation and survival. We assumed that the quantitative
measure of a particular phenotype Xi for a particular cellular condition i (in this case,
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control or SHP2 knockdown) can be described as a linear combination of the
phosphorylation levels of ERK and STAT3, pE,i and pS,i, respectively, where the
contribution of each pathway to Xi is determined as the product of a weighting coefficient
for ERK or STAT3, wE or wS, respectively, and the phosphorylation level of the protein.
With these assumptions, Xi takes the form:

( )

( )

X i = wE pE ,i + wS pS ,i

To evaluate pathway contributions to survival response to therapeutics, the percentages of
dead cells shown in Figure 3-1B were subtracted from 100%. Phosphorylated ERK and
STAT3 signals were normalized to the corresponding total protein signals, as in Figure 31C. Finally, phosphorylation and phenotype data were normalized to values from control
shRNA cells for each cell line, which leads to wE and wS summing to unity when the
equation above is evaluated for the control condition. Performing the analysis for the
proliferation phenotype for each cell line and averaging, we found average wE and wS
values of 0.77 and 0.23, respectively. For cell survival response to combined EGFR and
c-MET inhibition, we found average wE and wS values of -0.14 and 1.14, respectively.
These results suggest that ERK and STAT3 play dominant roles in proliferation and
survival responses, respectively. We note that a negative value for wE in the survival
analysis may seem to suggest that ERK activity somehow negatively contributes to cell
survival, but this is not the case. Rather, this result arises due to the form of our model
structure, which produces a wE < 0 whenever the fold-increase in survival exceeds the
fold-increase in STAT3 phosphorylation and the fold-increase in ERK phosphorylation
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does not exceed that for STAT3 phosphorylation, which is the case for three of the four
cell lines analyzed.

Figure 3-1: SHP2 knockdown differentially impacts GBM cell proliferation and
survival.
(A) U87MG, LN18, T98G, and U118MG cells expressing control or SHP2-targeting
shRNA were seeded at 100,000 cells/well and cells were counted 72 hrs later. Counts are
represented as mean ± s.e.m. (n = 3); * denotes p < 0.05. (B) The indicated cell lines were
co-treated with 20 μM gefitinib (G) and 1 μM PHA665752 (P). After 72 hrs, the
percentage of TO-PRO-3-positive cells was measured by flow cytometry (n = 3); *
denotes p < 0.05. (C) The indicated cell lines were maintained in complete media, and
lysates were analyzed by western blotting using antibodies against the indicated proteins.
Densitometry data are represented as mean ± s.e.m. (n = 3); * denotes p < 0.05.
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ERK and STAT3 inhibition further suggests differential pathway control of
proliferation and survival in GBM cells. We next used the ERK and STAT3 inhibitors
CI-1040 and Stattic to confirm experimentally the pathways’ relative contributions to cell
phenotypes. Cellular proliferation was reduced with either ERK or STAT3 pathway
inhibition (Figures 3-2A-B and S3-8A). Note that the incomplete inhibition of STAT3
Y705 phosphorylation (37% reduction) observed in Figure 3-2B resulted from our
selection of a STAT3 inhibitor concentration that was low enough to produce relatively
low cell death as a single agent across the panel of cell lines.

Using a lower

concentration of gefitinib than in Figure 3-1B to reduce baseline cell death, we also found
that ERK or STAT3 inhibition promoted cell death response to EGFR and c-MET coinhibition (Figure 3-2C). With the exception of U118MG cells where Stattic produced a
substantial amount of cell death by itself, the effect of ERK inhibition on proliferation
was generally greater than that of STAT3 inhibition. Conversely, the effect of STAT3
inhibition on death response to gefitinib and PHA665752 was larger than that of ERK
inhibition. Given that the same concentrations of CI-1040 and Stattic were used in
Figures 3-2A and 3-2C, we interpret these data as indicating that both the ERK and
STAT3 pathways participate in regulating cellular proliferation and survival, but
confirming the weighting coefficient analysis that ERK is the stronger determinant of
proliferation and STAT3 the stronger determinant of survival response to EGFR and cMET co-inhibition.

This suggests that the elevated phosphorylated STAT3 levels

observed with SHP2 knockdown promoted resistance to EGFR and c-MET co-inhibition
despite the impairment of ERK activity.
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To confirm this, we demonstrated that

combining Stattic with the concentrations of gefitinib and PHA665752 used in Figure 31B increased cell death response of cells with SHP2 knockdown (Figure 3-2D).
We note as well that, in some cell lines, increases in STAT3 Y705
phosphorylation may involve a mechanism wherein ERK negatively regulates STAT3
Y705 phosphorylation by phosphorylating STAT3 S727 [118].

Evidence for this

potential connectivity between ERK and STAT3 is provided by our finding that MEK
inhibition promoted STAT3 phosphorylation in some cell lines (Figure S3-8B).
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Figure 3-2: ERK and STAT3 pathways both control proliferation and survival of
GBM cells.
(A) U87MG, LN18, T98G, and U118MG cells were seeded at 100,000 cells/well and
treated 24 hrs later with 6 μM CI-1040 (C), 4 μM Stattic (S), or DMSO control for 72 hrs
prior to cell counting. Counts are represented as mean ± s.e.m. (n = 3); * denotes p <
0.05. (B) The indicated cell lines were treated with the same inhibitor concentrations as in
panel (A) for 30 min prior to lysis. Lysates were analyzed by western blotting with
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antibodies against the indicated proteins. Images are representative of three sets of
biological replicates. (C) The indicated cell lines were treated with the indicated
combinations of 10 μM gefitinib (G) and 1 μM PHA665752 (P), 6 μM CI-1040 (C), 4
μM Stattic (S), or DMSO. Gefitinib concentration was lower compared to Figure 3-1 and
(D) below to reduce cellular death in response to G and P. After 96 hrs, the percentage of
TO-PRO-3-positive cells was measured by flow cytometry (n = 3); * denotes p < 0.05.
(D) The indicated cell lines expressing control or SHP2-targeting shRNA were treated
with the indicated combinations of 20 μM gefitinib (G) and 1 μM PHA665752 (P), 4 μM
Stattic (S), or DMSO. After 72 hrs, the percentage of TO-PRO-3-positive cells was
measured by flow cytometry (n = 3); * denotes p < 0.05.

SHP2’s ability to regulate signaling and phenotypes is modulated by elevated
EGFRvIII expression. To evaluate SHP2’s regulatory functions in the context of
EGFRvIII expression, we stably depleted SHP2 in a panel of U87MG cells expressing
low, medium, or high levels of EGFRvIII or a high level of kinase-dead EGFRvIII
(U87MG-L, -M, -H, and -DK, respectively) [48]. SHP2 depletion reduced proliferation
in all four cell lines (Figure 3-3A). Similar to effects observed in Figure 3-1B, SHP2
knockdown also promoted survival in response to EGFR and c-MET co-inhibition in
U87MG-DK, -L, and -M cells, but there was no effect in U87MG-H cells Figure 3-3B).
To confirm specificity of the effects of SHP2 knockdown, we used an additional, nonoverlapping SHP2 shRNA to deplete SHP2 in U87MG-M cells, where cells with SHP2
knockdown were once again more resistance to EGFR and c-MET co-inhibition (Figure
S3-9A). To understand the basis for the lack of effect of SHP2 knockdown on survival
response in U87MG-H cells, we first probed signaling pathways by western blot in
resting cells (Figures 3-3C and S3-9B). STAT3 phosphorylation was increased by SHP2
depletion in all cell lines, including U87MG-H, which was surprising given our previous
80

findings that STAT3 controls survival response and that SHP2 knockdown did not rescue
U87MG-H cells from gefitinib and PHA665752 co-treatment. We also noticed reduced
ERK phosphorylation in all cell lines with SHP2 knockdown, although the reduction in
ERK phosphorylation in U87MG-H cells was very modest, an effect which we explore
further in Figure 3-4. In addition, we noticed potential effects of SHP2 knockdown on
the expression and phosphorylation of EGFRvIII and on phosphorylation of c-MET,
findings which we also revisit later.
To delve further into the lack of effect of SHP2 knockdown on cellular response
to inhibitors in U87MG-H cells, we compared the effects of SHP2 knockdown in
U87MG-M and -H cells co-treated with gefitinib and PHA665752 (Figures 3-3D and S39C).

Interestingly, in the presence of the inhibitors, SHP2 depletion significantly

increased STAT3 phosphorylation in U87MG-M cells, but had essentially no effect in
U87MG-H cells. Since STAT3 can be activated through direct binding with EGFR [81,
119] or EGFRvIII [120], we hypothesized that elevated STAT3 Y705 phosphorylation is
EGFRvIII-dependent in SHP2-depleted U87MG-H cells but potentially EGFRvIIIindependent in SHP2-depleted U87MG-M cells.

This scenario would lead to a

preferential reduction in STAT3 phosphorylation with EGFR inhibition in U87MG-H
cells. Consistent with this model, STAT3-pEGFRvIII association was much higher in
U87MG-H cells than in any other line (Figures 3-3E and S3-9D). In U87MG-H cells,
STAT3-pEGFRvIII association was further promoted by SHP2 knockdown, presumably
because of the concomitant increase in phosphorylated EGFRvIII levels observed in that
cell line with SHP2 depletion. The unchanged STAT3-pEGFRvIII association for SHP2depleted U87MG-M cells is consistent with the notion that EGFRvIII is not a primary
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driver of STAT3 phosphorylation below a threshold level of EGFRvIII expression.
Moreover, co-treatment with gefitinib and PHA665752 eliminated STAT3-pEGFRvIII
association in U87MG-H cells, consistent with reduced STAT3 phosphorylation in
response to gefitinib and PHA665752 co-treatment (Figure 3-3E). It should also be noted
that EGFRvIII and c-MET phosphorylation were greatly reduced in cells co-treated with
gefitinib and PHA665752 relative to DMSO-treated cells with or without SHP2
knockdown, which eliminates the possibility that a failure to reduce receptor
phosphorylation was responsible for resistance to EGFR and c-MET co-inhibition with
SHP2 knockdown (Figure S3-9E).

Finally, as in parental U87MG cells, combining

Stattic with gefitinib and PHA665752 enhanced cell death in SHP2-depleted U87MG-M
cells (Figure 3-3F).

82

Figure 3-3: Sufficiently high EGFRvIII expression diminishes the ability of SHP2 to
promote ERK activity and to reduce STAT3 phosphorylation in the presence of
EGFR and c-MET inhibitors.
(A) U87MG-DK, -L, -M, and -H cells expressing control or SHP2-targeting shRNA were
seeded at 75,000 cells/well and were counted 72 hrs later. Counts are represented as mean
± s.e.m. (n = 3); * denotes p < 0.05. (B) The indicated cell lines were co-treated with 20
μM gefitinib (G) and 1 μM PHA665752 (P). After 72 hrs, the percentage of TO-PRO-383

positive cells was measured by flow cytometry (n = 3); * denotes p < 0.05. (C) The
indicated cell lines were grown in complete media for 72 hrs, and lysates were analyzed
by western blotting using antibodies against the indicated proteins. Images are
representative of five sets of biological replicates. (D) U87MG-M and -H cells were cotreated with 20 μM gefitinib (G) and 1 μM PHA665752 (P) for 24 hrs were analyzed by
western blotting using antibodies against the indicated proteins.

Images are

representative of three sets of biological replicates. (E) The indicated cell lines were
treated with or without 20 μM gefitinib (G) and 1 μM PHA665752 (P) for 24 hrs and
lysed. STAT3 immunoprecipitates were analyzed by western blotting using antibodies
against the indicated proteins. Images are representative of three sets of biological
replicates. (F) U87MG-M cells were analyzed as in panel (B) with the addition of 4 μM
Stattic (S) where indicated (n = 3); * denotes p < 0.05.

SHP2 can be sequestered with EGFRvIII at high receptor expression levels. In
the same way that STAT3 can become preferentially bound with EGFRvIII, other
proteins may become EGFRvIII-sequestered when the receptor is expressed at high
levels. We hypothesized that such a preferential binding effect for SHP2 might explain
the modest effect of SHP2 knockdown on ERK phosphorylation in U87MG-H cells as
well as the gradual reduction in basal ERK phosphorylation in control cells with
increasing EGFRvIII expression in Figure 3-3C. Such an effect for SHP2 would be
analogous to one we described in lung cancer cells wherein kinase-activated and
internalization-impaired EGFR mutants appear to sequester adapter-bound SHP2 in such
a way that full ERK activation is prevented [108]. To explore this, we first probed the
basal and EGF-induced associations of SHP2 with GAB1 and EGFRvIII. Increasing
EGFRvIII expression clearly promoted GAB1-SHP2 association (Figure 3-4A and S310A), as well as pEGFRvIII-SHP2 association as previously reported [73]. Although
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GAB1-SHP2 association was EGF-inducible in U87MG-DK, -L, and –M cells, the high
basal association observed in U87MG-H cells was so elevated that it was not augmented
by EGF. We further noted a larger fraction of SHP2 in the membrane compartment along
with EGFRvIII in U87MG-H cells than in -DK cells (Figures 3-4B and S3-10B) with an
approximately 1.5-fold increase in SHP2 signal in the membrane compartment in
U87MG-H cells relative to U87MG-DK cells.

Thus, the activity of the EGFRvIII

receptor can promote sequestration of SHP2 in the membrane fraction. We also found
that elevated EGFRvIII expression altered the basal intracellular distribution of SHP2, as
observed by immunofluorescence. Whereas SHP2 moved from the cell interior toward
the cell periphery in response to EGF in U87MG-L cells, SHP2 was already more
peripherally distributed in U87MG-H cells in the basal condition and did not redistribute
in response to EGF (Figures 3-4C and S3-10C-D). Given that EGF-mediated endocytosis
of wild-type EGFR was significantly reduced in U87MG-H cells (Figure 3-4D), and that
EGFRvIII itself is also endocytosis impaired [45, 46], our data are indeed consistent with
the notion that active adapter- and EGFRvIII-bound SHP2 is sequestered at the plasma
membrane in U87MG-H cells. The effect of this on ERK activation is apparently so
pronounced that ERK phosphorylation cannot be induced in U87MG-H cells by
exogenous EGF, whereas ERK induction does occur in U87MG-DK, -L, and -M cells
(Figures 3-4E and S3-10E). To explore the possibility that altered expression of MKP3,
the primary phosphatase for ERK, was responsible for the failure of ERK to be induced
by EGF in U87MG-H cells, we probed for MKP3 expression across the panel of cells.
However, we observed no trends in MKP3 expression that would explain our data (Figure
S3-10F).
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Figure 3-4: Sufficiently high EGFRvIII expression suppresses EGF-mediated ERK
phosphorylation by SHP2 sequestration.
(A) Serum-starved U87MG-DK, -L, -M, and -H cells were treated with or without 10
ng/mL EGF for 5 min and lysed. SHP2 immunoprecipitates were analyzed by western
blotting using antibodies against the indicated proteins. Images are representative of
three sets of biological replicates. (B) Membrane and cytosolic fractions from serumstarved U87MG-DK and -H cells were analyzed by western blotting using antibodies
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against indicated proteins. Images are representative of four sets of biological replicates.
(C) Serum-starved U87MG-L and -H cells were treated with or without 10 ng/mL EGF
for 5 min, and slides were prepared for SHP2 immunofluorescence. Images are
representative of multiple frames from three biological replicates. (D) EGF endocytosis
rate constants (ke) were measured for the indicated cell lines using

125

I-EGF. Data are

represented as mean ± s.e.m. (n = 6); * denotes p < 0.05. (E) The indicated serumstarved cell lines were treated with 10 ng/mL EGF for up to 15 min and lysates were
analyzed by western blotting using antibodies against the indicated proteins. Images are
representative of three sets of biological replicates.

SHP2 negatively regulates EGFRvIII and c-MET phosphorylation. As
previously noted, the results of Figure 3-3C suggest the potential ability for SHP2 to
regulate EGFRvIII and c-MET phosphorylation. Specifically, the data showed that total
levels of phosphorylated EGFRvIII and c-MET were increased by SHP2 knockdown in
U87MG-H cells, but that EGFRvIII phosphorylation was reduced by SHP2 knockdown
in U87MG-L and -M cells. The apparent effect in U87MG-L and -M cells may arise
because of the concomitant decrease in EGFRvIII expression with SHP2 knockdown,
which may result from impaired ERK activity (Figure S3-11A). To clarify this further,
we ectopically expressed a constitutively active SHP2 (SHP2E76A) in all four cell lines.
This had a minimal effect on EGFRvIII expression, but increased ERK phosphorylation
and reduced EGFRvIII, c-MET, and STAT3 phosphorylation (Figures 3-5A and S3-11B).
SHP2E76A expression also promoted cell sensitivity to gefitinib and PHA665752 cotreatment in U87MG-M cells (Figure 3-5B). To further probe SHP2’s regulation of
EGFRvIII, c-MET, and STAT3, we transiently expressed SHP2WT or the substratetrapping SHP2 double mutant SHP2D425A/C459S (SHP2DM; [121]) in all four U87MG cell
lines.

This double point mutation abrogates SHP2’s catalytic activity and causes
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irreversible binding of the catalytic domain to its substrates. Importantly, expression and
immunoprecipitation of SHP2DM has previously allowed for the identification of direct
substrates of SHP2 including receptors such as EGFRWT and HER2 [96, 121].
Phosphorylated EGFRvIII and c-MET co-immunoprecipitated with SHP2DM (Figures 35C and S3-11C), but STAT3 did not (Figure S3-11D), suggesting that EGFRvIII and cMET may be substrates of SHP2. These specific interactions have not been reported
previously, but it has been reported that SHP2 can directly dephosphorylate other
receptors, including HER2 [96], based on experiments using SHP2DM.
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Figure 3-5: SHP2 mutant expression reveals negative regulation of EGFRvIII, cMET, and STAT3 phosphorylation.
(A) Lysates of U87MG-DK, -L, -M, and -H cells transduced with an empty pBabe vector
(pBP) or SHP2E76A (E76A) and grown in full media for 72 hrs were analyzed by western
blotting using antibodies against the indicated proteins. Images are representative of
three sets of biological replicates. (B) U87MG-M cells transduced with pBP or SHP2E76A
were co-treated with 20 μM gefitinib (G) and 1 μM PHA665752 (P). After 72 hrs, the
percentage of TO-PRO-3-positive cells was measured by flow cytometry (n = 3); *
denotes p < 0.05. (C) Serum-starved cells of the indicated cell lines transiently
transfected with SHP2WT or the double mutant SHP2D425A/C459S (SHP2DM) were lysed.
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SHP2 immunoprecipitates were analyzed by western blotting using antibodies against the
indicated proteins. Images are representative of three sets of biological replicates.

SHP2 knockdown impedes tumor xenograft growth and expression of hypoxiainducible factors. Female Nu/Nu mice were injected subcutaneously in both flanks with
U87MG-M control or SHP2 knockdown cells. Tumors arising from control cells grew
well and were highly responsive to gefitinib and PHA665752 co-treatment (Figures 36A-B), suggesting that this co-treatment strategy can be effective in EGFRvIIIexpressing GBM.

We had hoped to be able to grow tumors arising from SHP2

knockdown cells to probe for the potential ability of SHP2 depletion to promote tumor
resistance to gefitinib and PHA665752 co-treatment. However, after reaching an average
maximum volume of 40 mm3, tumors arising from cells with SHP2 knockdown gradually
shrank and never reached a sufficient size to begin treatment (Figure 3-6B).
Interestingly, HIF-1α and HIF-2α expression was reduced in tumors arising from SHP2
knockdown cells compared to controls (Figure 3-6C), which may explain their failure to
form tumors. In vitro studies revealed a similar effect of SHP2 knockdown on HIF-2α
expression under hypoxic and normoxic conditions and on HIF-1α expression for
normoxic culture (Figure 3-6D). Control cells treated with the MEK inhibitor U0126
displayed diminished HIF-1α expression in normoxia and HIF-2α expression in both
normoxia and hypoxia, suggesting that SHP2’s regulation of ERK is involved in
controlling HIF-1/2α expression.

90

Figure 3-6: Gefitinib and PHA665752 co-treatment or SHP2 knockdown impairs
U87MG tumor xenograft growth.
Mice were subcutaneously injected with control or SHP2-depleted U87MG-M cells.
When tumors reached an average size of 50 mm3 (control shRNA only), mice were
treated with vehicle or 100 mg/kg gefitinib (G) and 30 mg/kg PHA665752 (P) daily for 7
days (treatment initiation indicated by black arrow). (A) After treatment concluded,
pictures were taken and tumors were harvested. (B) Tumor volumes were measured
before and throughout treatment. Data are shown as mean ± s.e.m. (control shRNA:
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vehicle, SHP2 shRNA: no treatment, control shRNA: G + P; n = 12, 26, and 14 tumors,
respectively). (C) Tumor lysates were analyzed by western blotting using antibodies
against the indicated proteins. Densitometry data are shown as mean ± s.e.m. (n = 3). (D)
U87MG-M cells with control or SHP2-targeting shRNA were pretreated with DMSO or
40 μM U0126 (control shRNA only) for 24 hrs prior to hypoxic culture for 24 hrs.
Lysates were analyzed by western blotting using antibodies against the indicated proteins.
Densitometry data are shown as mean ± s.e.m. (n = 3); * denotes p < 0.05.
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3-5 DISCUSSION
Our results demonstrate for the first time that SHP2’s ability to exert multivariate
control over signaling in GBM cells enables it to regulate simultaneously and
differentially the phenotypes of proliferation and resistance to therapy. This effect arises,
at least in part, because ERK and STAT3, which are regulated in qualitatively different
ways by SHP2, play dominant roles in the regulation of proliferation and therapeutic
resistance, respectively. We uncovered a number of other previously undocumented
SHP2 regulatory functions, including SHP2-mediated antagonism of EGFRvIII and cMET phosphorylation and regulation of HIF-1/2α expression, which may also play roles
in determining GBM cell and tumor phenotypes.

These integrated SHP2 signaling

mechanisms and the ways they impact GBM cell phenotypes are summarized in Figure 37.
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Figure 3-7: Summary of SHP2’s oncogenic and anti-survival functions in GBM cells.
Consistent with its most well described role, SHP2 has oncogenic functions by promoting
the phosphorylation of ERK, which augments expression of EGFRvIII and HIF-1/2α.
Conversely, SHP2 antagonizes survival signaling by apparent activity against EGFRvIII
and c-MET as well as negative regulation of multiple modes of STAT3 phosphorylation.

A focus of our study is the impact of SHP2’s ability to simultaneously promote
ERK activity and suppress STAT3 phosphorylation. It has been shown in other contexts,
and we show it explicitly for GBM cells, that the ERK and STAT3 pathways both
promote proliferation and survival (here in response to EGFR and c-MET co-inhibition).
Overlap in the control of transcriptional events by ERK and STAT3 helps to explain their
overlapping control of phenotypes. For example, ERK and STAT3 both drive expression
of proteins that promote cell cycle progression and proliferation, promote expression of
anti-apoptotic proteins, and down-regulate proteins in apoptotic pathways [122-126].
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This functional overlap in the regulation of broad classes of genes also contains overlap
of specific gene products such as VEGF [122, 124] and c-MYC [124, 126]. Even with
this partial overlap, in GBM cell lines SHP2’s positive regulation of ERK is dominant in
determining the effect of SHP2 expression on cellular proliferation while SHP2-mediated
suppression of STAT3 dominates in determining the effect of SHP2 expression on
cellular sensitivity to EGFR and c-MET co-inhibition.

This updated view of the

consequences of SHP2’s multivariate control of signaling and phenotype fits within the
general paradigm that cells integrate and interpret multivariate signaling information in
different ways in the execution of cellular decisions [100-102].
Other novel aspects of our findings include the discovery that sufficiently high
expression of EGFRvIII diminishes the antagonism of STAT3 phosphorylation in the
presence of kinase inhibitors, in addition to diminishing SHP2’s contributions to ERK
activation, and the mechanisms underlying these effects.

Others have noted a

suppression of ERK activity with EGFRvIII expression [51], but the mechanistic basis
for this had not previously been explored. Our data suggest this effect may be related to a
mechanism we previously elucidated for structurally distinct EGFR mutants in NSCLC
cells wherein the kinase-activated EGFR mutants, which display a reduced ability to
activate ERK and a reduced rate of ligand-mediated endocytosis, also promote basal
sequestration of SHP2 with EGFR and GAB1 at the cell periphery [24, 108]. It is also
interesting to note that in NSCLC cells expressing wild-type EGFR, SHP2 knockdown
promotes response to gefitinib [108], rather than resistance. This presumably occurs
because SHP2 knockdown produces generally small effects on STAT3 Y705
phosphorylation in NSCLC cells [108] by comparison to what we observed here in GBM
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cell lines, further highlighting the contextual dependence of SHP2’s functions.
Interestingly, the ability of EGFRvIII to sequester proteins also underlies loss of SHP2
control of STAT3 phosphorylation in the presence of EGFR and c-MET inhibitors at high
EGFRvIII levels. As we demonstrate in Figure 3-3E, this effect involves a shift in
EGFRvIII’s ability to bind STAT3 when EGFRvIII is expressed at the highest levels. It
is also worth noting that SHP2’s ability to negatively regulate EGFR and c-MET
phosphorylation was most apparent with high EGFRvIII expression. This could also
result from sequestration of active SHP2 at the plasma membrane where it has ready
access to these receptors. We also note that the range of EGFRvIII expression explored
here is consistent with that observed in tumors [34]. Thus, the dependence of SHP2
functions on EGFRvIII expression may be clinically relevant.
There are of course additional signaling pathways regulated by EGFRvIII and
SHP2 that have not been explored here but which could play roles in some apparent
quantitative inconsistencies between the effects of altered SHP2 expression on signaling
pathways and the phenotypic roles we have ascribed to those pathways. One example
pertains to our observations in Figure 3-3 in U87MG-H cells, where control cells were
highly proliferative despite displaying relatively low basal ERK phosphorylation and
SHP2 knockdown produced a modest effect on ERK phosphorylation but a large effect
on proliferation. As just one possible explanation for this, we note that the increased
abundance of EGFRvIII in U87MG-H cells could drive other pathways which may
compensate for ERK in promoting proliferation. If the activities of those other pathways
are also regulated by SHP2 in a way that promotes proliferation, a large drop in
proliferation could still accompany SHP2 knockdown with only a modest effect on ERK.
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In the future, it will be important to probe these issues more broadly and quantitatively in
order to more fully understand the potential impact of targeting SHP2 or EGFRvIII in
GBM.
Our data on the effects of SHP2 knockdown, expression of constitutively active
SHP2, and expression of substrate-trapping SHP2 all suggest that SHP2 negatively
regulates EGFRvIII phosphorylation, potentially through direct interaction.

This

contrasts with previous reports that SHP2-mediated ERK activity increases levels of
phosphorylated EGFRvIII [112]. This discrepancy may be explained by our additional
finding that SHP2-mediated ERK activity enhances EGFRvIII expression, an effect
which has also been noted by others with SHP2 knockdown in certain GBM cell lines
[73]. Thus, SHP2 appears to exert two countervailing effects, either of which may be
dominant, in the determination of total cellular phosphorylated EGFRvIII levels. The
notion that SHP2 can negatively regulate EGFRvIII phosphorylation may seem at odds
with our finding that SHP2 knockdown impairs xenograft growth or the analogous
findings of Zhan et al. (2009) where a catalytically inactive SHP2 was expressed in an
EGFRvIII-positive tumor model. We interpret these aggregate results as indicating that
any potential ability for SHP2 to impair tumorigenesis by negatively regulating
EGFRvIII phosphorylation is trumped by SHP2’s positive regulatory functions in
tumorigenesis, including its apparent ability to control HIF-1/2α expression, at least in
the cell line model used here.
Given ongoing efforts to develop specific SHP2 inhibitors for clinical use, it is
worth noting that two distinct effects of SHP2 inhibition could arise in GBM cells and
tumors.

Based on our results, SHP2 inhibition would be expected to inhibit ERK
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activity, but simultaneously to promote STAT3 phosphorylation. In cell culture, the
integrated effect of these signaling perturbations was to slow cell growth while
simultaneously promoting resistance to EGFR and c-MET co-inhibition. Based on this
alone, it is unclear if SHP2 inhibition would be a useful therapeutic approach. Our
finding that SHP2 controls HIF-1/2α expression and GBM tumor xenograft growth may
obviate potential concerns about the ability of SHP2 inhibition to promote survival
signaling through the STAT3 pathway, but this remains to be demonstrated in more
detailed GBM tumor models that include exploration of the potential ability of very high
EGFRvIII expression to modulate SHP2 function. Assuming that SHP2 function is
indeed controlled by EGFRvIII levels in vivo, recent advances in detecting EGFRvIII
protein through magnetic resonance imaging [127], as opposed to traditional tumor tissue
biopsy approaches, may eventually advance our ability to predict the impact of SHP2
inhibition.
It should also be noted that our xenograft studies suggest promise for combining
EGFR and c-MET inhibitors in EGFRvIII-positive GBM. This has not been previously
demonstrated in vivo, but a previous study did demonstrate the utility of combining an
HGF-targeted antibody with an EGFR inhibitor [43]. Interestingly, the utility of certain
irreversible EGFR inhibitors in EGFRvIII-positive GBM may obviate the need to
combine c-MET and EGFR inhibitors [128]. Whether or not c-MET inhibitors are
needed moving forward, SHP2 inhibitors may eventually be an attractive alternative for
treating GBM where resistance to other inhibitors arises. Of course, our data support the
potential utility of STAT3 inhibitors in treating GBM. STAT3 has previously been
identified as a key regulator of GBM cell survival [47, 81], and at least one clinical trial
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(ClinicalTrials.gov NCT01904123) is scheduled to begin recruiting patients later this
year to test the efficacy of STAT3 inhibition in cancers including GBM.
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3-7 SUPPLEMENTARY MATERIAL

Figure S3-8: ERK and STAT3 inhibition differentially regulate GBM cell
phenotype.
(A) The indicated cell lines were treated with 6 μM CI-1040 (C), 4 μM Stattic (S), or
DMSO control for 30 min prior to lysis. Lysates were analyzed by western blotting using
antibodies against the indicated proteins. Densitometry data are represented as mean ±
s.e.m. (n = 3); * denotes p < 0.05. (B) LN18, T98G, and U118MG cells were treated with
3 μM CI-1040 for up to 360 min, and lysates were analyzed by western blotting using
antibodies against the indicated proteins.
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Figure S3-9: SHP2’s abilities to promote ERK phosphorylation in resting cells and
to antagonize STAT3 phosphorylation in drug-treated cells are diminished with
sufficiently high EGFRvIII expression.
(A) U87MG-M cells expressing a control shRNA or an SHP2 shRNA distinct from the
shRNA used in other experiments were lysed. Lysates were analyzed by western blotting
using antibodies against the indicated proteins. These cells were also treated with the
indicated concentrations of gefitinib (G) and/or PHA665752 (P) for 72 hrs, and cell
proliferation was measured by XTT assay. XTT signal (y-axis) from cells in a given
treatment condition was normalized by the signal measured from cells treated with
DMSO. Data are represented as mean ± s.e.m. for one experiment with six replicate
wells (n = 6); * denotes p < 0.05. (B) Lysates prepared from U87MG-DK, -L, -M, and -H
cells stably expressing control or SHP2-targeting shRNA grown in full media for 72 hrs
were analyzed by western blotting using antibodies against the indicated proteins.
Densitometry data are represented as mean ± s.e.m. (n = 5); * denotes p < 0.05. (C)
U87MG-M and -H cells with or without SHP2 knockdown were co-treated with 20 μM
gefitinib and 1 μM PHA665752 for 24 hrs, and lysates were analyzed by western blotting
using antibodies against the indicated proteins. Due to the large decrease in STAT3
expression in gefitinib/PHA665752-treated U87MG-H cells with SHP2 knockdown,
pSTAT3 was normalized by ERK to compare total relative levels of phospho-STAT3
among cell lines. Data are represented as mean ± s.e.m. (n = 3); * denotes p < 0.05. (D)
U87MG-DK, -L, -M, and -H cells expressing a SHP2-targeting or non-targeting control
shRNA were lysed. Lysates were immunoprecipitated with either a STAT3 antibody or a
control antibody (IgG), and immunoprecipitates were analyzed by western blotting using
antibodies against the indicated proteins. (E) U87MG-DK, -L, -M, and –H cells with or
without SHP2 knockdown were treated with DMSO or 20 μM gefitinib (G) and 1 μM
PHA665752 (P) for 24 hrs, and lysates were analyzed by western blotting using
antibodies against the indicated proteins.
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Figure S3-10: With high levels of EGFRvIII expression, SHP2 becomes increasingly
basally associated with EGFRvIII, SHP2 intracellular distribution is perturbed, and
EGF-mediated ERK induction becomes impaired.
(A) Serum-starved U87MG-DK, -L, -M, and -H cells treated with 10 ng/mL EGF for 5
min were lysed. Lysates were immunoprecipitated with either an SHP2 antibody or a
control antibody (IgG), and immunoprecipitates were analyzed by western blotting using
antibodies against the indicated proteins. (B) Membrane and cytosolic fractions from
serum-starved U87MG-DK and -H cells were analyzed by western blotting. Data are
represented as mean ± s.e.m. (n = 4); * denotes p < 0.05. (C) Slides of serum-starved
U87MG-M cells expressing a non-targeting control shRNA or an SHP2 shRNA were
prepared for SHP2 immunofluorescence and subsequently imaged using the same
exposure time. (D) Serum-starved U87MG-L and -H cells were treated with EGF and
slides were prepared for SHP2 immunofluorescence. Intracellular pixel intensities from
images were quantified as a function of normalized radial distance from cell centers (x =
0) to the cell periphery (x = 1). For seven images per condition, all cells contained within
the image were analyzed. Lines represent mean and shaded areas represent s.e.m. (n ≥ 10
cells). (E) Lysates from serum-starved U87MG-DK, -L, -M, and -H cells treated with or
without 10 ng/mL EGF for up to 15 min were analyzed by western blotting.
Densitometry data are represented as mean ± s.e.m. (n = 3); * denotes p < 0.05 relative to
DK cells. (F) U87MG-DK, -L, -M, and -H were lysed, and lysates were analyzed by
western blotting using antibodies against the indicated proteins. Densitometry data are
represented as mean ± s.e.m. (n = 3).
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Figure S3-11: SHP2 regulatory roles identified by SHP2 knockdown are confirmed
by ectopic expression of SHP2 mutants.
(A) U87MG-M and -H cells with or without SHP2 knockdown treated with 20 μM
U0126 or 3 μM CI-1040 for 24 hrs were lysed. Lysates were analyzed by western
blotting using antibodies against the indicated proteins. (B) U87MG-DK, -L, -M, and -H
cells were transduced with an empty pBabe vector or a pBabe vector encoding SHP2E76A.
Whole-cell lysates prepared from cells grown in complete media for 72 hrs were
analyzed by western blotting using antibodies against the indicated proteins.
Densitometry data are represented as mean ± s.e.m. (n = 3); * denotes p < 0.05. (C)
Serum-starved U87MG-DK, -L, -M, -H cells transiently transfected with SHP2WT or the
double mutant SHP2D425A/C459S (SHP2DM) were lysed. Lysates were immunoprecipitated
with either an SHP2 antibody or a control antibody (IgG), and immunoprecipitates were
analyzed by western blotting using antibodies against the indicated proteins. Images are
representative of three sets of biological replicates. (D) An SHP2 immunoprecipitate
from U87MG-H cells expressing SHP2DM and a cell lysate positive for phospho-EGFR,
phospho-MET, phospho-STAT3, and phospho-ERK were analyzed by western blotting
using antibodies against the indicated proteins.

107

Chapter 4: EGFR-activated Kinases Counteract GAB1
Dephosphorylation to Maintain GAB1-SHP2 Complexes Distal
from EGFR

4-1 ABSTRACT
Multi-membered complexes of signaling proteins nucleated in response to
receptor activation are often represented as static assemblies held together by
phosphotyrosine-SH2 domain and other interactions. However, reversible binding,
phosphatase activity, and other topological details allow for dynamic modes of protein
complex regulation that can significantly impact signal transduction. Here, we explore
these aspects of signaling protein complex regulation using EGFR as a model system.
Specifically, we demonstrate the ability of EGFR-activated SRC family kinases (SFKs)
to repeatedly counteract GAB1 dephosphorylation to maintain the association of SHP2
with phosphorylated GAB1, which promotes SHP2 activity, in the cytosolic compartment
distal from EGFR. Interpretation of our data using a computational model reveals that
SFKs amplify EGFR activity to enable GAB1 phosphorylation and GAB1-SHP2
complexes to decay more slowly than EGFR phosphorylation. Interestingly, this SFKdependent mechanism is not used downstream of c-MET. Thus, our results quantitatively
describe a regulatory mechanism used by some receptors to control signaling complex
persistence remotely.
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4-2 INTRODUCTION
In receptor-mediated cell signaling, outside-in information transfer occurs
because

ligand-receptor

binding

in

the

extracellular

compartment

promotes

intermolecular binding events in the cell interior mediated by phosphotyrosine-SH2
domain and other types of protein-protein interactions. Static textbook representations of
this process belie the fact that phosphotyrosine-SH2 domain interactions (and other
relevant protein-protein interactions) are reversible and relatively weak [64], and that
phosphotyrosines can be regulated by protein tyrosine phosphatases (PTPs) with times
scales that are small compared to the overall time scale for signal transduction [63, 64].
These issues, coupled with sometimes receptor- or cell context-dependent details of how
specific downstream protein-protein interactions are regulated, create complexities that
are typically absent in schematic representations of signaling pathways but which can
have significant impact on signal transduction. Many investigators undoubtedly recognize
these issues, but their full implications on the regulation of signaling protein complexes
and overall signaling dynamics have not been widely pursued or quantitatively
investigated. Here, we explore these issues to understand the ability of the epidermal
growth factor receptor (EGFR) to drive and maintain the association of SRC homology 2
domain-containing phosphatase 2 (SHP2) with the adaptor protein GRB2-associated
binder 1 (GAB1), a binding event that promotes SHP2 activity [52].
SHP2 regulates signaling through numerous pathways, with its most welldescribed function being to promote ERK activity [52]. SHP2 is basally auto-inhibited by
an intramolecular interaction between its N-terminal SH2 domain and its PTP domain
that limits PTP domain access to substrates [52]. Phosphotyrosine engagement of SHP2’s
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SH2 domains relieves this inhibition and activates SHP2 [52]. Downstream of EGFR, the
most common event leading to SHP2 activation involves SHP2 binding to
phosphorylated GAB1, which can complex with EGFR indirectly by binding with the
EGFR adaptor GRB2 and be phosphorylated by receptor tyrosine kinases (RTKs)
including EGFR [52, 65]. SHP2 binding to GAB1 occurs through phosphorylated GAB1
tyrosines 627 and 659, though binding of SHP2’s N-terminal SH2 domain to GAB1
Y627 is thought to be the dominant event in promoting SHP2 activity [52]. Interestingly,
compared to EGF, HGF promotes more sustained phosphorylation of GAB1 and ERK
[89, 129], as well as more substantial redistribution of GAB1 to the cell periphery [130].
Thus, well-characterized differences in ERK activation by different RTKs may involve
spatiotemporal differences in SHP2 engagement by GAB1.
Although GAB1-SHP2 complexes can be observed for 30 min or more in
response to RTK activation [e.g., [55]], the complexes are unlikely to exist in a stable
form for this amount of time since SH2 domain-containing proteins generally dissociate
from phosphotyrosines within seconds after initial complex formation [61, 62]. Given
that EGFR phosphotyrosines can be dephosphorylated with relatively small time scales
[63], it seems likely that similarly rapid regulation of GAB1 tyrosines could occur.
However, the kinetics of GAB1 dephosphorylation have not been quantified. If PTPmediated regulation of GAB1 is relevant during the time scale of overall GAB1-SHP2
complex persistence, re-phosphorylation of GAB1 by a tyrosine kinase could play an
important role in the persistence of GAB1-SHP2 complexes. Moreover, if RTKs were the
only kinases able to play this role, GAB1-SHP2 complexes might exist mainly as
membrane-associated species, as suggested by typical representations of the RTK-GRB2-
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GAB1-SHP2 complex [e.g., [52, 54, 131]]. Conversely, the ability of a cytosolic kinase
to drive GAB1 phosphorylation could extend the effective persistence time and length
scales of GAB1-SHP2 complexes distal from a signal-initiating receptor.
Here, we identify a mechanism in adenocarcinoma cells wherein EGFR regulates
the persistence of GAB1-SHP2 complexes distal from the receptor through many cycles
of GAB1 dephosphorylation by activating SRC family kinases (SFKs), a substantial
fraction of which are present in the cytosol. This picture stands in stark contrast to the
typical view of EGFR-mediated SHP2 activation involving the linear multi-protein
complex consisting of EGFR, GRB2, GAB1, and SHP2. To interpret our data, we
constructed a kinetic model comprised of 386 reactions and characterized by parameters
taken from the literature or fit to our data. To best recapitulate our data, the model
requires that SFKs effectively amplify EGFR activity to buffer GAB1 phosphorylation,
and thus GAB1-SHP2 association, against decreasing EGFR phosphorylation. This
amplification is required even with perturbations to the model topology motivated by
previously described feedback mechanisms involving SHP2’s ability to promote SFK
activity [55, 56] or to dephosphorylate GAB1 [132]. Interestingly, in response to HGF,
GAB1-SHP2 complexes form in an SFK-independent manner and remain in complex
with c-MET, suggesting that the mechanism identified downstream of EGFR may not be
generic. Thus, our findings quantitatively describe a previously undocumented “remote
control” mechanism wherein membrane-associated receptors amplify a signal originating
from the membrane by activating intracellular kinases to regulate the persistence of
functional protein complexes held together by phosphotyrosine-SH2 domain interactions.

111

4-3 MATERIALS AND METHODS
Experiments
Cell culture. H1666 cells (American Type Culture Collection) were maintained in
ACL4 [24]. 293T and HeLa cells (American Type Culture Collection) were maintained
in DMEM supplemented with 10% fetal bovine serum (FBS). For serum starvation, cells
were switched to media containing 0.1% FBS for 16-18 hrs.
Immunoblotting. Cell lysates were prepared using a standard buffer (Cell
Signaling Technology, Danvers, MA, USA; #9803) supplemented with 1 mM PMSF,
additional protease inhibitors (Sigma, St. Louis, MO, USA), and phosphatase inhibitors
(Sigma).

Proteins were resolved by SDS-PAGE and transferred to nitrocellulose

membranes, which were blocked in Odyssey Blocking Buffer (OBB; LI-COR, Lincoln,
NE, USA) and stripped with 0.2 M NaOH as needed. Images were obtained using a LICOR Odyssey Infrared Imaging System.
Immunoprecipitation. Cell lysates were prepared per the immunoblotting
protocol. 500 μg of total protein was incubated at 4°C overnight with agarose beads
conjugated to SHP2 or control antibody. Beads were washed three times with lysis
buffer, re-suspended in LDS sample buffer (Invitrogen), and boiled before
immunoblotting.
Stable shRNA and expression constructs. The pLKO vector containing a short
hairpin

sequence

targeting

the

3’

UTR

of

human

EGFR

(5’-

AGAATGTGGAATACCTAAGG-3’) was provided by Daniel Haber (Harvard Medical
School). Lentivirus was produced by calcium phosphate-mediated transfection of 293FT
cells (Invitrogen, Carlsbad, CA, USA) with vector and the packaging plasmids pCMV-
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VSVG, pMDL-gp-RRE, and pRSV-Rev (Marilyn Farquhar, UCSD). Virus was harvested
48 and 72 hrs post-transfection and used to infect target cells, which were selected in
puromycin. EGFR cDNA encoding Y845F EGFR (Sarah Parsons, University of Virginia)
was inserted in the pMSCV vector. Retrovirus was produced by calcium phosphatemediated transfection of amphotropic Phoenix cells (Gary Nolan, Stanford University)
with vector. Virus was harvested 24, 30, and 48 hrs post-transfection and used to infect
target cells, which were selected in hygromycin. Constructs were validated by
sequencing. EGFR knockdown was validated by Western blot.
Transient expression constructs. The p3xFlag-CMV-7.1 vector containing
SRCY527F cDNA was provided by Todd Miller (Stony Brook University). The pcDNA3
vector containing HA-tagged GAB1 was provided by Toshio Hirano (Osaka University).
Cells were plated in 6-well plates in media lacking antibiotics, and were transfected the
following day with 1 μg SRCY527F DNA and 1 μg GAB1 DNA using 6 μL Lipofectamine
2000 (Invitrogen). Cells were switched to serum-free media 4 hrs later, and treated and
lysed the next day before proceeding to immunoblotting/immunoprecipitation.
pCMV5 vector containing SRCWT and SRCK295R/Y527F cDNA were from Addgene
(Joan Brugge, Harvard University). Cells were plated in 6-well plates in media lacking
antibiotics, and were transfected the following day with 2 μg SRC DNA using 6 μL
Lipofectamine 2000 (Invitrogen). Cells were switched to serum-free media 4 hrs later,
and treated and lysed the next day before proceeding to immunoblotting.
Antibodies and other reagents. EGFR antibody (Ab-12) was from Thermo Fisher
Scientific (Waltham, MA, USA). ERK (#4695), pGAB1 Y627 (#3233), p-MET
Y1234/1235 (#3126), and MET (#8198) antibodies were from Cell Signaling
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Technology. SHP2 (sc-280), GAB1 (sc-9049), SRC (sc-8056; also detects the SFKs YES
and FYN), and GRB2 (sc-255) antibodies were from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Actin (MAB 1501) antibody was from Millipore. pEGFR Y1068
(#1727) antibody was from Epitomics (Burlingame, CA, USA). Infrared dye-conjugated
secondary antibodies were from Rockland Immunochemicals (Gilbertsville, PA, USA)
and Invitrogen, respectively. Gefitinib (LC Laboratories, Woburn, MA, USA), GDC0941 (LC Laboratories), and PP2 (Sigma) were reconstituted in DMSO. Recombinant
human EGF and HGF were from Peprotech (Rocky Hill, NJ, USA). Pervanadate was
prepared as previously described [63].
Subcellular fractionation. Membrane and cytosolic fractions were prepared as
described previously [108].
Statistics. Statistical analyses were performed using a paired two-tailed student’s
t-test.

Computational model
General model considerations and topology. The model consists of a set of
coupled ordinary differential equations to describe the processes leading to EGFR
phosphorylation, but includes the additions of the processes of SFK activation, GAB1
phosphorylation, and EGFR-GRB2, GRB2-GAB1, and GAB1-SHP2 associations. The
model topology leading from EGF binding to EGFR phosphorylation is based in part
upon a previously published model [63]. Essential processes and model parameters are
summarized in Figure 4-5A and Table S4-1, respectively. In total, the model includes 386
reactions, 101 species, and 29 parameters.
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EGF binding and concentration. EGF binding at the plasma membrane was
modeled as a reversible process characterized by association [133] and dissociation [134]
rate constants. EGF was modeled at a constant concentration of 10 ng/mL.
ATP and inhibitor binding. Association and dissociation rate constants for ATP
and gefitinib with EGFR were previously calculated [63]. ATP was assumed to be at a
constant cellular concentration of 1 mM [135]. Gefitinib, when included, was modeled at
a constant cellular concentration of 1 μM.
EGFR dimerization. The EGFR dimerization rate constant was calculated as
described previously [63] assuming 6×105 EGFR per H1666 cell, which was estimated by
a western blot based comparison of total EGFR levels in H1666 cells relative to PC9
cells, for which we have previously determined EGFR levels at the membrane using 125IEGF. Dimer uncoupling rate constants in the presence or absence of EGF were described
previously [136, 137]. All dimer species were assumed to be symmetric, with the
exception of allowing for asymmetric EGF binding.
EGFR phosphorylation. EGFR phosphorylation was modeled as a process which
occurs between ATP-bound EGFR dimers where both receptors are simultaneously
phosphorylated at a representative tyrosine which is able to bind GRB2, with distinct rate
constants for phosphorylation occurring in the presence or absence of EGF [138].
GAB1 phosphorylation. GAB1 phosphorylation at a representative tyrosine
which is able to bind SHP2 was modeled as a process catalyzed by an active SFK.
Because our experimental data suggest SFKs are the primary mediator of GAB1
phosphorylation in H1666 cells, we did not include the possibility of EGFR
phosphorylating GAB1.
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PTP activity. EGFR and GAB1 dephosphorylation were modeled as zeroth order
with respect to PTPs, which precludes the requirement for considering distinct PTP
species.
EGFR degradation. EGFR degradation was modeled as being permitted for any
GRB2-bound EGFR species since GRB2 mediates the interaction of CBL with EGFR,
which plays a primary role in ligand-mediated EGFR degradation [139]. Any proteins
bound to EGFR targeted for degradation were assumed to become instantaneously
unbound from that EGFR species.
GRB2, GAB1, and SHP2 binding. GRB2 was modeled as being able to bind
phosphorylated EGFR using experimentally derived rate constants for association and
dissociation [61]. GAB1 was modeled as being able to bind all GRB2 species through an
SH3 domain-mediated interaction using previously described rate constants for
association and dissociation [140]. SHP2 was modeled as being able to bind
phosphorylated GAB1 using the same association and dissociation rate constants as for
GRB2 binding EGFR, based on an assumption of similar SH2-domain mediated
interactions for GRB2-EGFR and GAB1-SHP2.
SFK activation. The biochemical steps leading to SFK activation are complex,
including separate steps for the dephosphorylation of a C-terminal regulatory tyrosine
(e.g., SRC Y530), autophosphorylation of SRC Y418, and binding of SRC’s SH2 domain
to proteins including EGFR [141]. We simplified this to a first-order rate equation where
phosphorylated EGFR activates SFK, using a previously derived kS,a for EGF-bound
EGFR [138], similar to topologies used in previous models [142]. Even with this
simplification, our model fit is able to accurately recapitulate our experimental data,
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indicating that our approach allows for sufficiently rapid SFK activation to reproduce the
GAB1 phosphorylation kinetics observed experimentally. SFK inactivation was modeled
as having c-SRC kinase (CSK) serve as the reaction enzyme, using a previously derived
kS,i for CSK [143, 144].
Parameter fitting. The four unknown parameters (kG1p, kG1dp, kdp, kdeg) were
determined by fitting the model to data gathered from parental H1666 cells, including the
phosphorylation of GAB Y627 and association of GAB1 with SHP2 in response to 10
ng/ml EGF or EGF chased with 1 μM gefitinib, dephosphorylation dynamics of EGFR in
response to gefitinib, and degradation of EGFR in response to EGF. Parameter fitting was
done using simulated annealing to minimize the total error between model output and
experimental data. Error was computed as the sum of the squares of the differences
between model outputs and the experimental values. The best-fit parameter results are
included in Table S4-1.
Sensitivity analysis. Model sensitivity to changes in parameters was computed by
increasing and decreasing parameter values by a factor of 10. Sensitivity was measured
by summing the integrated differences between the original model and the two perturbed
outputs over time. To compare differences among parameter perturbations, sensitivities
were reported as percentages of the maximum perturbed parameter.
Representative H1666 cell. Calculations reflect 6×105 EGFR per H1666 cell, as
noted previously. GRB2, GAB1, SHP2, SFK, and CSK were also assumed to be at
cellular concentrations of 6×105 species per cell, which is within the range of previously
reported intracellular protein concentrations [140].
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Model implementation. Codes were generated and compiled using the Systems
Biology Toolbox 2 (SBT2) package for MATLAB [145]. The simulannealbnd function in
the Global Optimization Toolbox was used to fit the unknown rate constants to
experimental data.
Process timescale calculations. Various process timescales () were estimated as:
 GAB1 _ phos = [(k G1 p )(aSFKmax )]-1 , where aSFKmax is the maximum concentration of active

SFKs possible in response to EGF (10 ng/mL).
 GAB1,dephosphorylation = kG1dp-1
 EGFR , phosphorylation = kcatE -1

 EGFR ,dephosphorylation = k dp-1
 SHP2 ,binding = [(k S 2 , f )( pGAB1max )]-1 , where pGAB1max is the maximum concentration of

phosphorylated GAB1 possible in response to EGF (10 ng/mL).
 SHP2 ,dissociation = k S 2 ,r -1

 diffusion,i = r 2 / 6Di , where r is the cell radius, and Di is the diffusivity of species i.
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4-4 RESULTS
In response to EGF, SHP2 remains in complex with GAB1 longer than with
EGFR, and GAB1-SHP2 maintenance requires kinase activity to counteract multiple
rounds of GAB1 dephosphorylation. To understand the dynamics of SHP2-containing
protein complex assembly in response to EGFR activation, we probed the
phosphorylation of EGFR Y1068 and GAB1 Y627 over 120 min in response to 10 ng/mL
EGFR in SHP2 immunoprecipitates and whole cell lysates from H1666 lung
adenocarcinoma cells, a cell line where the importance of SHP2 in driving ERK
phosphorylation has been demonstrated [108]. EGFR and GAB1 both associated with
SHP2 in response to EGF, but EGFR was lost more quickly than GAB1 from SHP2
immunoprecipitates, an effect that was most visible by western blot at t = 120 min and
which suggests a change in the stoichiometry of SHP2 complex assembly over time
(Figure 4-1A). In whole cell lysates, we observed measureable amounts of
phosphorylated EGFR at t = 120 min (Figure 4-1B), prompting the question of how and
why EGFR levels were so clearly reduced in SHP2 immunoprecipitates at 120 min.
Similar, but even more pronounced, trends were observed in HeLa cells (Figure S4-8A).
To determine if these findings were related to a potential difference in EGFR and
GAB1 dephosphorylation rates, we measured phosphorylated EGFR and GAB1 levels in
EGF-treated cells chased with 1 µM gefitinib, an EGFR kinase inhibitor. In response to
gefitinib, EGFR dephosphorylation occurred within about 1 min, similar to the rate we
previously observed in HeLa cells [63]. GAB1 dephosphorylation proceeded slightly
more slowly, but the dephosphorylation timescale was one to two min for both proteins
(Figures 4-1C and S4-8B), which is significantly shorter than the timescale with which
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Figure 4-1: Timescales of protein dephosphorylation and signaling complex
disassembly.

120

H1666 cells were treated with 10 ng/mL EGF for up to 120 min, and SHP2
immunoprecipitates (A) or whole cell lysates (B) were analyzed by western blotting with
antibodies against the indicated proteins. (C and D) H1666 cells were treated with 10
ng/mL EGF for 15 or 120 min prior to a 1 μM gefitinib chase for up to 5 min. Whole cell
lysates and SHP2 immunoprecipitates were analyzed by western blotting with antibodies
against the indicated proteins. (E and F) H1666 cells were treated with 10 ng/ml EGF for
up to 15 min, with or without 100 μM pervanadate, followed by a 1 μM gefitinib chase
for 5 min. Whole cell lysates and SHP2 immunoprecipitates were analyzed by western
blotting with antibodies against the indicated proteins. Throughout the figure panels, blot
signals for phosphorylated GAB1 were quantified and normalized by ERK signal (whole
cell lysates) or SHP2 signal (SHP2 immunoprecipitates). All blot images are
representative of three sets of biological replicates, and densitometry data are represented
as mean ± s.e.m. (n = 3); * denotes p < 0.05 when comparing normalized pGAB1 signals
to pEGFR signals at a given time point.

SHP2 appears to stay in complex with GAB1 even without EGFR in the complex. We
also noted that GAB1 remained associated with SHP2 for several min following gefitinib
treatment, at times when EGFR was no longer present in the immunoprecipitated
complex (Figures 4-1D and S4-8C). Using pervanadate as a PTP inhibitor, we also
demonstrated that PTP inhibition resulted in EGFR and GAB1 phosphorylation and
EGFR-SHP2 and GAB1-SHP2 associations that were insensitive to EGFR inhibition
(Figures 4-1E-F). The apparent decreased expression and electrophoretic mobility of
GAB1 with pervanadate treatment have been reported in cells displaying elevated GAB1
phosphorylation [52, 90].
The results shown thus far demonstrate the need for multiple rounds of GAB1 rephosphorylation to counteract the effects of PTPs in the maintenance of GAB1-SHP2
complexes over hours of EGF-mediated signaling. The fact that GAB1 can remain in
121

complex with SHP2 in the absence of EGFR, with GAB1 undergoing many rounds of
dephosphorylation during the time of the maintenance of the complex, may suggest that
kinases other than EGFR may be responsible for playing this re-phosphorylation role.
SRC family kinases are required for EGFR-initiated GAB1 phosphorylation
and maintenance of GAB1-SHP2 association. In COS7 cells, SRC family kinases
(SFKs) play a major role in EGF-mediated GAB1 total tyrosine phosphorylation [52, 66].
We thus explored the possibility that SFKs play a role in maintaining GAB1 Y627
phosphorylation and GAB1-SHP2 association in response to EGF. We used H1666 cells
with stable knockdown of endogenous EGFR and EGFRY845F reconstitution to decouple
SFK activity from regulation of EGFR activity, which arises through SRC’s ability to
phosphorylate EGFR Y845 [146]. Pretreating cells with the SFK inhibitor PP2 prior to
EGF treatment did not affect EGFR phosphorylation, but it greatly reduced GAB1
phosphorylation and GAB1 binding to SHP2 (Figure 4-2A-B). We note that some
pEGFR immunoprecipitated with SHP2 with PP2 treatment, but the amount was reduced
relative to that found without PP2 and also dissociated from SHP2 with similar kinetics
(Figure S4-9A). We interpret this result, which we discuss in further detail later, to
indicate that some fraction of SHP2 associated with EGFR in a GAB1-independent
manner, perhaps through direct SHP2-EGFR interaction. Chasing EGF-treated cells with
PP2 also greatly reduced GAB1-SHP2 association (Figures 4-2C and S4-9B-C). In 293T
cells expressing constitutively active SRCY527F, GAB1 was constitutively phosphorylated
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Figure 4-2: Requirement of SFKs for EGF-initiated GAB1 phosphorylation and
GAB1-SHP2 binding.
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(A, B, and C) H1666 cells with knockdown of endogenous EGFR and reconstitution with
EGFRY845F were pretreated with DMSO or 10 μM PP2 for 30 min and subsequently
treated with 10 ng/mL EGF for up to 120 min and lysed, or treated with 10 ng/mL EGF
for up to 120 min and subsequently chased with DMSO or 10 μM PP2 for up to 15 min
prior to lysing cells. Whole cell lysates and SHP2 immunoprecipitates were analyzed by
western blotting. Blot signals for phosphorylated GAB1 were quantified and normalized
by ERK signal (whole cell lysate) or SHP2 signal (SHP2 immunoprecipitate). * denotes p
< 0.05 when comparing normalized pGAB1 signals from DMSO-treated cells to signals
from PP2-treated cells at a given time point. (D) 293T cells transiently expressing either:
1) GAB1 and p3xFlag empty vector (EV); 2) GAB1 and SRCY527F; 3) pcDNA3 empty
vector (EV) and SRCY527F, were treated with 10 ng/mL EGF for 15 min and subsequently
chased with 1 μM gefitinib for 5 min prior to lysing cells. SHP2 immunoprecipitates
were analyzed by western blotting with antibodies against the indicated proteins.
Throughout the figure panels, all blot images are representative of three sets of biological
replicates, and densitometry data are represented as mean ± s.e.m. (n = 3).

and constitutively associated with SHP2 in the absence of EGF and in the presence of
gefitinib (Figures 4-2D and S4-9D). However, expression of dominant negative
SRCK295R/Y527F did not impair GAB1 phosphorylation (Figure S4-9E), consistent with
findings that SRC, YES, and FYN, the only three ubiquitously expressed SFK members
[147], can compensate for one another [141]. Combined with the fact that the antibody
used here detects SRC, FYN, and YES, these data create ambiguity regarding the specific
SFK member that is primarily responsible for GAB1 phosphorylation. Accordingly, we
will refer to SFKs as the intermediary species driving GAB1 phosphorylation henceforth.
GAB1-SHP2 complexes exist mainly in the cytosol. The fact that GAB1-SHP2
complexes lacking EGFR can exist suggests, but does not guarantee, that GAB1-SHP2
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complexes could be present in the cytosol. When we performed subcellular fractionation,
essentially all EGF-induced GAB1-SHP2 complexes were found in the cytosolic fraction,

Figure 4-3: Subcellular localization of GAB1-SHP2 complexes.
(A and B) Membrane and cytosolic fractions were prepared from H1666 cells treated
with or without 10 ng/mL EGF for 15 min. SHP2 immunoprecipitates (A) or whole cell
lysates (B) were analyzed by Western blotting with antibodies against the indicated
proteins. (C and D) H1666 cells were pretreated with DMSO or 0.5 μM GDC-0941 for
30 min and subsequently treated with 10 ng/mL EGF for 15 min and lysed. Whole cell
lysates (C) or SHP2 immunoprecipitates (D) were analyzed by western blotting with
antibodies against the indicated proteins. All blot images are representative of three sets
of biological replicates.

whereas essentially all SHP2 complexes containing EGFR were located in the membrane
fraction (Figure 4-3A). While some reports suggest that SFKs are mainly located in the
membrane due to myristoylation [148] and that a significant amount of GRB2 may be
associated with EGFR in response to EGFR activation [149, 150], we also note that the
125

majority of SFKs and GRB2 were located in the cytosol, suggesting that SFKs can
regulate GAB1 phosphorylation in the cytosol and that GRB2-GAB1-SHP2 (and GAB1SHP2) complexes can exist there (Figure 4-3B). The presence of non-specific protein
bands prevented the unequivocal detection of GRB2 in SHP2 immunoprecipitate western
blots, but we assume GRB2 was present in at least some fraction of GAB1-SHP2
complexes due to the nature of the interaction between GRB2 and GAB1. Since the
PI3K-dependent recruitment of GAB1 to the plasma membrane is essential for GAB1’s
function in some cell settings [130], we also probed the effect of PI3K inhibition on
GAB1-SHP2 complexes, even though we did not detect a significant amount of GAB1 in
membrane fractions. In H1666 cells treated with the PI3K inhibitor GDC-0941, EGFmediated AKT S473 phosphorylation was inhibited but GAB1-SHP2 association was not
impaired (Figure 4-3C-D).
EGF and HGF promote different dynamics of GAB1-SHP2 complex
persistence. In some cell systems, GAB1 phosphorylation and GAB1-SHP2 association
are sustained longer in response to HGF than EGF. This has been proposed as an
explanation for HGF’s ability to promote more sustained ERK phosphorylation in these
cell systems [89, 129], but the mechanistic details by which c-MET and EGFR promote
GAB1-SHP2 association for different time scales have not been fully explored. To
compare GAB1-SHP2 association in response to EGF or HGF on a fair basis, we used
equivalent dissociation constant-normalized concentrations of the ligands (38 or 50
ng/mL for EGF or HGF, respectively) [151, 152]. In H1666 cells, HGF promoted a lower
but more persistent GAB1-SHP2 association than EGF, and c-MET remained in complex
with SHP2 throughout the duration of GAB1-SHP2 binding (Figures 4-4A and S4-10A).
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This may have occurred because c-MET phosphorylation was more persistent and the
total protein level was more stable compared to EGFR (Figures 4-4B and S4-10B).

Figure 4-4: Sustained association of GAB1 and SHP2 downstream of c-MET.
H1666 cells were treated with 38 ng/mL EGF or 50 ng/mL HGF for up to 240 min, and
SHP2 immunoprecipitates (A) or whole cell lysates (B) were analyzed by western
blotting. Blot signals for MET, phospho-EGFR, and phospho-GAB1 were quantified and
normalized by SHP2 signal (SHP2 immunoprecipitate loading control) for (A) and ERK
signal (whole cell lysate loading control) for (B). (C) Cells were pretreated with DMSO
or 10 μM of the SFK inhibitor PP2 for 30 min and subsequently treated with HGF or
EGF for 15 min and lysed, or treated with HGF or EGF for 15 min and subsequently
chased with DMSO or 10 μM PP2 for 5 min prior to lysing cells (D). SHP2
immunoprecipitates were analyzed by western blotting. Blot signals for c-MET and
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phosphorylated GAB1 were quantified and normalized by SHP2 signal. (E) Cells were
treated with HGF for 15 min and subsequently chased with 1 μM PHA665752 for up to 5
min prior to lysing cells. SHP2 immunoprecipitates were analyzed by western blotting.
Blot signals for c-MET and phosphorylated GAB1 were quantified and normalized by
SHP2 signal (loading control). Throughout the figure panels, densitometry data are
represented as mean ± s.e.m. (n = 3).

Although SFKs can be activated by c-MET [153], pretreating cells with PP2 prior to
HGF addition or chasing HGF-treated cells with PP2 did not significantly reduce GAB1SHP2 association, suggesting that a kinase other than a SFK (possibly c-MET itself)
regulates GAB1 phosphorylation in response to HGF (Figures 4-4C-D and S4-10C-D).
We note that the smaller effect of PP2 on EGF-mediated GAB1-SHP2 association
observed in Figure 4-4 compared to that observed in Figure 4-2 is probably due to the
larger EGF concentration used in Figure 4-4.

Similar to observations with EGF

treatments and gefitinib chases, GAB1-SHP2 association was prolonged relative to cMET-SHP2 association in cells treated with HGF and chased with the c-MET inhibitor
PHA665752 (Figures 4-4E and S4-10D).
A computational model reveals that SFKs amplify EGFR activity to maintain
GAB1-SHP2 complexes distal from EGFR. To quantitatively explore the relationships
between EGFR and GAB1 phosphorylation, SFK activity, and GAB1-SHP2 binding, we
developed a computational mechanistic model of GAB1-SHP2 complex dynamics that
includes the processes of protein phosphorylation and dephosphorylation and reversible
protein binding for the complexes shown in Figure 4-5A. Model development details are
provided in Materials and Methods (Section 4-3). Most parameters were taken from the
literature, as indicated in Table S4-1. Importantly, four key rate constants were
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determined through fitting. The rate constant for EGFR dephosphorylation (kdp) was fit to
the decrease in pEGFR levels throughout the course of a 5 min gefitinib treatment (Figure

Figure 4-5: Model topology and validation.
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(A) The model topology includes the depicted processes leading to EGFR and SFK
phosphorylation and activation, respectively, as well as all allowed protein complexes
which can exist with EGFR monomers (not shown) and dimers (shown). Model
predictions for EGFR-SHP2 and GAB1-SHP2 association (lines) were compared to
experimental data (points) from: (B) an EGF-pulse gefitinib-chase experiment and (C) an
EGF stimulation time course. (D) H1666 cells were treated with 10 ng/mL EGF for 15
min, and lysates were immunoprecipitated with SHP2 antibody. Percent SHP2-bound
GAB1 was determined for experimental data by first calculating the percent of GAB1
unbound with SHP2, which was calculated by dividing the normalized GAB1 signal in
the SHP2 immunoprecipitate supernatant by that of the GAB1 signal in whole cell
lysates. This value was subtracted from 100% to calculate percent SHP2-bound GAB1,
which was then compared to the model prediction for percent SHP2-bound GAB1 in
response to 15 min EGF. (E) Model predictions for normalized levels of phosphorylated
EGFR and GAB1 and active SFK following a gefitinib chase were calculated. (F) Model
predictions for the number of EGFR and GAB1 molecules phosphorylated throughout a
120 min EGF treatment were calculated. (G) Model error was calculated for ranges of kdp
and kG1dp. Red circle indicates error minimum. (H) Based on rapid forward and reverse
cycling of several cellular components leading to GAB1-SHP2 binding, the picture which
emerges is that phosphorylation and binding events leading to SHP2 activation are
exceedingly transient, rather than static.

S4-11A). The rate constants for GAB1 phosphorylation (kG1p) and dephosphorylation
(kG1dp) were fit to the response of GAB1 Y627 phosphorylation and GAB1-SHP2
association to both long and short EGF treatments (Figures 4-1A-B and S4-11B) and an
EGF-gefitinib pulse-chase experiment (Figures 4-1C-D). The rate constant for EGFR
degradation (kdeg), a process needed to allow pEGFR and pGAB1 levels to decrease with
time (Figure S4-11C) because we assume a constant activity level of protein tyrosine
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phosphatases, was fit to the response of EGFR levels over the course of a 2 hrs EGF
treatment (Figure 4-1B).
Before proceeding, we note that the previously mentioned GAB1-independent
mechanism of SHP2-EGFR association is not accounted for in our model topology.
However, this omission should not affect model conclusions since our parameter fits do
not rely upon EGFR-SHP2 association data. Moreover, since our data suggest EGFR and
SHP2 dissociate immediately following a gefitinib chase (Figure 4-1D), and since GAB1dependent and -independent EGFR-SHP2 complexes dissociate with similar kinetics over
the course of a 2 hrs EGF treatment (Figure S4-9A), our model predictions for relative
abundances of EGFR-SHP2 and GAB1-SHP2 complexes would be unchanged even if
model fits did account for EGFR-SHP2 association data.

We also note that

approximately half of EGFR-SHP2 complexes are dependent on SFK activity and thus
likely GAB1-dependent (Figure 4-2B). Therefore, the capacity for GAB1 to recruit SHP2
to EGFR is an important mechanism of EGFR-SHP2 complex formation and a valid
inclusion for our model topology.
The parameterized model recapitulates differences in the rates of EGFR-SHP2
and GAB1-SHP2 dissociation following a gefitinib chase (Figure 4-5B). While both
EGFR-SHP2 and GAB1-SHP2 complexes return to basal levels after 1-2 min of gefitinib
treatment, EGFR-SHP2 complexes fall to 50% of their peak concentration approximately
5 times faster than do GAB1-SHP2 complexes. The model also accurately predicts
differences in the relative abundances of EGFR-SHP2 and GAB1-SHP2 complexes over
a 120 min EGF treatment time course (Figure 4-5C). The model further predicts that 22%
of GAB1 was bound with SHP2 15 min after treatment with EGF, which is in line with
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an experimental measurement of 26 ± 5% (Figures 4-5D and S4-11D). Finally, the model
predicts that even at peak levels of EGFR phosphorylation, only 1.5% of SHP2 exists in
complex with EGFR (Figure S4-11E), which is qualitatively consistent with our
experimental findings of SHP2 and GAB1-SHP2 complexes existing almost exclusively
in the cytosol (Figures 4-3A-B).
Interestingly, the fitted rate constant for GAB1 dephosphorylation (kG1dp) is
similar in magnitude to that for EGFR dephosphorylation (kdp), with each implying a
dephosphorylation timescale of ~0.1 min, despite a GAB1 dephosphorylation rate in cells
that is smaller than the rate of EGFR dephosphorylation following a gefitinib chase Table
S4-1, Figure 4-1B, and Figure 4-5E). This apparent contradiction is explained by a time
lag between the reductions in EGFR and GAB1 phosphorylation rates following gefitinib
addition (Figure S4-11F), which arises because SFK inactivation, which is tied to EGFR
phosphorylation, does not occur instantaneously after EGFR inactivation (Figure 4-5E).
If SFKs are instead assumed to deactivate instantaneously upon EGFR inactivation, the
rates of EGFR and GAB1 dephosphorylation are nearly identical, with GAB1 actually
being slightly faster because of a difference in dephosphorylation rate constants (Figure
S4-11G). Beyond this time lag in SFK inactivation, the difference in cellular EGFR and
GAB1 dephosphorylation rates is exacerbated by an SFK-mediated amplification process
that occurs in the parameterized model and generally produces a larger concentration of
phosphorylated GAB1 (pGAB1) than pEGFR at any time, as can be seen in predictions
of absolute phosphorylated levels of EGFR and GAB1 in response to EGF (Figure 4-5F).
This amplification occurs as a combined result of a smaller timescale for the GAB1
phosphorylation step (~3 s) than for EGFR phosphorylation (~4.5 s) and as a result of the
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relative slowness of other process steps leading to EGFR phosphorylation, including
ligand binding and EGFR dimerization (Figure S4-11H). When parameter values are
adjusted to remove this amplification process from the model, the difference between
EGFR and GAB1 dephosphorylation rates is reduced, but not eliminated because of the
time lag for SFK inactivation (Figure S4-11G).
Plotting the model error for a range of kG1dp and kdp values provides additional
insight into the system’s behavior (Figure 4-5G). While the error minimum is achieved
for kG1dp and kdp of similar magnitudes, a relatively low model error is still achieved if one
rate constant is increased and the other is decreased by up to an order of magnitude.
Model error significantly increases when either rate constant is changed by more than an
order of magnitude from its best-fit value. Thus, there is some capacity to explain the
data by speeding one dephosphorylation process and slowing the other, but both rate
processes must be fairly rapid to explain the experimental data reasonably.
Returning to the values of our fitted parameters for GAB1 phosphorylation and
dephosphorylation and making some order of magnitude estimates, we note that the
parameters suggest that when phosphorylation/dephosphorylation reaction rates are
maximized, GAB1 Y627 undergoes ~6 cycles of dephosphorylation and rephosphorylation per minute in response to EGF (Figure 4-5H), based on characteristic
GAB1 phosphorylation and dephosphorylation times (see Materials and Methods).
SHP2 cycles between GAB1-bound and -unbound states ~14 times during the time that
GAB1 is phosphorylated in each GAB1 cycle, or ~100 times per minute at maximal rates.
Robustness and sensitivity analyses confirm the need for an SFK-mediated
amplification mechanism and reveal key processes controlling system behavior. To
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further explore model predictions surrounding the need for the amplification process that
produces pGAB1/pEGFR ratios greater than one, we undertook two types of robustness
analyses. Since we had no direct quantitative data available for the cellular

Figure 4-6: Model requirement for SFK-mediated amplification of EGFR and
model sensitivity.
(A) A metric for the degree of amplified EGFR signal, pGAB1/pEGFR, and model error
were calculated for 10-fold combinatorial variations in GAB1, SHP2, and SFK
concentrations. (B) Model predictions for pGAB1/pEGFR were calculated for 300
random parameter sets, where each parameter was randomly varied up to an order of
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magnitude above or below its base value. (C) Sensitivity of model predictions for timeintegrated GAB1-SHP2 association for a 5 min, 1 μM gefitinib-chase (preceded by a 15
min, 10 ng/mL EGF-pulse) to 10-fold changes in the model parameters was calculated.
(D and E) Model predictions for the percent of GAB1-bound SHP2 following a gefitinib
chase were compared with predictions when kdp and kG1dp were varied by a factor of 10.
Representative times for GAB1-SHP2 dissociation (dashed lines) were calculated by
determining the time at which 50% of dissociation had occurred relative to maximum and
minimum values. (F) Model predictions for percent phosphorylated GAB1 and
representative GAB1 dephosphorylation times following a gefitinib chase were
calculated when SHP2 concentration was increased by a factor of ten or set to zero.
Representative times for GAB1 dephosphorylation (dashed lines) were calculated by
determining the time at which 50% of dephosphorylation had occurred relative to
maximum and minimum values.

concentrations of GAB1, SHP2, and SFKs, we checked if our assumption of equivalent
expression levels of these proteins could somehow be responsible for the model’s
identification of a need for the SFK-mediated amplification mechanism. For a range of
GAB1, SHP2, and SFK concentrations, we refit the model and calculated errors and an
average pGAB1/pEGFR ratio, a metric for amplification of EGFR’s activity through
SFKs. Across all combinations of concentrations tested, the smallest model errors were
associated with amplification (pGAB1/pEGFR > 1) (Figure 4-6A). We further tested the
robustness of our model’s prediction of SFK-mediated amplification by creating random
parameter sets, where each parameter was randomly perturbed by up to an order of
magnitude above or below its base value. For 78% of the parameter sets (234/300),
pGAB1/pEGFR was greater than unity (Figure 4-6B). Therefore, even if the base model
parameters are not well estimated, the model prediction of amplification of EGFR’s
signal by SFKs appears robust.
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To further understand the processes that control amplification and its effects, we
performed a parameter sensitivity analysis to identify processes controlling the
persistence of GAB1-SHP2 complexes following a gefitinib chase (preceded by an EGF
pulse), since complex persistence is augmented by the amplification processes, as we
have already discussed. GAB1-SHP2 persistence had a strong dependence on a number
of model parameters, but kdp was chief among these (Figure 4-6C). EGF-gefitinib pulsechase simulations show that either elevating or decreasing kdp by an order of magnitude
altered both the dynamic and steady state percentage of SHP2 bound by GAB1, as well as
the rate at which GAB1-SHP2 dissociation occurred following a gefitinib-chase (Figure
4-6D). Analogous, but smaller, predicted effects were seen when altering kG1dp (Figure 46E). The finding that altering kdp has a larger effect on GAB1-SHP2 association than
altering kG1dp is further indication of the importance of the amplification of the EGFR
signal by SFKs. Not surprisingly, the model was sensitive to perturbations to other
parameters that affect EGFR phosphorylation, such as parameters for EGF, ATP,
gefitinib, and GRB2 binding, and parameters that affect SFK activity including kS,a and
kS,i. GAB1-SHP2 association was also sensitive to changes in kS2,f and kS2,r.
As others have shown that binding of SH2 domains to phosphotyrosines can
protect them from dephosphorylation, as in the case of overexpression of PLCγ SH2
domains preventing EGFR tyrosine dephosphorylation [154], we used the model to
predict the consequences of SHP2 overexpression or depletion on the dynamics of GAB1
dephosphorylation (Figure 4-6F). Compared to the base model, elevating the cellular
concentration of SHP2 by an order of magnitude resulted in little change to the dynamics
of GAB1 dephosphorylation, but did produce a roughly two-fold increase in steady state
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GAB1 phosphorylation. Conversely, complete removal of SHP2 from the model had
relatively no effect on either the dynamics or steady state levels of GAB1
phosphorylation, suggesting that SHP2 offers little protection against GAB1
dephosphorylation at endogenous expression levels. This is due to the rate of SHP2
unbinding from GAB1 being over an order of magnitude faster than GAB1
dephosphorylation, such that GAB1 will generally be accessible to phosphatases unless
there is a massive surplus of SHP2.
We went on to explore the potential effects of changes to the model topology
motivated by several previously documented findings. Since SHP2 can promote SFK
activity for some SFK members by preventing proper localization of c-SRC kinase (CSK)
[55, 56], we updated the model to allow for active SHP2, in addition to EGFR, to activate
SFKs. Relative to the base model (Figure S4-12A), allowing SHP2 activity to enhance
SFK activity resulted in a significant effect on GAB1 phosphorylation (Figure S4-12B),
as the rate constant for GAB1 phosphorylation needed to be reduced by several orders of
magnitude to counteract the addition of this positive feedback loop. The rate constant for
GAB1

dephosphorylation

was

unchanged

with

the

model

extension,

as

dephosphorylation kinetics were sufficiently rapid such that gefitinib addition still
quickly returned GAB1 phosphorylation to basal levels. However, this topological
addition did not reduce the minimum model error relative to the base model (Figures S412A-B). We also computed model error by adding in a distinct reaction for GAB1
dephosphorylation mediated by SHP2 [132], but this topological addition also did not
result in an improved ability for the model to more accurately recapitulate the
experimental data despite broadening the error basin (Figure S4-12C).
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4-5 DISCUSSION
Here, we describe a mechanism in which EGFR drives the persistence of
cytosolic GAB1-SHP2 complexes through many cycles of GAB1-SHP2 dissociation and
GAB1 dephosphorylation via the ability of SFKs, activated by EGFR, to rephosphorylate GAB1 repeatedly in a way that effectively amplifies EGFR activity
(Figure 4-7). This mechanism may allow EGFR to control signaling processes via SHP2
at intracellular locations where it may not otherwise be able to do so because of EGFR’s
confinement to the cell surface or endomembrane compartments. Moreover, the
amplification aspect of this process may enable a relatively small amount of activated
EGFR to exert significant control over signaling events via GAB1-bound and active
SHP2.

Figure 4-7: Schematic of EGFR-mediated GAB1-SHP2 complex maintenance.
Basally, SHP2 activity is suppressed through an intramolecular interaction between
SHP2’s N-terminal SH2 domain and the catalytic domain. When SHP2 SH2 domains
engage tyrosine phosphorylated GAB1, the SHP2 intramolecular tethering is relieved and
SHP2 activity increases. EGFR activation appears to promote this process primarily
through the intermediary SFKs, which counteract many rounds of GAB1 tyrosine
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dephosphorylation to enable GAB1-SHP2 complexes to persist distal from the receptor.
With a lower abundance, GAB1-SHP2 complexes may also exist at the membrane in
complex with EGFR, and some SHP2 may also engage with EGFR directly in GAB1independent fashion.

The quantitative insights achieved here were possible because of the application
of a mechanistic model in the interpretation of experimental data. In particular, the model
provides confidence that an amplification step from EGFR to GAB1 is needed to fully
explain the kinetics we measured and that this conclusion is robust even accounting for
uncertainty in certain system properties (e.g., quantitative expression levels for certain
proteins). The model also enables quantitative estimates of the phosphorylation cycles
EGFR and GAB1 undergo in response to EGFR activation. Of course, other EGFR
signaling models have been developed, with a few even considering EGFR-induced
GAB1-SHP2 association [140, 142, 155]. However, none of those previous models
included rigorous consideration of differential compartmentation of GAB1, SHP2, and
the GAB1-SHP2 complex, realistic timescales for EGFR and GAB1 dephosphorylation,
or the role for intermediary kinases in maintaining GAB1 phosphorylation.
The amplification mechanism described here bears some resemblance to ERK
pathway amplification mechanisms wherein one RAF can promote the phosphorylation
of a larger number of ERKs [156]. By analogy, our model requires that EGFR-activated
SFKs effectively amplify EGFR activity such that stoichiometric ratios of
pEGFR/pGAB1 exceed unity in order to explain our data reasonably well. It is worth
noting that the model results reveal that there may be several ways to achieve such
amplification. For example, SFKs need not be in stoichiometric excess of EGFR or
GAB1 to produce an amplification from EGFR to GAB1 (Figure 4-6A), which appears to
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be required for reasonable explanation of the data. Within the framework of our model,
this is achieved by an increased fitted value of kG1p permitting a decreased number of
SFKs to phosphorylate GAB1 as efficiently as an elevated number of SFKs. Another
commonly discussed feature of the ERK cascade is ultrasensitivity, which enables a
graded input at the level of RAF to produce a switch-like output at the level of ERK
[157]. The mechanism we describe here does not involve an analogous kind of
ultrasensitivity. That is, a switch-like GAB1 phosphorylation response to increasing EGF
concentration is not predicted by our model.
The specific location within the cell where SFKs phosphorylate GAB1 has
important potential implications for how far within the cell GAB1-SHP2 complexes
persist. While our results with PI3K inhibition may argue against a need for GAB1 to be
membrane bound to be phosphorylated by SFKs, certain lines of evidence argue for SFK
activity mainly at the membrane. Indeed, SFKs are typically thought of as membranebound species due in part to N-terminal myristoylation. Myristoylation itself may
promote SFK activity [148], and some studies do suggest a requirement for SFKs to
move to the membrane to become activated [158]. Still, in some cancer cell settings
significant SFK fractions are found in the cytosol [159], as found here for H1666 cells,
and other studies have demonstrated the presence of activated SFKs in the cytosol [160].
The potential importance of this detail can be further understood through order of
magnitude estimates of specific process time scales. Assuming a cell radius of 10 μm
[161] and a diffusivity of 0.94 μm2/s, based on the diffusivity of tubulin and an
adjustment due to estimated hydrodynamic radii of tubulin and the GAB1-SHP2 complex
[162, 163], the characteristic time for a GAB1-SHP2 complex to diffuse from the plasma
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membrane to the cell center is ~18 s. Comparison of that timescale with the characteristic
time for GAB1 dephosphorylation of ~6 s, computed as the inverse of the rate constant
for GAB1 dephosphorylation from our model fits, suggests that GAB1-SHP2 complexes
formed exclusively at the plasma membrane may not persist over the entire cellular
length scale. The ability of SFKs to drive GAB1 phosphorylation in the cytosol would
overcome this limitation, potentially increasing SHP2’s ability to regulate signaling
processes over a larger intracellular length scale.
Of course, the endocytic trafficking of EGFR may also move the most upstream
processes in this signaling pathway into the cell interior in ways that could help to
overcome diffusional limitations that might otherwise limit GAB1-SHP2 complex access
to intracellular locations. Along those lines, it should be noted that the ability of
endocytosis-impaired and constitutively active EGFR mutants to sequester SHP2 at the
cell periphery appears to antagonize SHP2’s ability to participate fully in the activation of
ERK [164]. To what extent this functional impairment of SHP2 activity involves a
perturbation to the ability of GAB1-SHP2 complexes to exist distal from EGFR mutants
remains unclear, but this will be worth pursuing in future studies.
The work presented here may also offer insight into the documented ability of
HGF to drive more sustained GAB1 phosphorylation, GAB1-SHP2 association, and ERK
activation than EGF [89, 129]. In our experiments, EGF-mediated EGFR activation
resulted in relatively rapid degradation of EGFR over the course of an hour (55%
degraded; Figure 4-1B), which may diminish GAB1 phosphorylation and GAB1-SHP2
association by reducing the pool of EGFR available to drive SFK activity. By
comparison, c-MET degradation following HGF addition occurs quite slowly, which may
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explain the more protracted downstream activation of ERK. Differences in the dynamics
of HGF- and EGF-mediated ERK activation may also be due to differential recruitment
of GAB1 to the cell periphery, given HGF but not EGF addition results in recruitment of
GAB1 to the plasma membrane [130]. We also note that while SFKs are required for
EGF-mediated GAB1 phosphorylation, our experiments suggest that SFKs are
dispensable for GAB1 phosphorylation downstream of c-MET, suggesting there are
different modes for RTK-mediated induction of GAB1-SHP2 association.
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4-7 SUPPLEMENTARY MATERIAL

Figure S4-8: Differential rates of EGFR-SHP2 and GAB1-SHP2 complex
disassemblies.
(A) HeLa cells were treated with 10 ng/mL EGF for up to 30 min, and lysates were
immunoprecipitated with SHP2 antibody. Immunoprecipitates were analyzed by western
blotting using antibodies against the indicated proteins. Blot signals for phosphorylated
EGFR and GAB1 were quantified and normalized by SHP2 signal (loading control). (B
and C) H1666 cells were treated with 10 ng/mL EGF for 15 or 120 min, and
subsequently chased with 1 μM gefitinib for up to 5 min prior to lysing cells. Whole cell
lysates (B) and SHP2 immunoprecipitates (C) were analyzed by western blotting, and
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blot signals for phosphorylated EGFR and GAB1 were quantified and normalized by
ERK signal (whole cell lysate loading control) or SHP2 signal (SHP2 immunoprecipitate
loading control). Throughout the figure panels, all blot images are representative of three
sets of biological replicates, and densitometry data are represented as mean ± s.e.m. (n =
3); * denotes p < 0.05 when comparing normalized pGAB1 signals to pEGFR signals at a
given time point.
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Figure S4-9: SFK-mediated GAB1 phosphorylation and GAB1-SHP2 binding.
(A) Blot signals for phosphorylated EGFR from Figure 2B were quantified and
normalized by SHP2 signal. In order to compare pEGFR-SHP2 association kinetics with
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or without PP2 pretreatment, all data points for each treatment condition were further
normalized by their respective maximum pEGFR/SHP2 signal (i.e., pEGFR/SHP2 at 15
min EGF).

(B and C) H1666 cells with knockdown of endogenous EGFR and

reconstitution with EGFRY845F were treated with 10 ng/mL EGF for up to 120 min and
subsequently chased with DMSO or 10 μM PP2 for up to 15 min prior to lysing cells.
Whole cell lysates (B) and SHP2 immunoprecipitates (C) were analyzed by western
blotting with antibodies against the indicated proteins. Blot signals from whole cell
lysates for phosphorylated GAB1 were quantified and normalized by ERK signal
(loading control). (D) 293T cells transiently expressing either: 1) GAB1 and p3xFlag
empty vector (EV); 2) GAB1 and SRCY527F; 3) pcDNA3 empty vector (EV) and
SRCY527F, were treated with 10 ng/mL EGF for 15 min and subsequently chased with 1
μM gefitinib for 5 min prior to lysing cells. Whole cell lysates were analyzed by western
blotting with antibodies against the indicated proteins. (E) H1666 cells with knockdown
of endogenous EGFR and reconstitution with EGFRY845F were transfected with SRCWT
cDNA, SRCDM cDNA (dominant negative SRCK295R/Y527F), or no DNA and were treated
with or without 10 ng/mL EGF for 15 min. Whole cell lysates were analyzed by western
blotting with antibodies against the indicated proteins. Throughout the figure panels, all
blot images are representative of three sets of biological replicates, and densitometry data
are represented as mean ± s.e.m. (n = 3).
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Figure S4-10: Sustained HGF-mediated association of GAB1 and SHP2.
H1666 cells were treated with 38 ng/mL EGF or 50 ng/mL HGF for up to 240 min, and
SHP2 immunoprecipitates (A) or whole cell lysates (B) were analyzed by western
blotting with antibodies against the indicated proteins. (C and D) Cells were pretreated
with DMSO or 10 μM PP2 for 30 minutes and subsequently treated with HGF or EGF for
15 min and lysed, or treated with HGF or EGF for 15 min and subsequently chased with
DMSO, 10 μM PP2, or 1 μM PHA665752 for up to 5 min prior to lysing cells. SHP2
immunoprecipitates were analyzed by western blotting with antibodies against the
indicated proteins. Throughout the figure panels, all blot images are representative of
three sets of biological replicates.
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Figure S4-11: Model fitting to experimental data.
H1666 cells were treated with 10 ng/mL EGF for 15 min and subsequently chased with 1
μM gefitinib for up to 2 min prior to lysing cells (A), or treated with 10 ng/mL EGF for
up to 45 s and lysed (B). Lysates were analyzed by western blotting with antibodies
against the indicated proteins. Blot signals for phosphorylated EGFR and GAB1 were
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quantified and normalized by ERK signal (loading control), which were then compared
with model predictions. (C) Normalized percent phosphorylated EGFR and GAB1
throughout a 2 hr EGF treatment model simulation were computed when EGFR
degradation was neglected. (D) H1666 cells were treated with 10 ng/mL EGF for 15 min,
and lysates were immunoprecipitated using an SHP2 antibody. Immunoprecipitates
(capture), non-immunoprecipitated proteins (supernatant), and the original whole cell
lysate were analyzed by western blotting using antibodies against the indicated proteins.
(E) Model predictions for the percent of SHP2 bound with EGFR throughout a 120 min
EGF treatment were calculated. (F) Normalized net rates of EGFR and GAB1
phosphorylation were predicted throughout a 1 min gefitinib treatment. (G) Model
predictions for the normalized number of phosphorylated EGFR or GAB1 molecules
throughout a 1 min gefitinib treatment were calculated, either for the base model
topology, for a model topology where SFK-mediated amplification of GAB1
phosphorylation does not occur, or for a model topology where SFKs inactivate instantly
following gefitinib addition. (H) Model predictions for the number of phosphorylated
EGFR or GAB1 molecules throughout a 5 min EGF treatment were calculated, either for
the base model parameters, for model parameters where the timescales for EGFR and
GAB1 phosphorylation (τEGFRphos and τGAB1phos) are equal, or for model parameters where
both the EGFR and GAB1 phosphorylation timescales are equal and all forward and
reverse rate constants for EGF binding, ATP binding, and EGFR dimerization are
increased or decreased by an order of magnitude to speed up the processes which occur
prior to EGFR phosphorylation. Throughout the figure panels, all blot images are
representative of three sets of biological replicates, and densitometry data are represented
as mean ± s.e.m. (n = 3).
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Figure S4-12: Effect of variations in GAB1 phosphorylation (kG1p) and
dephosphorylation (kG1dp) rate constants on model error.
Model error was calculated for ranges of kG1p and kG1dp for the base model (A), a model
which includes the capacity for GAB1-bound (active) SHP2 to contribute to SFK activity
(B), and a model which includes the capacity for GAB1-bound (active) SHP2 to
dephosphorylate GAB1 (C). Red circles indicate error minima.
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Table S4-1: Model parameters
Parameter (units)

Description

Value

kE,f (μM-1 min-1)

EGF binding to EGFR, forward

3.1×102

-1

Source
-1

[133]

kE,r (min )

EGF binding to EGFR, reverse

8.0×10

kA,f (μM-1 min-1)

ATP binding to EGFR, forward

1.0×105

[63]

7

[63]

-1

[134]

kA,r (min )

ATP binding to EGFR, reverse

1.1×10

ki,f (μM-1 min-1)

Gefitinib binding to EGFR, forward

1.0×105

[63]

2

[63]

-1

ki,r (min )

Gefitinib binding to EGFR, reverse

2.1×10

kd,f (cell min-1)

EGFR dimerization, forward

9.2×10-4

-1

4

kd,r (min )

EGFR dimerization, reverse, unoccupied

1.4×10

kdE,r (min-1)

EGFR dimerization, reverse, EGF-occupied

1.0×10-1

-1

[138]

2.7×10

kcatE (min-1)

EGFR phosphorylation, EGF-occupied dimer

1.3×101
0

kdp (min )

EGFR dephosphorylation

8.0×10

kS,a (cell min-1)

SFK activation

1.3×101
1

kS,i (cell min )

SFK inactivation

1.0×10

kG2,f (cell min-1)

GRB2 binding to EGFR, forward

3.8×10-3

-1

2

kG2,r (min )

GRB2 binding to EGFR, reverse

4.6×10

kG1,f (cell min-1)

GAB1 binding to GRB2, forward

2.4×10-3

-1

1

kG1,r (min )

GAB1 binding to GRB2, reverse

6.0×10

kG1p (cell min-1)

GAB1 phosphorylation

1.0×10-4

-1

0

kG1dp (min )

GAB1 dephosphorylation

9.5×10

kS2,f (cell min-1)

SHP2 binding to phosphorylated GAB1, forward

3.8×10-3

-1

[136]
[138]

EGFR phosphorylation, unoccupied dimer

-1

[137]

0

kcat (min )
-1

Calculated

2

kS2,r (min )

SHP2 binding to phosphorylated GAB1, reverse

4.6×10

kdeg (min-1)

EGFR degradation

1.1×10-1
3

ATP (μM)

Cellular ATP concentration

1.0×10

EGF (μM)

Extracellular EGF concentration

1.7×10-3

Fit
[138]
[143, 144]
[61]
[61]
[140]
[140]
Fit
Fit
[62]
[62]
Fit
[135]
See text

0

See text
See text

gefitinib (μM)

Gefitinib concentration

1.0×10

EGFR (cell-1)

EGFR molecules per cell

6.0×105

GRB2 (cell )

GRB2 molecules per cell

6.0×10

5

[140]

GAB1 (cell-1)

GAB1 molecules per cell

6.0×105

[140]

5

[140]

-1

-1

SHP2 (cell )

SHP2 molecules per cell

6.0×10

SFK (cell-1)

SFK molecules per cell

6.0×105

[140]

CSK molecules per cell

5

[140]

-1

CSK (cell )

6.0×10
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Chapter 5: A Reaction-diffusion Model Predicts the
Intracellular Length Scale Over Which EGFR-initiated GAB1SHP2 Complexes Persist

5-1 ABSTRACT
Activation of receptor tyrosine kinases (RTKs) leads to the assembly of cytosolic
protein complexes linked through interactions including those between phosphotyrosines
and SH2 domains.

However, these interactions are relatively weak and reversible,

allowing for complex disassembly to occur on a time scale that permits intracellular
phosphatases to dephosphorylate complex members and ultimately regulate complex
persistence, which may limit the intracellular length scale over which RTKs can maintain
the association of distal complexes. Here, we develop a computational reaction-diffusion
model using the epidermal growth factor receptor (EGFR) as a model system to gain
quantitative understanding of the regulation of cytosolic protein complexes containing
SRC homology 2 domain-containing phosphatase 2 (SHP2) and GRB2-associated binder
1 (GAB1), the primary phosphorylated adapter protein which binds and activates SHP2
downstream of EGFR. The model predicts that by activating intermediary SRC family
kinases (SFKs), which phosphorylate GAB1, EGFR can remotely maintain the
association of GAB1 and SHP2 throughout the entire cell volume, a finding which is
dependent on the capacity for SFKs to diffuse through the cytosol after being activated by
EGFR at the plasma membrane.

Further model investigation through a parameter

sensitivity analysis identifies protein diffusivity and the rate constants for SFK
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inactivation and GAB1 dephosphorylation as the most important parameters for
determining the intracellular length scale of GAB1-SHP2 complex persistence. Based on
calculations for characteristic protein diffusion, dephosphorylation, and dissociation
times, our model suggests that each GAB1 molecule needs to be phosphorylated ~4 times
throughout the cytosol to permit a GAB1-SHP2 complex originating from the plasma
membrane to reach the cell center.

Overall, our results suggest that GAB1-SHP2

complexes can persist distal from EGFR due to re-phosphorylation of GAB1 throughout
the cytosol by EGFR-activated SFKs, which could allow membrane-bound EGFR to
remotely control signaling events through SHP2 at subcellular locations where EGFR is
not present.

154

5-2 INTRODUCTION
Receptor tyrosine kinases (RTKs), such as the epidermal growth factor receptor
(EGFR), promote the activity of downstream signaling pathways by initially recruiting
SH2 and PTB domain-containing cytosolic adapter proteins to RTK phosphotyrosines.
However, receptor-adapter and other phosphorylation-dependent protein complexes
exhibit rapid dissociation kinetics [61, 64], enabling protein tyrosine phosphatases (PTPs)
to promote reversible complex disassembly by dephosphorylating tyrosines that
participate in complex formation. In addition to directly binding cytosolic proteins to
facilitate the formation of phosphorylation-dependent multi-membered protein complexes
[150], RTKs can also activate cytosolic kinases to promote complex assembly (Chapter
4), which may serve as a means of extending the length scale of complex persistence
distal from RTKs by counteracting the activity of cytosolic phosphatases that
dephosphorylate key tyrosines.

However, the intracellular length scales over which

RTKs can remotely control the association of such complexes via this type of mechanism
are unknown. Here, we use EGFR as a model RTK to computationally investigate the
distance from the plasma membrane over which EGFR maintains the association of the
cytosolic protein tyrosine phosphatase SRC homology 2 domain-containing phosphatase
2 (SHP2) with the adapter protein GRB2-associated binder 1 (GAB1) via the action of
intermediary SRC family kinases (SFKs).
SHP2 is a key signaling intermediate responsible for promoting the activity of
ERK downstream of many RTKs [28]. SHP2 is basally auto-inhibited by intramolecular
interactions between its N-SH2 and PTP domains [28]. In most cell lines, activation of
SHP2 downstream of EGFR primarily results from binding of SHP2 to phosphorylated
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GAB1, where GAB1 phosphorylation can potentially occur through EGFR-activated
SFKs (Chapter 4; [52, 66] ) or through the activity of EGFR itself [65]. GAB1-SHP2
association is mediated through binding of SHP2’s N- and C-SH2 domains to
phosphorylated GAB1 tyrosines 627 and 659, which disrupts auto-inhibitory SHP2
interactions and activates SHP2 [28]. In addition to activating SHP2, binding of SHP2 to
GAB1 also permits the redistribution of cytosolic SHP2 to the plasma membrane through
an EGFR-GRB2-GAB1-SHP2 protein linkage [54]. Via similar mechanisms receptor
tyrosine kinases such as Ret, HER2, and c-MET can also recruit SHP2 to the plasma
membrane [96, 131, 165]. However, some RTKs may more preferentially promote the
association of GAB1 with SHP2 at the plasma membrane than others. Indeed HGF
promotes more substantial recruitment of GAB1 to the plasma membrane than EGF in
Madin-Darby canine kidney (MDCK) cells [130]. In a lung adenocarcinoma cell line,
EGF-initiated GAB1-SHP2 complexes exist primarily in the cytosol with SFKs serving
as the primary driver of GAB1 phosphorylation (Chapter 4).
As SFKs can be activated at the plasma membrane through events including
binding of SRC’s SH2 domain to EGFR [141], yet are inactivated within the cytosol
through c-SRC kinase-mediated phosphorylation of negative regulatory tyrosines on
SFKs [143], the number of active SFKs able to phosphorylate GAB1 may rapidly decline
distal from the plasma membrane (i.e., towards the cell center). Furthermore, because
GAB1 and SHP2 continuously dissociate and re-associate throughout the cytosol due to
relatively fast rates of phosphotyrosine-SH2 domain binding/unbinding (Chapter 4; [64]
), which permits GAB1 to be dephosphorylated by cytosolic phosphatases throughout
these binding cycles (Chapter 4), the local cytosolic concentration of GAB1-bound SHP2
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may decline as this complex becomes inaccessible to active SFKs. Ultimately, the
distance over which GAB1-SHP2 complexes persist distal from EGFR depends on how
quickly SFKs and GAB1-SHP2 complexes are able to diffuse through the cytosol before
becoming irreversibly inactivated and dissociated, respectively. Of course, in addition to
diffusion, processes such as receptor internalization may also serve to extend the length
scale of GAB1-SHP2 complexes distal from the plasma membrane, as others have shown
that receptors including EGFR and TrkA continue to remain active and serve as
nucleation sites for signaling complex formation within endosomes [67, 166-168].
Previous findings from our group suggest an important aspect of SHP2-mediated
signaling involves the subcellular localization of active, GAB1-bound SHP2 [164, 169],
although no prior studies have attempted to explore the spatial distribution of GAB1SHP2 complexes throughout a cell. Here, we predict the spatiotemporal behavior of
GAB1-SHP2 complexes within a representative EGF-treated cell by constructing a
computational reaction-diffusion model of the processes that regulate GAB1-SHP2
complex assembly both at the plasma membrane and throughout the cytosol. The model
predicts that GAB1 and SHP2 remain highly associated distal from EGFR, with the
concentration of GAB1-SHP2 complexes at the cell center being 84% of the
concentration of GAB1-SHP2 complexes at the plasma membrane.

This result is

sensitive to our assumption that EGFR-activated SFKs diffuse away from EGFR to
phosphorylate GAB1 throughout the cytosol, as modifying the model topology to only
permit GAB1 phosphorylation at the plasma membrane results in the concentration of
GAB1-SHP2 complexes at the cell center being only 30% of that at the plasma
membrane. A parameter sensitivity analysis further revealed that the total concentration
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of GAB1-SHP2 complexes is most sensitive to perturbations in the rate constant for
SHP2 binding GAB1, while the distance over which GAB1-SHP2 complexes persist
distal from EGFR is most sensitive to perturbations in protein diffusivities and the rate
constants for SFK inactivation and GAB1 dephosphorylation. Altogether, our findings
suggest that in the absence of kinase activity distal from the plasma membrane, the extent
of GAB1-SHP2 association rapidly decays due to the processes of GAB1-SHP2
unbinding and GAB1 dephosphorylation occurring more quickly than diffusion can
permit GAB1-bound SHP2 to traverse the radius of a cell. Furthermore, our results
suggest that EGFR-mediated activation of SFKs could permit membrane-localized EGFR
to regulate signaling events at a distance through the cytosolic activity of SHP2.
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5-3 MATERIALS AND METHODS
General model considerations and topology. The model consists of a set of
coupled reaction-diffusion equations which describe the processes of protein diffusion,
protein binding, and protein phosphorylation for a representative H1666 lung
adenocarcinoma cell with a radius of 10 μm.

The resulting ordinary and partial

differential equations for surface-associated proteins and cytosolic proteins, respectively,
were solved in MATLAB using finite difference methods. Boundary conditions were
also approximated using finite difference methods to solve for relevant protein
concentrations at the cell surface and center. The system of equations was modeled in
rectangular coordinates, based on the assumption of radial symmetry throughout the cell.
At a given time point, all partial differential equations for cytosolic proteins were
approximated using an explicit finite difference method, where the first-order time and
second-order space derivatives were approximated using forward and central differences,
respectively. The system of algebraic equations which results from discretizing over the
entire space domain was then explicitly solved for using known concentrations from the
previous time point.
Next, the equations for surface-associated proteins and the boundary conditions
for cytosolic proteins, which are coupled through the cell surface boundary, were
simultaneously solved using an implicit finite difference method.

The discretized

boundary conditions for cytosolic proteins were evaluated first, where initial guesses for
the concentrations of surface-associated proteins were provided.

Subsequently, the

discretized equations for surface-associated proteins were evaluated using the
concentrations of cytosolic proteins previously solved for.
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This scheme was then

iterated, where the initial guess for concentrations of surface-associated was updated until
convergence was reached.
This system of equations was then advanced to the next time point, where this
process was repeated until the final time point was reached. The overall method is
summarized according to the steps below:
1) All partial and ordinary differential equations for cytosolic and membraneassociated species, respectively, were discretized using finite difference
methods.
2) Concentrations of all protein species were defined for the initial time.
3) The model was advanced one time step, and the concentrations of all cytosolic
species were solved for throughout the bulk (i.e., everywhere except the cell
center and cell surface boundaries).
4) At the same time step, the concentrations of all cytosolic species at the cell
center were solved for using the appropriate boundary conditions at the cell
center.
5) At the same time step, the concentrations of all cytosolic species at the cell
surface were solved for using the appropriate boundary conditions at the cell
surface, where initial guesses for concentrations of all membrane-associated
species were provided.
6) The concentrations of all membrane-associated species were solved for using
the concentrations of cytosolic species at the cell surface calculated in step 5.
7) Steps 5 and 6 were repeated, where the initial guesses for the concentrations
of membrane-associated species in step 5 were updated using the
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concentrations calculated in the previous iteration of step 6. This process was
iterated until the concentrations solved for in step 5 and 6 converged.
8) Steps 3-7 were repeated until the final time point was reached.
Boundary conditions.

No-flux boundary conditions were imposed on all

cytosolic proteins at the cell center. The boundary conditions for SFKs at the cell surface
consist of flux conditions, where the inward flux of inactive or active SFKs is equal to the
reaction for EGFR-catalyzed conversion of inactive SFK to active SFK. Thus, the
inward flux for inactive SFKs will be negative because inactive SFKs are being depleted
at the surface, while the inward flux for active SFKs will be positive because active SFKs
are being generated at the surface. The boundary conditions for all other cytosolic
proteins at the cell surface consist of flux conditions, where the outward flux is equal to
the reaction rate for these proteins binding to EGFR at the cell surface and the inward
flux is equal to the reaction rate for these proteins unbinding from EGFR at the cell
surface.
Example equations. Concentrations of cytosolic species were solved for as a
function of time (t) and space (x) using equations of the following form:

Ci
 2 Ci
 Di
 Ri , where Di and Ci correspond to the diffusivity and concentration of
t
x 2
a given cytosolic protein, respectively, and Rνi corresponds to the net volumetric rate of
production [moles per volume per time] for a given cellular process leading to the
generation or consumption of the cytosolic species designated by Ci.
Boundary conditions at the cell center for cytosolic species were implemented
using equations of the following form:
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Di

Ci
 0 , which corresponds to no flux of the cytosolic species designated by Ci
x

across the cell center boundary.
Boundary conditions at the plasma membrane for cytosolic species were
implemented using equations of the following form:
Di

Ci
 Rsi , where Ci corresponds to the concentration of a given cytosolic protein and
x

Rsi corresponds to the net volumetric rate of production at a surface [moles per area per
time] for a given cellular process leading to the generation or consumption of that protein
at the cell surface boundary.
Concentrations of membrane-associated species were solved for as a function of
time (t) only, based on the assumption that membrane-associated species do not diffuse
through the plasma membrane or endocytose, using equations of the following form:

Ci
 Rsi , where Ci corresponds to the concentration of a given membrane-associated
t
species and Rsi corresponds to the net volumetric rate of production at a surface [moles
per area per time] for a given cellular process leading to the generation or consumption of
that protein.
EGFR phosphorylation. The process of EGFR phosphorylation was simplified
to sequentially depend on the processes of EGF binding, EGFR dimerization, and EGFR
phosphorylation. EGF binding at the plasma membrane was modeled as a reversible
process characterized by association [133] and dissociation [134] rate constants. EGF was
modeled at a constant concentration of 10 ng/mL. The EGFR dimerization rate constant
was calculated as described previously (Chapter 4). Dimer uncoupling rate constants in
the presence of EGF were described previously [137]. All dimer species were assumed
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to be symmetric.

EGFR phosphorylation was modeled as a process which occurs

between EGF-bound EGFR dimers, where both receptors are simultaneously
phosphorylated at a representative tyrosine (Y1068) which is able to bind GRB2. EGFR
dephosphorylation was modeled as a zeroth order process with a previously described
rate constant (Chapter 4).
GAB1 phosphorylation.

GAB1 phosphorylation at a representative tyrosine

(Y627) which is able to bind SHP2 was modeled as a process catalyzed by active SFKs
throughout the cytosol. GAB1 dephosphorylation was modeled as zeroth order and
occurred throughout the cytosol.
SFK activation. Similar to our previous model (Chapter 4), the process of SFK
activation was modeled as a first-order rate equation where phosphorylated EGFR
activates SFK, which only occurs at the cell surface boundary for this model. SFK
inactivation was modeled as zeroth order and occurred throughout the cytosol.
GRB2, GAB1, and SHP2 binding. Reactions for GRB2, GAB1, and SHP2
association/dissociation were described previously (Chapter 4).
Phosphatase activity. EGFR and GAB1 dephosphorylation were modeled as
zeroth order with respect to protein tyrosine phosphatases, which precludes the
requirement for considering distinct phosphatase species.
EGFR inhibition.

Following treatment with EGF, EGFR inhibition was

simulated by setting the rate constant for EGFR phosphorylation to zero at the desired
timepoint post-EGF addition.
Protein diffusivity. Diffusivities for each cytosolic protein monomer or complex
were calculated based on the diffusivity of tubulin [162], which was adjusted based on
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differences in the hydrodynamic radii of tubulin and a given protein monomer or
complex [163].
Parameter fitting. Due to topological differences between this model and our
previously developed model which did not include spatial considerations, we chose to
refit

parameters

for

SFK

activation/inactivation

and

GAB1

phosphorylation/dephosphorylation to match our previous model’s predictions for
concentrations of phosphorylated GAB1 and active SFKs in response to EGF addition.
The four relevant parameters (kG1p, kG1dp, kS,a, kS,i) were determined by computing the
spatial average of [pGAB1] and [aSFK] in response to EGF and fitting these
concentrations to prior predictions for [pGAB1] and [aSFK]. Parameter fitting was done
using simulated annealing to minimize the total error between model output and
experimental data. The error was computed as the square of the difference between
model output and the experimental value. The best-fit results are included in Table 1.
Sensitivity analysis. Model sensitivity to changes in parameters was computed by
increasing and decreasing parameter values by a factor of 10. Sensitivity was measured
by summing the integrated differences between the original model and the two perturbed
outputs over time. To compare differences among parameter perturbations, sensitivities
were reported as percentages of the maximum perturbed parameter.
Representative Cell. EGFR, GRB2, GAB1, SHP2, and SFKs were assumed to be
at cellular concentrations of 6×105 species per cell, as described previously (Chapter 4).
The cell radius was assumed to be 10 μm, as described previously for other epithelial
cells [161].
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Model implementation. Codes were generated and compiled in MATLAB. The
simulannealbnd function in the Global Optimization Toolbox was used to fit the
unknown rate constants. For all calculations, the space dimension was discretized into
100 nodes. For base model calculations, a time step of 0.00001s was used, while a time
step of 0.000001s was used for parameter sensitivity analyses. To reduce the memory
required to store solutions at every time point, solutions were only stored once per 100
time steps.
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Table 5-1: Model parameters
Parameter (units)

Description

Value

kE,f (μM-1 min-1)

EGF binding to EGFR, forward

3.1×102

-1

Source
-1

kE,r (min )

EGF binding to EGFR, reverse

8.0×10

kd,f (cell min-1)

EGFR dimerization, forward

9.2×10-4

-1

-1

kdE,r (min )

EGFR dimerization, reverse

1.0×10

kcatE (min-1)

EGFR phosphorylation, EGF-occupied dimer

1.3×101

-1

0

kdp (min )

EGFR dephosphorylation

8.0×10

kS,a (cell min-1)

SFK activation

4.0×10-4

-1

0

kS,i (min )

SFK inactivation

5.0×10

kG2,f (cell min-1)

GRB2 binding to EGFR, forward

3.8×10-3

-1

2

kG2,r (min )

GRB2 binding to EGFR, reverse

4.6×10

kG1,f (cell min-1)

GAB1 binding to GRB2, forward

2.4×10-3

-1

1

kG1,r (min )

GAB1 binding to GRB2, reverse

6.0×10

kG1p (cell min-1)

GAB1 phosphorylation

1.0×10-4

-1

0

kG1dp (min )

GAB1 dephosphorylation

9.5×10

kS2,f (cell min-1)

SHP2 binding to phosphorylated GAB1, forward

3.8×10-3

-1

2

kS2,r (min )

SHP2 binding to phosphorylated GAB1, reverse

4.6×10

EGF (μM)

Extracellular EGF concentration

1.7×10-3

-1

5

[133]
[134]
(Chapter 4)
[136]
[138]
(Chapter 4)
Fit
Fit
[61]
[61]
[140]
[140]
Fit
Fit
[62]
[62]
See text

EGFR (cell )

EGFR molecules per cell

6.0×10

GRB2 (cell-1)

GRB2 molecules per cell

6.0×105

[140]

GAB1 (cell )

GAB1 molecules per cell

6.0×10

5

[140]

SHP2 (cell-1)

SHP2 molecules per cell

6.0×105

[140]

5

[140]

-1

-1

(Chapter 4)

SFK (cell )

SFK molecules per cell

6.0×10

DS (μm2 min-1)

Diffusivity of SFK molecules

8.2×101

[162, 163]

2

[162, 163]

2

-1

DG2 (μm min )

Diffusivity of GRB2 molecules

1.3×10

DG2G1 (μm2 min-1)

Diffusivity of GRB2-GAB1 molecules

6.1×101

[162, 163]

1

[162, 163]

2

-1

DG2G1S2 (μm min )

Diffusivity of GRB-GAB1-SHP2 molecules

5.5×10

DG1 (μm2 min-1)

Diffusivity of GAB1 molecules

6.6×101

[162, 163]

1

[162, 163]
[162, 163]

2

-1

DG1S2 (μm min )

Diffusivity of GAB1-SHP2 molecules

5.6×10

DS2 (μm2 min-1)

Diffusivity of SHP2 molecules

7.8×101

R (μm)

Cell radius

1.0×10
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1

[161]

5-4 RESULTS
Model predictions with baseline parameterization. To predict the concentration
of GAB1-SHP2 complexes as a function of time and position following EGFR activation
within a representative H1666 lung adenocarcinoma cell with an assumed radius of 10
μm, we developed a computational model, the full details of which can be found in
Materials and Methods (Section 5-3). The model considers cellular processes including
EGFR phosphorylation, SFK activation, GAB1 phosphorylation, GAB1-SHP2 binding,
and diffusion of cytosolic proteins. Model parameters were taken from a previous model
we developed (Chapter 4), with the exception of parameters for SFK activation and
inactivation and GAB1 phosphorylation and dephosphorylation, which were re-fit due to
topological differences between the models. The rate constants for these processes were
fit to predictions from our previously developed model to preserve similar average
concentrations of active SFK and phosphorylated GAB1. The model thus fit is able to
accurately recapitulate the previously predicted dynamics of SFK activation and GAB1
phosphorylation in response to EGF (Figure 5-1A). While the rate constants for GAB1
phosphorylation and dephosphorylation were relatively consistent between the models,
the fitted parameters for SFK activation and inactivation had to be decreased by roughly
four and six orders of magnitude, respectively. Consistent with our previous model’s
finding of amplification of SFK activity downstream of EGFR, this model predicts that
each active EGFR molecule leads to the phosphorylation of an average of ~2 GAB1
molecules throughout a 5 minute EGF treatment simulation (Figure 5-1B).
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Figure 5-1: Base model predictions and fits.
(A) Reaction-diffusion model predictions for the spatially averaged concentrations of
active SFKs and phosphorylated GAB1 were fit to predictions from our previous model
(reaction-only), as described in Materials and Methods. (B) Average concentrations of
phosphorylated EGFR and GAB1 throughout 5 min of EGF treatment were calculated
and normalized to the average concentration of phosphorylated EGFR. (C-E) Model
predictions for the cellular concentrations of active SFKs (aSFK), phosphorylated GAB1
(pGAB1), and GAB1-SHP2 complexes were plotted as a function of distance from the
cell center and time following treatment with 10 ng/mL EGF. (F) For 100 random
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parameter sets, the frequency with which the distance for the concentration of GAB1SHP2 complexes to decay to 50%, 20%, or 10% of the plasma membrane GAB1-SHP2
concentration was greater than the cell radius R (10 μm) was calculated.

We next used the model to calculate protein concentrations as a function of
distance from the cell surface. We found that the concentration of active SFKs rapidly
decayed throughout the cytosol while the concentration of phosphorylated GAB1
remained relatively unchanged (Figures 5-1C-D). We also note that the concentration of
GAB1-SHP2 complexes was essentially unchanged as a function of position with the
cell, suggesting that EGFR-activated SHP2 retains its activity distal from the plasma
membrane (Figure 5-1E). We tested the robustness of this prediction by creating random
parameter sets, where each model parameter was randomly perturbed by up to an order of
magnitude above or below its base value. For 75%, 88%, and 93% of the 100 parameter
sets generated, the length scale for the concentration of GAB1-SHP2 complexes to reach
50%, 20%, and 10% of the maximal GAB1-SHP2 concentration at the cell surface,
respectively, was greater than the cell radius R (10 μm; Figure 5-1F). Therefore, the
model prediction of GAB1-SHP2 complexes being maintained distal from the cell
surface appears robust even if the model parameters are not well estimated.
Model parameter sensitivity. To identify model processes that strongly influence
both the average concentration and concentration gradient of GAB1-SHP2 complexes
within the cell, we performed a parameter sensitivity analysis for steady state GAB1SHP2 complex formation in response to EGF treatment when individually perturbing
each model parameter by a factor of ten (Figure 5-2A). We found that the average
GAB1-SHP2 concentration was most sensitive to perturbations to the rate constants for
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SHP2 binding to or unbinding from GAB1. To determine parameters which control the
spatial distribution of GAB1-SHP2 complexes, we calculated the ratio of the
concentration of GAB1-SHP2 complexes at the cell center to the cell surface and also
defined r1/2 and r1/10 as length scales for GAB1-SHP2 association distal from the cell
surface, which are the distances from the cell surface where the concentration of GAB1SHP2 reaches 50% or 10% of its maximal value, respectively. Here, model predictions
were exquisitely sensitive to changes in protein diffusivity, as well as rate constants for
SFK inactivation and GAB1 dephosphorylation (Figure 5-2A-D).
We next performed a sensitivity analysis where the concentration of each protein
considered in the model was perturbed by a factor of ten to determine which species most
strongly control the steady state ratio of the GAB1-SHP2 concentration at the cell center
to that at the cell surface.

We noted that SFKs most strongly control the spatial

distribution of GAB1-SHP2 complexes, while interestingly EGFR had relatively little
control over the GAB1-SHP2 complex distribution (Figures 5-2E-F). Given that we
previously identified the processes of SFK inactivation and GAB1 dephosphorylation as
strong determinants of the GAB1-SHP2 length scale, we sought to determine the
relationship between SFK concentration and the rates of these two processes in
determining the GAB1-SHP2 length scale. As noted previously, a ten-fold increase in
the rate constant for GAB1 dephosphorylation greatly reduces the GAB1-SHP2
persistence length scale, but, interestingly, a simultaneous ten-fold increase in SFK
concentration negates the effect of an increased GAB1 dephosphorylation rate constant
(Figure 5-2G). Similarly, a ten-fold increase in the rate constant for SFK inactivation
also greatly reduces the GAB1-SHP2 length scale, but in this case an increase in SFK
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Figure 5-2: Model sensitivity analysis.
(A) The sensitivity of model predictions of the spatially averaged concentration of
GAB1-SHP2 complexes, distances over which the GAB1-SHP2 concentration decays to
50% (r1/2) or 10% (r1/10) of the maximum GAB1-SHP2 concentration (i.e., at the cell
surface), and the ratio of GAB1-SHP2 concentrations at the cell center to the cell surface
to 10-fold changes in model parameters was calculated for a 5 min treatment with 10
ng/mL EGF. Sensitivity to diffusivity (D) was calculated by making simultaneous 10fold increases or decreases in the diffusivity of every cytosolic protein. Sensitivity of
each model parameter was normalized to the maximum sensitivity for a given
calculation. (B-D) Model predictions for the normalized concentration of GAB1-SHP2
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after 5 min 10 ng/mL EGF treatment were compared with predictions when all protein
diffusivities (D), kG1dp, and kS,i were increased or decreased by a factor of 10. (E) The
sensitivity of model predictions for the ratio of GAB1-SHP2 concentration at the cell
center to the cell surface to 10-fold changes in the indicated protein concentrations was
calculated for a 5 min 10 ng/mL EGF treatment. (F-G) Model predictions for the
concentration of GAB1-SHP2 as a function of distance from the cell center, which was
normalized to the concentration of GAB1-SHP2 at the plasma membrane, after 5 min
EGF treatment were compared with predictions when the indicated parameters or protein
concentrations were varied by a factor of 10.

(H)

Model predictions for the

concentration of phosphorylated GAB1 as a function of distance from the cell center,
which was normalized to the concentration of phosphorylated GAB1 at the plasma
membrane, after a 5 min 10ng/mL EGF treatment were compared with predictions when
the concentration of SHP2 was either increased 10-fold or set to zero.

concentration is unable to overcome a faster rate of SFK inactivation due to the elevated
number of active SFKs generated at the plasma membrane becoming more quickly
inactivated throughout the cytosol. Based on previous findings from our lab and others
(Chapter 4; [154] ), we also sought to determine if SHP2’s binding to GAB1 could
protect GAB1 from being dephosphorylated throughout the cytosol. While our previous
model, which did not take the spatial distribution of proteins into consideration, found
very little effect of SHP2 depletion or overexpression on altering the total concentration
of GAB1 phosphorylation, the current model predicts that both SHP2 depletion and
overexpression can greatly change the extent of GAB1 phosphorylation throughout the
cytosol (Figure 5-2H). This is due to the fact that in the current model, unbound and
dephosphorylated GAB1 molecules near the cell center are in the proximity of a
relatively low concentration of active SFKs compared to the cell surface, which makes
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the protective effect of SHP2’s binding to GAB1 much more apparent as there are fewer
SFKs available to rephosphorylate GAB1 upon GAB1’s dissociation from SHP2 and
subsequent dephosphorylation.
EGFR pulse-chase dynamics. To determine the consequences of acute EGFR
inhibition on the spatiotemporal profile of GAB1-SHP2 complexes, we simulated a
pulse-chase experiment where 10 ng/mL EGF was added for 5 min, followed by the
simulated inhibition of EGFR modeled by setting the rate constant for EGFR
phosphorylation to zero. We verified that this pulse-chase topology produced EGFR
dephosphorylation kinetics similar to those achieved by our previous model, which
explicitly included the EGFR inhibitor gefitinib in the model topology (Figure 5-3A;
Chapter 4). When predicting the concentration of GAB1-SHP2 complexes as a function
of cell position over a 2 min period following EGFR inhibition, we noted that this
concentration decayed most rapidly near the cell surface throughout the chase (Figure 53B). A similar and even more pronounced trend was observed for the rate of SFK
inactivation based on cell position (Figure 5-3C). Since our previous predictions suggest
that both GAB1-SHP2 and active SFK concentrations are highest near the cell surface
(Figures 5-1B and D), these data suggest that the net rate of GAB1-SHP2 dissociation
and SFK inactivation are largest where these proteins and protein complexes are most
highly concentrated. This result has interesting implications related to protein complex
cycling, as this suggests that the total number of GAB1-SHP2 dissociation and reassociation events, as well as GAB1 dephosphorylation and re-phosphorylation events, is
largest closer to the cell surface over a given time interval.
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Figure 5-3: EGF-pulse EGFR inhibition-chase predictions.
(A) The concentration of phosphorylated EGFR at the plasma membrane, which was
normalized to the maximum phospho-EGFR concentration, was predicted for an EGFpulse EGFR inhibitor-chase simulation, where a 5 min 10 ng/mL EGF treatment was
followed by a 2 min EGFR inhibition simulation.

The reaction-diffusion model

prediction for the concentration of phosphorylated EGFR as a function of time following
EGFR inhibition was compared to predictions from our previous model (reaction-only)
where the EGFR inhibitor gefitinib was explicitly included in the model topology. (B-C)
The concentrations of GAB1-SHP2 complexes and active SFKs at the indicated times
following EGFR inhibition were normalized by their concentrations prior to EGFR
inhibition and plotted as a function of distance from the cell center.
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Model extensions.

While our previous experimental data suggest that a

significant fraction of SFKs exist within the cytosol (Chapter 4), where in some cases
SFKs have been shown to be phosphorylated at the active site [160], other reports suggest
that SFKs may only exist in an active state primarily at the plasma membrane due to SFK
myristoylation [158]. To investigate how this aspect of SFK localization would affect
our model prediction of the cellular GAB1-SHP2 length scale, we altered our model
topology to allow SFKs to exist in an active state only at the plasma membrane. This
change caused GAB1-SHP2 association to drop rapidly away from the cell surface
(Figure 5-4A), with the length scale for GAB1-SHP2 association mirroring that for active
SFKs from the base model topology (Figure 5-1C).

The model parameters can be

adjusted for this topology to generate a steady-state GAB1-SHP2 concentration gradient
similar to that predicted by the base model, such as by increasing protein diffusivity or
decreasing the GAB1 dephosphorylation rate constant (Figures 5-4B-C), however these
adjustments do not fully recapitulate the average concentration of GAB1-SHP2
complexes or the precise dynamics of GAB1-SHP2 complex formation represented by
the best-fit model.
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Figure 5-4: Model predictions for SFKs only existing at the cell surface.
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(A-C) Model predictions for the concentrations GAB1-SHP2 complexes were plotted as
a function of distance from the cell center and time following treatment with 10 ng/mL
EGF when SFKs were only permitted to be active at the cell surface for either the base
model parameters (A), a 10-fold increase in the diffusivity (D) of all cytosolic proteins
(B), or a 10-fold decrease in kG1dp (C).
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5-5 DISCUSSION
Our analysis reveals that GAB1 and SHP2 are predicted to remain associated
throughout the cytosol to a significant degree due to the capacity for EGFR to activate
intermediary SFKs to maintain cytosolic GAB1 phosphorylation throughout GAB1
phosphorylation/dephosphorylation cycles (Figure 5-5). This mechanism could permit
EGFR to regulate signaling events through SHP2 at intracellular locations where EGFR
is not present. Indeed, this possibility is suggested by a previous study which found that
EGFR-activated SHP2 was required to dephosphorylate paxillin at focal adhesions,
which themselves could be located a cell diameter away from EGFR if EGFR were
activated at the apical membrane, rather than the basolateral membrane [55].
We note that the model conclusion of GAB1 and SHP2 remaining associated
throughout the cytosol is based in part on this model’s parameterization to previous
experimental data gathered from a representative lung adenocarcinoma cell line
expressing wild-type EGFR (Chapter 4), and that this conclusion may not be broadly
applicable to EGFR-mediated induction of GAB1-SHP2 association in all cell
backgrounds. This possibility is suggested by a previous study which noted impaired
phosphorylation of the SFK member SRC at Y418 [24], an autophosphorylation site
required for SRC activity, in an NSCLC cell line expressing a kinase-activated EGFR
mutant, suggesting that SFK activity may be impaired in this setting. However, these
cells still exhibited GAB1 phosphorylation on par with wild-type EGFR-expressing cells,
which require SFKs for GAB1 phosphorylation (Chapter 4; [24] ). Thus, there may be a
different mode of GAB1 phosphorylation in the context of EGFR mutation, potentially
via direct phosphorylation of GAB1 by constitutively active mutant EGFR. Based on our

178

model predictions for GAB1 phosphorylation occurring only at the plasma membrane
(Figure 5-4A), this mechanism would significantly decrease the length scale over which
phospho-GAB1 and GAB1-SHP2 complexes extend into the cytosol away from the
membrane. This possibility may offer additional insight into the impairment of SHP2’s
function observed in cells with EGFR mutation [164], as a previous study from our group
revealed that SHP2 function is impaired in mutant EGFR-expressing cells through
apparent sequestration of active SHP2 at the plasma membrane with internalizationimpaired EGFR mutants [164].

Figure 5-5: Cytosolic SRC family kinases (SFKs) extend the intracellular GAB1SHP2 length scale by rephosphorylating GAB1.
Because SFKs can only be activated at the plasma membrane by EGFR and can be
inactivated ubiquitously throughout the cytosol by c-SRC kinase, our model predictions
suggest that the local cytosolic concentration of active SFKs drops steeply as a function
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of distance from the plasma membrane. Conversely, while GAB1 and SHP2 dissociate
and GAB1 is dephosphorylated throughout the cytosol, the length scale of GAB1
phosphorylation and GAB1-SHP2 association are extended relative to that of active SFKs
due to the capacity for GAB1 to be phosphorylated throughout the cytosol.

Our analysis revealed that the GAB1-SHP2 length scale was sensitive to
perturbations in the rate constants for SFK inactivation and GAB1 dephosphorylation, but
interestingly was much less sensitive to the rate constants for SFK activation and GAB1
phosphorylation (Figure 5-2A).

In fact, the rate constant for SFK activation had

essentially no control over the steady state cellular distribution of GAB1-SHP2
complexes. This is likely the result of the model topology only permitting SFKs to be
activated at the cell surface by membrane-bound EGFR, as SFKs will still be rapidly
inactivated throughout the cytosol even if the surface concentration of active SFKs is
increased or reaches steady state more quickly. This is similar to our finding that shows
that despite the requirement for surface-associated EGFR to temporally activate cytosolic
SFKs, EGFR only weakly controls the spatial gradient of GAB1-SHP2 complexes within
the cell (Figure 5-2E).

Our parameter analysis also revealed that an increased

concentration of SFKs can offset a reduction in the GAB1-SHP2 length scale caused by
an enhanced rate of GAB1 dephosphorylation, but not a reduction in this length scale
caused by an enhanced rate of SFK inactivation, exemplifying that there are diverse
relationships among cellular processes in dictating the spatial distribution of GAB1-SHP2
complexes.
Characteristic GAB1-SHP2 reaction-diffusion time scales based on the diffusivity
of a GAB1-SHP2 complex and the rate constant for GAB1 dephosphorylation suggest
that GAB1 needs to be phosphorylated ~4 times by SFKs throughout the cytosol to
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permit an individual GAB1-SHP2 complex to diffuse to the cell center from the cell
surface. While our model suggests that this does occur, as the concentration of GAB1SHP2 complexes remain essentially the same at the cell center relative to the cell surface,
the concentration of active SFKs is substantially reduced distal from the plasma
membrane. However, even this relatively low concentration of intracellular active SFKs
is still sufficient to permit the necessary number of GAB1 phosphorylation events
required to maintain a much higher extent of GAB1 phosphorylation and GAB1-SHP2
association in proximity to the cell center, consistent with findings from our previous
study which showed that SFKs amplify EGFR activity to maintain GAB1-SHP2
association at low levels of EGFR phosphorylation (Chapter 4).
While our model utilized parameters either taken from literature or fit to
predictions from a model we previously developed (Chapter 4), the refinement and
verification of this model’s parameters will be aided by the generation of experimental
data specifying the spatial distribution of GAB1-SHP2 complexes within a cell, such as
data which could be obtained from FRET microscopy. While no such data currently
exists, our previous findings show that GAB1-SHP2 complexes do exist primarily in the
cytosol rather than membrane compartments (Chapter 4). It would also be beneficial to
experimentally measure the diffusivity of all the cytosolic proteins included in the model
by microscopy techniques such as fluorescence recovery after photobleaching (FRAP), as
current predictions rely on the assumption of a previously reported estimate for protein
diffusivity in the cytosol [161], which is assumed to be the same for all species in our
model.

In addition to the verification of model predictions through refining model

parameters based on fitting to newly acquired experimental data, additional cellular
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processes can be incorporated into the model to more completely recapitulate all cellular
processes relevant to cytosolic protein complex assemblies. Some of these processes to
consider which can control the spatial organization of multiprotein complexes include
receptor internalization [166-168] and coordinated protein complex assembly via
cytosolic scaffold proteins [170].
In a broad sense, the model described in this study offers a platform to study the
spatial distribution of cytosolic phospho-proteins or protein complexes initiated by the
activity of plasma membrane-associated receptors. In cases where experimental data is
unavailable to compare against model predictions, the model can still be used to both
identify individual cellular processes which strongly control a protein’s spatial
distribution and to study how multiple processes interact with or compensate for one
another. The capacity for relevant model parameters to be fit to experimental data such
as that which could be obtained by FRET microscopy will enable a more quantitative
understanding of how the dynamics of cellular reactions such as dephosphorylation
compete against diffusion to ultimately control the cellular length scale over which a
receptor tyrosine kinase can orchestrate the assembly of cytosolic protein complexes.
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5-7 SUPPLEMENTAL MODEL DEVELOPMENT
Reaction-diffusion equations and initial and boundary conditions. The
equations and initial and boundary conditions for all protein monomers and complexes
included in the model are described according to the following abbreviations:
Concentrations of cytosolic protein monomers and complexes:
CSFK,i = inactive SFK
CSFK,a = active SFK
CG1 = GAB1
CPG1 = pGAB1
CG2 = GRB2
CG2G1 = GRB2-GAB1
CG2PG1 = GRB2-pGAB1
CS = SHP2
CPG1S = pGAB1-SHP2
CG2PG1S = GRB2-pGAB1-SHP2
Concentrations of membrane protein monomers and complexes:
CmE = EGFR monomer
CmES = EGF-bound EGFR monomer
CmESmES = EGF-bound EGFR dimer
CE_p = EGF-bound pEGFR dimer
CEG2 = EGF-bound, GRB2-bound pEGFR dimer
CEG2G1 = EGF-bound, GRB2-GAB1-bound pEGFR dimer
CEG2PG1 = EGF-bound, GRB2-pGAB1-bound pEGFR dimer
CEG2PG1S = EGF-bound, GRB2-pGAB1-SHP2-bound pEGFR dimer
Model parameters:
DS = SFK diffusivity
DG2 = GRB2 diffusivity
DG2G1 = GRB2-GAB1 diffusivity
DG2G1S2 = GRB2-GAB1-SHP2 diffusivity
DG1 = GAB1 diffusivity
DG1S2 = GAB1-SHP2 diffusivity
DS2 = SHP2 diffusivity
kS,i = SFK inactivation
kS,a = SFK activation
kG1,f = GAB1 binding, forward
kG1,r = GAB1 binding, reverse
kG1p = GAB1 phosphorylation
kG1dp = GAB1 dephosphorylation
kG2,f = GRB2 binding, forward
kG2,r = GRB2 binding, reverse
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kS2,f = SHP2 binding, forward
kS2,r = SHP2 binding, reverse
kE,f = EGF binding, forward
kE,r = EGF binding, reverse
kdE,f = EGFR dimerization, forward
kdE,r = EGFR dimerization, reverse
kcatE = EGFR phosphorylation
kdp = EGFR dephosphorylation
[EGF] = EGF concentration
Equations and boundary conditions:
Equation and initial and boundary conditions for CSFK,i as a function of time (t) and space
(x), where t = 0 corresponds to the initial time prior to EGF treatment, x = 0 corresponds
to the cell center, and x = 10 corresponds to the cell surface:
C SFK ,i
 2 C SFK ,i
 DS
 k S ,i C SFK ,a
t
x 2
DS

DS

C SFK ,i
x
C SFK ,i
x

(10)  k S ,a C SFK ,i C E _ tot

(0)  0

C SFK ,i (0)  600,000

Equation and initial and boundary conditions for CSFK,a:
C SFK ,a
 2 C SFK ,a
 DS
 k S ,i C SFK ,a
t
x 2
DS

DS

C SFK ,a
x

C SFK ,a
x

(10)  k S ,a C SFK ,i C E _ tot

(0)  0

C SFK ,a (0)  0

Equation and initial and boundary conditions for CG1:
CG1
 2 CG1
 DG1
 k G1, f CG1CG 2  k G1,r CG 2G1  k G1 p C SFK ,a CG1  k G1dpC PG1
t
x 2
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DG1

CG1
(10)  k G1, f CG1C EG 2  k G1,r C EG 2G1
x

DG1

CG1
(0)  0
x

CG1 (0)  600,000

Equation and initial and boundary conditions for CPG1:
dC PG1
 2 C PG1
 DG1
 k G1, f C PG1CG 2  k G1,r CG 2 PG1  k G1 p C SFK ,a CG1
dt
x 2
 k G1dpC PG1  k S 2, f C PG1C S  k S 2,r C PG1S
DG1

C PG1
(10)  k G1, f C PG1C EG 2  k G1,r C EG 2 PG1
x

DG1

C PG1
(0)  0
x

C PG1 (0)  0

Equation and initial and boundary conditions for CG2:
dCG 2
 2 CG 2
 DG 2
 k G1, f CG1CG 2  k G1,r CG 2G1  k G1, f C PG1CG 2  k G1,r CG 2 PG1
dt
x 2
 k G1, f CG 2 C PG1S  k G1,r CG 2 PG1S
DG 2

CG 2
(10)  k G 2, f CG 2 C E  k G 2,r C EG 2
x

DG 2

CG 2
(0)  0
x

CG 2 (0)  600,000

Equation and initial and boundary conditions for CG2G1:
dCG 2G1
 2 CG 2G1
 DG 2G1
 k G1, f CG1CG 2  k G1,r CG 2G1  k G1 p C SFK ,a CG 2G1  k G1dpCG 2 PG1
dt
x 2
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DG 2G1

CG 2G1
(10)  k G 2, f CG 2G1C E  k G 2,r C EG 2G1
x

DG 2G1

CG 2G1
(0)  0
x

CG 2G1 (0)  0

Equation and initial and boundary conditions for CG2PG1:
dCG 2 PG1
 2 CG 2 PG1
 DG 2G1
 k G1, f C PG1CG 2  k G1,r CG 2 PG1  k G1 p C SFK ,a CG 2G1
dt
x 2
 k G1dpCG 2 PG1  k S 2, f CG 2 PG1C S  k S 2,r CG 2 PG1S
DG 2G1

CG 2 PG1
(10)  k G 2, f CG 2 PG1C E  k G 2,r C EG 2 PG1
x

DG 2G1

CG 2 PG1
(0)  0
x

CG 2 PG1 (0)  0

Equation and initial and boundary conditions for CS:
dC S
 2CS
 DS 2
 k S 2, f C PG1C S  k S 2,r C PG1S  k S 2, f CG 2 PG1C S  k S 2,r CG 2 PG1S
dt
x 2
DS 2

C S
(10)  k S 2, f C S C EG 2 PG1  k S 2,r C EG 2 PG1S
x

DS 2

C S
(0)  0
x

C S (0)  600,000

Equation and initial and boundary conditions for CPG1S:
dC PG1S
 2 C PG1S
 DG1S 2
 k S 2, f C PG1C S  k S 2,r C PG1S  k G1, f CG 2 C PG1S  k G1,r CG 2 PG1S
dt
x 2
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DG1S 2

C PG1S
(10)  k G1, f C PG1S C EG 2  k G1,r C EG 2 PG1S
x

DG1S 2

C PG1S
(0)  0
x

C PG1S (0)  0

Equation and initial and boundary conditions for CG2PG1S:
dCG 2 PG1S
 2 CG 2 PG1S
 DG 2G1S 2
 k S 2, f CG 2 PG1C8  k S 2,r CG 2 PG1S
dt
x 2
 k G1, f CG 2 C PG1S  k G1,r CG 2 PG1S
DG 2G1S 2

CG 2 PG1S
(10)  k G 2, f CG 2 PG1S C E  k G 2,r C EG 2 PG1S
x

DG 2G1S 2

CG 2 PG1S
(0)  0
x

CG 2 PG1S (0)  0

Equation and initial condition for CmE:
dC mE
 [ EGF ]k E , f C mE  k E ,r C mES
dt

CmE (0)  600,000

Equation and initial condition for CmES:
dC mES
 [ EGF ]k E , f C mE  k E ,r C mES  k dE, f C mES C mES  k dE,r C mESmES
dt

CmES (0)  0
Equation and initial condition for CmESmES:
dC mESmES
 k dE, f C mES C mES  k dE,r C mESmES  k catE C mESmES  k dpC E
dt
CmESmES (0)  0
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Equation and initial condition for CE:
dC E
 k G 2, f CG 2 C E  k G 2,r C EG 2  k G 2, f CG 2G1C E  k G 2,r C EG 2G1  k G 2, f CG 2 PG1C E
dt
 k G 2,r C EG 2 PG1  k G 2, f CG 2 PG1S C E  k G 2,r C EG 2 PG1S  k catE C mESmES  k dpC E

C E (0)  0

Equation and initial condition for CEG2:
dC EG 2
 k G1, f CG1C EG 2  k G1,r C EG 2G1  k G1, f C PG1C EG 2  k G1,r C EG 2 PG1
dt
 k G 2, f CG 2 C E  k G 2,r C EG 2  k G1, f C PG1S C EG 2  k G1,r C EG 2 PG1S

C EG 2 (0)  0

Equation and initial condition for CEG2G1:
dC EG 2G1
 k G1, f CG1C EG 2  k G1,r C EG 2G1  k G 2, f CG1C EG 2  k G 2,r C EG 2G1
dt
C EG 2G1 (0)  0

Equation and initial condition for CEG2PG1:
dC EG 2 PG1
 k G1, f C PG1C EG 2  k G1,r C EG 2G1  k G 2, f CG 2 PG1C E  k G 2,r C EG 2 PG1
dt
 k S 2, f C S C EG 2 PG1  k S 2,r C EG 2 PG1S

C EG 2 PG1 (0)  0

Equation and initial condition for CEG2PG1S:
dC EG 2 PG1S
 k S 2, f C S C EG 2 PG1  k S 2,r C EG 2 PG1S  k G1, f C PG1S C EG 2
dt
 k G 2,r C EG 2 PG1S  k G 2, f CG 2 PG1S C E  k G 2,r C EG 2 PG1S

C EG 2 PG1S (0)  0
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Discretization scheme using finite difference methods. Ordinary differential
equations were discretized using a forward explicit finite difference method as follows,
where h is the step size between two discretized time points (h = ti+1 – ti):

C
 k1C
t
Ci 1  Ci
 k1Ci
h
This discretized equation can then be rearranged to solve for C at time point ti+1, given
that values for C at time point ti are known:

Ci 1  (h  k1  1)Ci
Partial differential equations were discretized using a forward explicit finite
difference method for first-order derivatives, where h is the step size between two
discretized time points (h = ti+1 – ti), and a central explicit finite difference method for
second-order derivatives, where r is the step size between two discretized space points (r
= xj+1 – xj), as follows:

C
 2C
D 2
t
x
Ci 1, j  Ci , j
h

D

Ci , j 1  2Ci , j  Ci , j 1
r2

This discretized equation can then be rearranged to solve for C at time point ti+1 and space
point xj, given that values for C at space points xj-1, xj, and xj+1 at time point ti are known.

Ci 1, j  (1 

2D  h
Dh
Dh
)Ci , j  2 Ci , j 1  2 Ci , j 1
2
r
r
r

To simultaneously solve the discretized equations for membrane-associated
species which are coupled with the discretized boundary conditions for cytosolic species,
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an implicit finite difference method was utilized as follows, shown here for an example
involving the discretized equations for two membrane-associated species (C1 and C2)
and the discretized boundary condition for one cytosolic species (C3):
Discretized equation for C1:

dC1
 C 3  C1  C 2
dt
C1i 1  C1i
 C 3i 1, j  C1i  C 2 i
h
Discretized equation for C2:

dC 2
 C 3  C1  C 2
dt
C 2 i 1  C 2 i
 C 3i 1, j  C1i  C 2 i
h
Discretized boundary condition for C3:
D

D

C 3
 C 3  C1  C 2
x
C 3i 1, j  C 3i 1, j 1
r

 C 3i 1, j 1  C1i 1  C 2 i 1

Due to the fact that C1i+1, C2i+1, and C3i+1,j are all unknown, initial guesses are provided
for C1i+1 and C2i+1 to solve for C3i+1,j, which is then used to solve for C1i+1 and C2i+1
according to the discretized equations above. These updated values are then used to
resolve for C3i+1,j, and this process is iterated until convergence is reached.
Discretization of boundary conditions for cytosolic species at the cell center
results in the requirement for the concentration of a given cytosolic species to be
equivalent at the cell center node and the space node immediately adjacent to it, as
illustrated below:
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D

dC
(0)  0
dx

D

Ci 1  Ci
0
r

Ci 1  Ci
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Chapter 6: Conclusions and Future Work

6-1 SUMMARY
One of the more clinically relevant findings of this thesis is that SHP2, as a driver
of cell proliferative and survival through its activation of ERK, can promote resistance to
the EGFR inhibitor gefitinib in wild-type EGFR-expressing NSCLC cells (Chapter 2).
Consequently, NSCLC cells expressing kinase-activated EGFR mutants display enhanced
cellular sensitivity to gefitinib at least partially due to impaired cellular function of SHP2.
This study further identified a mechanism for impairment of SHP2’s function in these
cells via sequestration of biochemically active SHP2 with internalization-impaired
mutant EGFR at the plasma membrane, a phenomenon that could also potentially be of
relevance to other cytosolic signaling proteins that can either directly or indirectly bind
EGFR. While this work identified SHP2 as a potential therapeutic target for subsets of
NSCLCs, additional studies conversely identified SHP2 as a promoter of sensitivity to
targeted therapeutics in GBM cells (Chapter 3).

Despite the necessity of SHP2

expression for optimal response of GBM cells to EGFR/c-MET co-inhibition, SHP2 was
also required for GBM tumorigenesis in a mouse xenograft model, potentially as a result
of a newly discovered regulatory role for SHP2 in promoting the expression of hypoxia
inducible factors.

While previous studies have explored either oncogenic or tumor

suppressor roles of SHP2 in various cell backgrounds [59, 71, 73, 109], this work
provides the first evidence for SHP2 to simultaneously promote and antagonize
proliferative/survival phenotypes in the same cell line.

193

Additional experimental and computational work undertaken in this thesis
resulted in an improved understanding of the dynamics of SHP2’s activation downstream
of EGFR through SHP2’s association with GAB1 (Chapter 4), as well as computational
modeling predictions that suggest EGFR can potentially regulate SHP2’s association with
GAB1 throughout the entire cell volume as a result of EGFR’s activation of cytosolic
SFKs (Chapter 5). These results not only offer an updated view on how EGFR activates
SHP2, which was traditionally considered to only be maintained in an active state when
in complex with receptors such as EGFR [28], but may also offer broad insight into the
means by which receptor proteins regulate the assembly of phosphorylation-dependent
cytosolic signaling protein complexes, given that phosphotyrosine-SH2 domain
interactions are exceedingly transient [61, 62] and cellular phosphatase activity is high
[63, 64]. In the remainder of this chapter, we discuss the implications of our findings and
suggest directions for future studies.

6-2 DEVELOPMENT AND APPLICATION OF SHP2 INHIBITORS
As SHP2 was shown to promote resistance to EGFR inhibitors in NSCLC cells
and to promote tumorigenesis in GBM cells (Chapters 2 and 3), and also given that there
exist numerous other reports detailing SHP2’s oncogenic roles and overexpression in
many cancers [69-71], it would be worthwhile to develop a specific and effective SHP2
inhibitor as a possible cancer therapeutic to use as either a single agent or in combination
with other therapeutics such as EGFR inhibitors. While the development of specific and
cell permeable small molecular inhibitors for protein kinases has been relatively
successful, with 26 currently approved by the FDA, the development of inhibitors for
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protein tyrosine phosphatases has been far more challenging. Due to the highly polar
nature of the active site of phosphatases, compounds that tightly bind this site and inhibit
phosphatase activity tend to be highly charged anionic phosphate mimics that are unable
to pass through the plasma membrane [171]. In addition, since the phosphatase active
site tends to be highly conserved among PTP family members, such as for PTP1B and
TCPTP [171], the development of phosphatase inhibitors lacking undesirable off-target
effects is also difficult.
Despite these challenges, several promising SHP2 inhibitors have been identified
and tested in both cell culture and mouse models [171]. Among these include NSC87877, an SHP2 inhibitor with a reported IC50 value of 0.3 μM in vitro [172]. However,
this inhibitor has not been widely used in laboratory studies, suggesting its specificity and
efficacy may not be on par with other methods of antagonizing cellular SHP2 activity
such as SHP2 knockdown.

While this inhibitor was selective over most other

phosphatases, it unfortunately also targets SHP1 [172], a submember of the SHP family
of phosphatases that is highly homologous to SHP2 [28]. Additional screens that sought
to identify SHP2 inhibitors that target both the active site of SHP2 as well as an adjacent
region for specificity identified the inhibitor II-B08, that possesses an IC50 value of 5.5
μM for SHP2 and includes the added benefit of selectivity against SHP1 [173]. While
not an exceptionally potent inhibitor, a recent study found that II-B08 could slow
proliferation of H1975 NSCLC cells in vitro and could also slightly reduce the growth
rate of H1975 tumor xenografts [174]. Given the promising results from this study, it
will be interesting to see if the development of improved SHP2 inhibitors will be able to
more closely resemble the effects achieved with near complete knockdown of SHP2
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observed with SHP2 shRNA or siRNA, which in some cases can completely inhibit the
growth of certain tumors in mouse models [109].
As potent, selective, and cell permeable inhibitors developed for the phosphatase
PTP1B have made it to clinical trial testing [171], the possibility for the development of
similarly functional SHP2 inhibitors seems promising. While clinical trials involving the
inhibition of SHP2 will require the development of better SHP2 inhibitors than currently
available, it may still be useful now to examine whether SHP2 serves as a biomarker for
cancer aggressiveness and patient survival. Due to the high frequency with which SHP2
has been found to be overexpressed in cancers including those of the lung and breast [69,
70, 175], it is highly likely that SHP2 plays an important role in the tumorigenesis and
progression of solid tumors in humans, as suggested by the copious number of studies
identifying oncogenic roles of SHP2 in cell culture and xenograft models [71]. Given
that increasingly more paired data for protein expression with patient outcome is
becoming publicly available through programs such as The Cancer Genome Atlas, we
would recommend a study seeking to correlate the expression level of SHP2 in various
cancers with patient outcomes including survival, metastasis, and response to therapy.
Furthermore, it would be interesting to undertake additional studies similar to those
performed in Chapters 2 and 3 of this thesis to explore the role of SHP2 in mediating
therapeutic response, both for other cancers that are dependent on EGFR as well as
cancers normally treated with chemotherapeutics or other targeted inhibitors. It would
also be worthwhile to explore the potential requirement for SHP2 in the tumorigenesis of
cancers originating from aberrant phosphorylation of SHP2 adapters, such as for

196

BCR/ABL-mediated lymphoid cancers requiring GAB2 hyperphosphorylation for
transformation [176].

6-3

INVOLVEMENT

OF

SHP2

IN

EPITHELIAL-TO-MESENCHYMAL

TRANSITION
A recent study from Buonato and Lazzara showed that NSCLC cells require ERK
for epithelial-to-mesenchymal transition (EMT) [177], a process whereby epithelial cells
lose cell-cell adhesions to obtain a mesenchymal cell phenotype that imparts enhanced
motility, invasiveness, and resistance to therapeutics [178, 179]. Specifically, Buonato
and Lazzara showed that inhibiting ERK for a sufficiently long time caused NSCLC cells
to revert from a mesenchymal phenotype to an epithelial phenotype, which enhanced
cellular response to the EGFR inhibitor gefitinib [177]. Given that the study performed
in Chapter 2 of this thesis showed that SHP2 strongly controls both ERK activity and
cellular response to EGFR inhibition, it is possible that SHP2 also regulates EMT in a
way which may connect SHP2’s control over ERK with determining therapeutic
response. While this hypothesis has not been explored in the context of NSCLC cells,
other studies showed that SHP2 can regulate EMT in breast cancer cells [74], although
the mechanism by which SHP2 regulated EMT and the implications of SHP2’s control
over EMT on dictating cellular response to therapeutics were not explored.
To investigate a possible link between SHP2 function and EMT in NSCLC cells,
we propose a study that would first seek to measure the impact of SHP2 knockdown on
the expression of epithelial and mesenchymal markers, such as E-cadherin and vimentin,
respectively, in cells exhibiting a mesenchymal phenotype. Provided SHP2 regulates
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EMT in these cells and SHP2 knockdown shifts cells to a more epithelial phenotype, it
could then be determined whether SHP2 controls EMT in an ERK-dependent or –
independent manner by attempting to restore cells to their basal mesenchymal status by
expressing kinase-activated mutant MEK, the kinase immediately upstream of ERK in
the MAPK cascade [180]. If constitutively active MEK expression overrides the effect of
SHP2 knockdown on ERK phosphorylation and restores the mesenchymal status of cells,
this would suggest that SHP2’s control over ERK regulates EMT.

However, if

constitutively active MEK expression in SHP2-depleted cells restores ERK
phosphorylation to basal levels but fails to revert cells back to a mesenchymal phenotype,
this would suggest that SHP2 regulates EMT through an ERK-independent pathway.
Since the study by Buonato and Lazzara determined that cells co-treated with a
MEK and EGFR inhibitor are optimally sensitized when initially pretreated with a MEK
inhibitor to first induce a mesenchymal-to-epithelial transition before initiating treatment
with an EGFR inhibitor [177], it would be worthwhile to relate this finding to the study
performed in Chapter 2 of this thesis. Because our study utilized stable rather than
transient knockdown of SHP2, it is likely that our study would have essentially mimicked
that of Buonato and Lazzara in that SHP2-depleted cells would have had decreased levels
of ERK activity and potentially an epithelial phenotype for a prolonged period of time
prior to treatment with gefitinib. To determine whether SHP2 regulates response to
EGFR inhibition by controlling cellular processes that occur over a long period of time,
such as EMT, or solely by transiently controlling the activity of signaling pathways, such
as ERK, we would recommend the use of an inducible SHP2 shRNA or an SHP2
inhibitor to transiently inhibit SHP2 immediately before treating cells with gefitinib.
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Alternatively, if SHP2 is confirmed to regulate EMT in NSCLC cells, a study attempting
to restore SHP2-depleted cells back to a mesenchymal phenotype through the
overexpression of transcription factors known to be promote EMT, such as ZEB1, could
be performed. It would be interesting to see if merely converting SHP2-depleted cells
back to a mesenchymal phenotype is sufficient to prevent SHP2 knockdown from
enhancing cellular response to gefitinib.

6-4 INDUCIBLE KNOCKDOWN OF SHP2 IN GLIOBLASTOMA XENOGRAFTS
In Chapter 3 of this thesis, we sought to determine whether the net effect of SHP2
function in glioblastoma cells in vitro, where SHP2 simultaneously promotes
proliferation and antagonizes cell survival in response to co-inhibition of EGFR and cMET, could be reproduced in vivo through the use of a mouse xenograft model. While
tumors arising from glioblastoma cells with SHP2 knockdown grew much more slowly
than tumors arising from control cells, tumors consisting of cells with SHP2 knockdown
never grew to a sufficient size to compare treatment with gefitinib and PHA665752
against control tumors. To confirm whether SHP2 function still enhances response to
EGFR/c-MET co-inhibition in vivo, we propose the use of a xenograft model using cells
where SHP2 can be conditionally knocked down using shRNA-expression systems such
as pSico [86]. This would allow for tumors consisting of cells that conditionally express
control or SHP2-targeted shRNA to grow to the appropriate size before inducing shRNA
expression, at which point treatment with gefitinib and PHA665752 could begin after
SHP2 protein levels are reduced in the appropriate tumors. While STAT3 appears to be
the most important determinant downstream of SHP2 in dictating glioblastoma cell

199

response to EGFR/c-MET co-inhibition in vitro, it is possible that SHP2-mediated
antagonism of STAT3 may be superseded by pro-survival functions of SHP2 in vivo such
that tumors with reduced SHP2 expression respond as well if not better than control
tumors to gefitinib and PHA665752.

6-5 ROLE OF SHP2 PHOSPHORYLATION
While not focused upon in this thesis, an additional purported aspect of SHP2
regulation asides from SHP2’s association with adapter proteins such as GAB1 is the
phosphorylation of SHP2 on C-terminal tyrosines 542 and 580 [28]. Some studies
suggest that these tyrosines, when phosphorylated, enhance SHP2’s catalytic activity and
ability to activate ERK [29, 181]. When phosphorylated, Y542 and Y580 are suggested
to recruit GRB2 [182] or bind SHP2’s N-SH2 and C-SH2 domains, respectively, to
mimic binding of SHP2 to an adapter protein and thus promote SHP2’s catalytic activity
[181, 182]. However, SHP2 phosphorylation does not appear to be required for SHP2mediated ERK activation downstream of all receptor tyrosine kinases, including EGFR
[29]. Consistent with this finding, the work performed in Chapter 2 of this thesis
determined that rescue of SHP2-depleted NSCLC cells with re-expression of SHP2Y542F
was able to restore ERK phosphorylation and reduce cellular response to gefitinib just as
effectively as rescue with re-expression of wild-type SHP2 (Figure 2-3). However, this
study also found that there was a diminished functional role of SHP2 in activating ERK
in EGFR mutant-expressing cells exhibiting impaired phosphorylation of SHP2, although
sequestration of SHP2 with internalization-impaired EGFR mutants is more likely the
direct cause of reduced SHP2 function rather than impaired SHP2 phosphorylation [24].
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Given the conflicting evidence for the role of SHP2 phosphorylation in regulating SHP2mediated ERK activation, both from the work in this thesis and from other studies,
additional work aimed at elucidating the importance of SHP2 phosphorylation in SHP2mediated signaling would be worthwhile to undertake. It would be useful to screen for
proteins besides GRB2 that bind phosphorylated SHP2, as GRB2-SHP2 binding does not
appear to be required for ERK phosphorylation downstream of growth factor receptors
where SHP2 phosphorylation itself is required for maximal ERK phosphorylation [29].
This screen could be accomplished through quantitative mass spectrometry experiments,
where SHP2 immunoprecipitates obtained from ligand-treated cells expressing wild-type
SHP2 are compared against SHP2 immunoprecipitates from cells expressing SHP2 Y542F,
SHP2Y580F, or SHP2Y542F/Y580F to determine differences in proteins that coimmunoprecipitate with wild-type or mutant SHP2.

6-6 LOCALIZATION OF SHP2 COMPLEXES IN MUTANT EGFR-EXPRESSING
CELLS
While our initial work in NSCLC cells suggested that SHP2 function can be
impaired via its sequestration with GAB1 and EGFR at the plasma membrane in cells
expressing EGFR mutants (Chapter 2), our following studies in a representative cell line
expressing wild-type EGFR found that nearly all GAB1-SHP2 complexes were present
within the cytosol (Chapter 4).

It will be interesting to perform the appropriate

subcellular fractionation and subsequent SHP2 immunoprecipitation experiments to
determine whether this also occurs in cells expressing mutant EGFR, or whether GAB1bound SHP2 exists primarily at the plasma membrane as suggested by our hypothesis of
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sequestration of activated SHP2 with membrane-bound EGFR. The fraction of bound
SHP2 in mutant EGFR-expressing cells could potentially be shifted towards a higher
ratio of EGFR:GAB1-bound SHP2 relative to wild-type cells, possibly through
sequestration of SHP2 with EGFR in a GAB1-independent manner, such that cytosolic
GAB1-SHP2 complexes only represent a small proportion of bound and active SHP2 in
cells with EGFR mutation. Regardless of whether there are a significant number of
GAB1-SHP2 complexes in the cytosol of mutant EGFR-expressing cells, it is clear that
GAB1 and thus GAB1-SHP2 complexes are not required for ERK phosphorylation in
these cells based on GAB1 knockdown experiments (Figure 2-6).
While we determined that SFKs were required for GAB1 phosphorylation in a
wild-type EGFR-expressing NSCLC cell line (Chapter 4), data from a previous study by
Lazzara et al. hints that this may not necessarily be true for NSCLC cells expressing
mutant EGFR [24]. While GAB1 is phosphorylated to roughly similar extents in H1666
(EGFRWT) and H3255 (EGFRL858R) NSCLC cells, phosphorylation of the SFK member cSRC at Y418, an autophosphorylation site required for c-SRC’s activity, is severely
impaired in H3255 cells relative to H1666 cells [24]. This suggests that there may
potentially be different modes of GAB1 phosphorylation depending on EGFR mutation
status, where wild-type EGFR utilizes cytosolic SFKs to promote GAB1 phosphorylation
in the cytosol, while mutant EGFR can sufficiently phosphorylate GAB1 directly at the
plasma membrane due to the enhanced kinase activity of this mutant receptor [22]. To
test this hypothesis, mutant EGFR-expressing H3255 cells could be treated with the SFK
inhibitor PP2 either in the presence of absence of EGF to determine whether SFKs are
required for GAB1 phosphorylation in these cells. However, these results could be
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confounded by several factors related to either non-specific effects related to PP2’s
potential inhibition of EGFR [183] or the capacity for SFKs to phosphorylate and
increase the activity of EGFR [146], either of which would lead to the false conclusion
that SFKs, rather than EGFR, are responsible for phosphorylating GAB1 in these cells.
Similar to experiments performed in Chapter 4, H3255 cells would need to be engineered
to have knockdown of endogenous EGFRL858R and ectopic expression of EGFRL858R/Y845F
to decouple SFKs from promoting EGFR activity through SFK-mediated phosphorylation
of EGFR at Y845.

If PP2 addition still results in a significant effect on EGFR

phosphorylation, which we did not see for cells expressing wild-type EGFR, either a
more specific SFK inhibitor would need to be used, or the ubiquitously expressed SFK
members SRC, YES, and FYN will need to be simultaneously knocked down instead, as
has been done for previous studies seeking to draw conclusions about the net activity of
all SFK members [184]. The results from this study could have important implications
for better understanding the impaired functional role of SHP2 in mutant EGFRexpressing cells, which could occur not only due to impairments in the rate of cellular
processes such as EGFR internalization (Chapter 2) but also by potential impairments in
the activity of cytosolic kinases that regulate SHP2’s activity. There also exists the
possibility that impaired EGFR internalization prevents the activation of SFKs within the
cytosol by endosomal EGFR in such a way that active SFKs are only located near the
plasma membrane, as a previous study showed that the SFK member c-SRC traffics with
activated EGFR following EGF stimulation [185]. Furthermore, if SFK activity is altered
in EGFR mutant-expressing cells in such a way that SFK-mediated amplification of
EGFR activity does not occur as it does in a representative cell line expressing wild-type
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EGFR, this could cause GAB1-SHP2 dissociation and GAB1 dephosphorylation to occur
more quickly in EGFR mutant-expressing cells relative to their wild-type counterparts.
This could be tested by comparing the rates of GAB1 dephosphorylation and GAB1SHP2 dissociation in these cells by western blotting and SHP2 immunoprecipitation
EGF-pulse gefitinib-chase experiments, as performed in Chapter 4.

6-7 CYTOSOLIC DISTRIBUTION OF GAB1-SHP2 COMPLEXES
Experiments performed in Chapter 4 concluded that the majority of GAB1-SHP2
complexes exist in the cytosol, at least for a wild-type EGFR-expressing cell line.
Computational studies performed in Chapter 5 predicted that these cytosolic GAB1-SHP2
complexes are present at a fairly constant concentration throughout the entire cell
volume. Given our findings from Chapter 2 that suggest the importance of SHP2’s
activity within the cytosol, it will be essential to validate these computational predictions
experimentally to determine if SHP2 is indeed active and GAB1-bound at a constant
concentration throughout the cytosol. However, live-cell experiments that could measure
the catalytic activity of SHP2 as a function of cellular localization would be impossible to
develop. As an alternative, fluorescence resonance energy transfer (FRET) microscopy, a
technique that utilizes the capacity for energy to be transferred between fluorophores
located within 10-100 angstroms of one another [186], would be a much more feasible
approach to determine where GAB1 and SHP2 are bound within a cell based on transfer
of energy between fluorophore-tagged GAB1 and SHP2.
In fact, as part of this thesis work, we attempted to use fluorescence-lifetime
imaging microscopy (FLIM), an imaging technique based on FRET principles, to
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measure GAB1-SHP2 association in live cells by ectopically expressing fluorophoretagged GAB1 and SHP2 fusion proteins, GAB1-YPET and SHP2-Cerulean, in cells.
Despite attempting these measurements with: 1. all combinations of GAB1 and SHP2
fusion proteins with either N-terminal or C-terminal fluorophore tags, 2. all combinations
of GAB1 and SHP2 fusion proteins with fluorophore-protein linkers consisting of either
6, 15, 25, or 35 amino acids, and 3. GAB1-Cerulean and SHP2-YPET instead of the
original fluorophore-protein pairs, we were unable to obtain a positive signal from FLIM
indicating interaction between GAB1 and SHP2, despite using conditions known to
promote association between fluorescently-tagged GAB1 and SHP2 based on
immunoprecipitation experiments.

While FRET microscopy and FLIM are inherently

challenging techniques [187], suggesting that technical issues may have potentially
impeded our ability to detect association of GAB1-YPET and SHP2-Cerulean by live-cell
microscopy, it is also possible that GAB1 and SHP2 are inherently poorly suited for
FRET measurements. The requirement for an extremely small distance to exist between
two fluorophores in order to elicit energy transfer, paired with the necessity for the
fluorophores to be tagged on only the N- or C-terminus of GAB1 and SHP2, suggests the
possibility that even when GAB1 and SHP2 are bound, their termini may not reach a
sufficient distance from one another to permit the fluorophores to come within close
enough proximity to generate a FRET signal.
Despite these experimental difficulties, additional considerations and topologies
could also be added to our computational reaction-diffusion model in order to more
completely represent all cellular processes that could regulate the spatial distribution of
GAB1-SHP2 complexes.

The parameter value for protein diffusivity, which we
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estimated based on diffusion coefficients used in previous models [161], was considered
to be constant among all the cytosolic proteins and protein complexes included in our
model, which may or may not be a valid simplification. As the effective diffusivity of
proteins such as GRB2 can be altered due to sequestration with phosphorylated EGFR at
the plasma membrane [61], it may be worthwhile to experimentally measure relative rates
of diffusion for GRB2, GAB1, SHP2, and a representative SFK member using
microscopy techniques such as fluorescence recovery after photobleaching (FRAP).
Additional model processes could also be included in the model topology such as the
process of EGFR internalization, which has been incorporated in previous computational
models of EGFR-mediated signaling [63]. As endosomal EGFR has been shown to retain
its phosphorylation and capacity to bind GRB2 and regulate signaling pathways such as
ERK [67], the propensity for endosomal EGFR to activate SFKs from within the cytosol
could have a significant effect on the predicted intracellular distribution of GAB1-SHP2
complexes. The inclusion of this process in our reaction-diffusion model would require
modifying the topology such that all EGFR species capable of internalizing, which could
initially be simplified to include all phosphorylated EGFR, translocate from the plasma
membrane through the cytosol. The velocity with which internalized EGFR traverses the
cytosol could be approximated experimentally by using microscopy to measure the rate at
which fluorescently-tagged EGFR moves through a cell following stimulation with EGF.
However, fully modeling the process of EGFR internalization would necessitate many
other considerations beyond a constant rate of EGFR trafficking, such as recycling of
endosomal EGFR back to the plasma membrane and degradation of internalized EGFR.

206

BIBLIOGRAPHY

1.

Scott, J.D. and T. Pawson, Cell signaling in space and time: where proteins come
together and when they're apart. Science, 2009. 326(5957): p. 1220-4.

2.

Hunter, T. and J.A. Cooper, Protein-tyrosine kinases. Annu Rev Biochem, 1985.
54: p. 897-930.

3.

Schlessinger, J. and M.A. Lemmon, SH2 and PTB domains in tyrosine kinase
signaling. Sci STKE, 2003. 2003(191): p. RE12.

4.

Lippincott-Schwartz, J., E. Snapp, and A. Kenworthy, Studying protein dynamics
in living cells. Nat Rev Mol Cell Biol, 2001. 2(6): p. 444-56.

5.

Tonks, N.K., Protein tyrosine phosphatases: from genes, to function, to disease.
Nat Rev Mol Cell Biol, 2006. 7(11): p. 833-46.

6.

Lemmon, M.A. and J. Schlessinger, Cell signaling by receptor tyrosine kinases.
Cell, 2010. 141(7): p. 1117-34.

7.

Hynes, N.E. and H.A. Lane, ERBB receptors and cancer: the complexity of
targeted inhibitors. Nat Rev Cancer, 2005. 5(5): p. 341-54.

8.

Mukohara, T., S. Kudoh, S. Yamauchi, T. Kimura, N. Yoshimura, H. Kanazawa,
K. Hirata, H. Wanibuchi, S. Fukushima, K. Inoue, and J. Yoshikawa, Expression
of epidermal growth factor receptor (EGFR) and downstream-activated peptides
in surgically excised non-small-cell lung cancer (NSCLC). Lung Cancer, 2003.
41(2): p. 123-30.

9.

Fukuoka, M., S. Yano, G. Giaccone, T. Tamura, K. Nakagawa, J.Y. Douillard, Y.
Nishiwaki, J. Vansteenkiste, S. Kudoh, D. Rischin, R. Eek, T. Horai, K. Noda, I.
207

Takata, E. Smit, S. Averbuch, A. Macleod, A. Feyereislova, R.P. Dong, and J.
Baselga, Multi-institutional randomized phase II trial of gefitinib for previously
treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial)
[corrected]. J Clin Oncol, 2003. 21(12): p. 2237-46.
10.

Aldape, K.D., K. Ballman, A. Furth, J.C. Buckner, C. Giannini, P.C. Burger,
B.W. Scheithauer, R.B. Jenkins, and C.D. James, Immunohistochemical detection
of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic
significance. J Neuropathol Exp Neurol, 2004. 63(7): p. 700-7.

11.

Frederick, L., X.Y. Wang, G. Eley, and C.D. James, Diversity and frequency of
epidermal growth factor receptor mutations in human glioblastomas. Cancer Res,
2000. 60(5): p. 1383-7.

12.

Ng, M. and D. Cunningham, Cetuximab (Erbitux)--an emerging targeted therapy
for epidermal growth factor receptor-expressing tumours. Int J Clin Pract, 2004.
58(10): p. 970-6.

13.

Wakeling, A.E., S.P. Guy, J.R. Woodburn, S.E. Ashton, B.J. Curry, A.J. Barker,
and K.H. Gibson, ZD1839 (Iressa): an orally active inhibitor of epidermal growth
factor signaling with potential for cancer therapy. Cancer Res, 2002. 62(20): p.
5749-54.

14.

Lynch, T.J., D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, B.W.
Brannigan, P.L. Harris, S.M. Haserlat, J.G. Supko, F.G. Haluska, D.N. Louis,
D.C. Christiani, J. Settleman, and D.A. Haber, Activating mutations in the
epidermal growth factor receptor underlying responsiveness of non-small-cell
lung cancer to gefitinib. N Engl J Med, 2004. 350(21): p. 2129-39.

208

15.

Sordella, R., D.W. Bell, D.A. Haber, and J. Settleman, Gefitinib-sensitizing EGFR
mutations in lung cancer activate anti-apoptotic pathways. Science, 2004.
305(5687): p. 1163-7.

16.

Rich, J.N., D.A. Reardon, T. Peery, J.M. Dowell, J.A. Quinn, K.L. Penne, C.J.
Wikstrand, L.B. Van Duyn, J.E. Dancey, R.E. McLendon, J.C. Kao, T.T. Stenzel,
B.K. Ahmed Rasheed, S.E. Tourt-Uhlig, J.E. Herndon, 2nd, J.J. Vredenburgh,
J.H. Sampson, A.H. Friedman, D.D. Bigner, and H.S. Friedman, Phase II trial of
gefitinib in recurrent glioblastoma. J Clin Oncol, 2004. 22(1): p. 133-42.

17.

Lassman, A.B., M.R. Rossi, J.J. Raizer, L.E. Abrey, F.S. Lieberman, C.N. Grefe,
K. Lamborn, W. Pao, A.H. Shih, J.G. Kuhn, R. Wilson, N.J. Nowak, J.K. Cowell,
L.M. DeAngelis, P. Wen, M.R. Gilbert, S. Chang, W.A. Yung, M. Prados, and
E.C. Holland, Molecular study of malignant gliomas treated with epidermal
growth factor receptor inhibitors: tissue analysis from North American Brain
Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res, 2005. 11(21): p.
7841-50.

18.

Kobayashi, S., T.J. Boggon, T. Dayaram, P.A. Janne, O. Kocher, M. Meyerson,
B.E. Johnson, M.J. Eck, D.G. Tenen, and B. Halmos, EGFR mutation and
resistance of non-small-cell lung cancer to gefitinib. N Engl J Med, 2005. 352(8):
p. 786-92.

19.

Yun, C.H., K.E. Mengwasser, A.V. Toms, M.S. Woo, H. Greulich, K.K. Wong,
M. Meyerson, and M.J. Eck, The T790M mutation in EGFR kinase causes drug
resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A, 2008.
105(6): p. 2070-5.

209

20.

Pao, W., V.A. Miller, K.A. Politi, G.J. Riely, R. Somwar, M.F. Zakowski, M.G.
Kris, and H. Varmus, Acquired resistance of lung adenocarcinomas to gefitinib or
erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS
Med, 2005. 2(3): p. e73.

21.

Engelman, J.A., K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J.O. Park, N.
Lindeman, C.M. Gale, X. Zhao, J. Christensen, T. Kosaka, A.J. Holmes, A.M.
Rogers, F. Cappuzzo, T. Mok, C. Lee, B.E. Johnson, L.C. Cantley, and P.A.
Janne, MET amplification leads to gefitinib resistance in lung cancer by
activating ERBB3 signaling. Science, 2007. 316(5827): p. 1039-43.

22.

Yun, C.H., T.J. Boggon, Y. Li, M.S. Woo, H. Greulich, M. Meyerson, and M.J.
Eck, Structures of lung cancer-derived EGFR mutants and inhibitor complexes:
mechanism of activation and insights into differential inhibitor sensitivity. Cancer
Cell, 2007. 11(3): p. 217-27.

23.

Hendriks, B.S., G.J. Griffiths, R. Benson, D. Kenyon, M. Lazzara, J. Swinton, S.
Beck, M. Hickinson, J.M. Beusmans, D. Lauffenburger, and D. de Graaf,
Decreased internalisation of erbB1 mutants in lung cancer is linked with a
mechanism conferring sensitivity to gefitinib. Syst Biol (Stevenage), 2006. 153(6):
p. 457-66.

24.

Lazzara, M.J., K. Lane, R. Chan, P.J. Jasper, M.B. Yaffe, P.K. Sorger, T. Jacks,
B.G. Neel, and D.A. Lauffenburger, Impaired SHP2-mediated extracellular
signal-regulated kinase activation contributes to gefitinib sensitivity of lung
cancer cells with epidermal growth factor receptor-activating mutations. Cancer
Res, 2010. 70(9): p. 3843-50.

210

25.

Akca, H., M. Tani, T. Hishida, S. Matsumoto, and J. Yokota, Activation of the
AKT and STAT3 pathways and prolonged survival by a mutant EGFR in human
lung cancer cells. Lung Cancer, 2006. 54(1): p. 25-33.

26.

Guo, A., J. Villen, J. Kornhauser, K.A. Lee, M.P. Stokes, K. Rikova, A.
Possemato, J. Nardone, G. Innocenti, R. Wetzel, Y. Wang, J. MacNeill, J.
Mitchell, S.P. Gygi, J. Rush, R.D. Polakiewicz, and M.J. Comb, Signaling
networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A,
2008. 105(2): p. 692-7.

27.

Janmaat, M.L., J.A. Rodriguez, M. Gallegos-Ruiz, F.A. Kruyt, and G. Giaccone,
Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or
phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. Int J
Cancer, 2006. 118(1): p. 209-14.

28.

Neel, B.G., H. Gu, and L. Pao, The 'Shp'ing news: SH2 domain-containing
tyrosine phosphatases in cell signaling. Trends Biochem Sci, 2003. 28(6): p. 28493.

29.

Araki, T., H. Nawa, and B.G. Neel, Tyrosyl phosphorylation of Shp2 is required
for normal ERK activation in response to some, but not all, growth factors. J Biol
Chem, 2003. 278(43): p. 41677-84.

30.

Fenstermaker, R.A. and M.J. Ciesielski, Deletion and tandem duplication of exons
2 - 7 in the epidermal growth factor receptor gene of a human malignant glioma.
Oncogene, 2000. 19(39): p. 4542-8.

31.

Sugawa, N., A.J. Ekstrand, C.D. James, and V.P. Collins, Identical splicing of
aberrant epidermal growth factor receptor transcripts from amplified rearranged

211

genes in human glioblastomas. Proc Natl Acad Sci U S A, 1990. 87(21): p. 86026.
32.

Wong, A.J., J.M. Ruppert, S.H. Bigner, C.H. Grzeschik, P.A. Humphrey, D.S.
Bigner, and B. Vogelstein, Structural alterations of the epidermal growth factor
receptor gene in human gliomas. Proc Natl Acad Sci U S A, 1992. 89(7): p. 29659.

33.

Garcia de Palazzo, I.E., G.P. Adams, P. Sundareshan, A.J. Wong, J.R. Testa, D.D.
Bigner, and L.M. Weiner, Expression of mutated epidermal growth factor
receptor by non-small cell lung carcinomas. Cancer Res, 1993. 53(14): p. 321720.

34.

Moscatello, D.K., M. Holgado-Madruga, A.K. Godwin, G. Ramirez, G. Gunn,
P.W. Zoltick, J.A. Biegel, R.L. Hayes, and A.J. Wong, Frequent expression of a
mutant epidermal growth factor receptor in multiple human tumors. Cancer Res,
1995. 55(23): p. 5536-9.

35.

Heimberger, A.B., R. Hlatky, D. Suki, D. Yang, J. Weinberg, M. Gilbert, R.
Sawaya, and K. Aldape, Prognostic effect of epidermal growth factor receptor
and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res, 2005. 11(4):
p. 1462-6.

36.

Zhang, X., W. Zhang, W.D. Cao, G. Cheng, and Y.Q. Zhang, Glioblastoma
multiforme: Molecular characterization and current treatment strategy (Review).
Exp Ther Med, 2012. 3(1): p. 9-14.

212

37.

Sathornsumetee, S., D.A. Reardon, A. Desjardins, J.A. Quinn, J.J. Vredenburgh,
and J.N. Rich, Molecularly targeted therapy for malignant glioma. Cancer, 2007.
110(1): p. 13-24.

38.

Furnari, F.B., T. Fenton, R.M. Bachoo, A. Mukasa, J.M. Stommel, A. Stegh,
W.C. Hahn, K.L. Ligon, D.N. Louis, C. Brennan, L. Chin, R.A. DePinho, and
W.K. Cavenee, Malignant astrocytic glioma: genetics, biology, and paths to
treatment. Genes Dev, 2007. 21(21): p. 2683-710.

39.

Cecchi, F., D.C. Rabe, and D.P. Bottaro, Targeting the HGF/Met signalling
pathway in cancer. Eur J Cancer, 2010. 46(7): p. 1260-70.

40.

Wen, P.Y., D. Schiff, T.F. Cloughesy, J.J. Raizer, J. Laterra, M. Smitt, M. Wolf,
K.S. Oliner, A. Anderson, M. Zhu, E. Loh, and D.A. Reardon, A phase II study
evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with
recurrent glioblastoma. Neuro Oncol, 2011. 13(4): p. 437-46.

41.

Cohen, M.H., Y.L. Shen, P. Keegan, and R. Pazdur, FDA drug approval
summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma
multiforme. Oncologist, 2009. 14(11): p. 1131-8.

42.

Nishikawa, R., X.D. Ji, R.C. Harmon, C.S. Lazar, G.N. Gill, W.K. Cavenee, and
H.J. Huang, A mutant epidermal growth factor receptor common in human glioma
confers enhanced tumorigenicity. Proc Natl Acad Sci U S A, 1994. 91(16): p.
7727-31.

43.

Lal, B., C.R. Goodwin, Y. Sang, C.A. Foss, K. Cornet, S. Muzamil, M.G.
Pomper, J. Kim, and J. Laterra, EGFRvIII and c-Met pathway inhibitors synergize

213

against PTEN-null/EGFRvIII+ glioblastoma xenografts. Mol Cancer Ther, 2009.
8(7): p. 1751-60.
44.

Modjtahedi, H., D.K. Moscatello, G. Box, M. Green, C. Shotton, D.J. Lamb, L.J.
Reynolds, A.J. Wong, C. Dean, H. Thomas, and S. Eccles, Targeting of cells
expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR
MAb ICR62: a two-pronged attack for tumour therapy. Int J Cancer, 2003.
105(2): p. 273-80.

45.

Huang, H.S., M. Nagane, C.K. Klingbeil, H. Lin, R. Nishikawa, X.D. Ji, C.M.
Huang, G.N. Gill, H.S. Wiley, and W.K. Cavenee, The enhanced tumorigenic
activity of a mutant epidermal growth factor receptor common in human cancers
is mediated by threshold levels of constitutive tyrosine phosphorylation and
unattenuated signaling. J Biol Chem, 1997. 272(5): p. 2927-35.

46.

Grandal, M.V., R. Zandi, M.W. Pedersen, B.M. Willumsen, B. van Deurs, and
H.S. Poulsen, EGFRvIII escapes down-regulation due to impaired internalization
and sorting to lysosomes. Carcinogenesis, 2007. 28(7): p. 1408-17.

47.

Lo, H.W., X. Cao, H. Zhu, and F. Ali-Osman, Constitutively activated STAT3
frequently coexpresses with epidermal growth factor receptor in high-grade
gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin
Cancer Res, 2008. 14(19): p. 6042-54.

48.

Huang, P.H., A. Mukasa, R. Bonavia, R.A. Flynn, Z.E. Brewer, W.K. Cavenee,
F.B. Furnari, and F.M. White, Quantitative analysis of EGFRvIII cellular
signaling networks reveals a combinatorial therapeutic strategy for glioblastoma.
Proc Natl Acad Sci U S A, 2007. 104(31): p. 12867-72.

214

49.

Zhu, H., J. Acquaviva, P. Ramachandran, A. Boskovitz, S. Woolfenden, R.
Pfannl, R.T. Bronson, J.W. Chen, R. Weissleder, D.E. Housman, and A. Charest,
Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene
functions in gliomagenesis. Proc Natl Acad Sci U S A, 2009. 106(8): p. 2712-6.

50.

Antonyak, M.A., D.K. Moscatello, and A.J. Wong, Constitutive activation of cJun N-terminal kinase by a mutant epidermal growth factor receptor. J Biol
Chem, 1998. 273(5): p. 2817-22.

51.

Moscatello, D.K., R.B. Montgomery, P. Sundareshan, H. McDanel, M.Y. Wong,
and A.J. Wong, Transformational and altered signal transduction by a naturally
occurring mutant EGF receptor. Oncogene, 1996. 13(1): p. 85-96.

52.

Gu, H. and B.G. Neel, The "Gab" in signal transduction. Trends Cell Biol, 2003.
13(3): p. 122-30.

53.

Shi, Z.Q., D.H. Yu, M. Park, M. Marshall, and G.S. Feng, Molecular mechanism
for the Shp-2 tyrosine phosphatase function in promoting growth factor
stimulation of Erk activity. Mol Cell Biol, 2000. 20(5): p. 1526-36.

54.

Montagner, A., A. Yart, M. Dance, B. Perret, J.P. Salles, and P. Raynal, A novel
role for Gab1 and SHP2 in epidermal growth factor-induced Ras activation. J
Biol Chem, 2005. 280(7): p. 5350-60.

55.

Ren, Y., S. Meng, L. Mei, Z.J. Zhao, R. Jove, and J. Wu, Roles of Gab1 and
SHP2 in paxillin tyrosine dephosphorylation and Src activation in response to
epidermal growth factor. J Biol Chem, 2004. 279(9): p. 8497-505.

56.

Zhang, S.Q., W. Yang, M.I. Kontaridis, T.G. Bivona, G. Wen, T. Araki, J. Luo,
J.A. Thompson, B.L. Schraven, M.R. Philips, and B.G. Neel, Shp2 regulates SRC

215

family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol
Cell, 2004. 13(3): p. 341-55.
57.

Shi, Z.Q., W. Lu, and G.S. Feng, The Shp-2 tyrosine phosphatase has opposite
effects in mediating the activation of extracellular signal-regulated and c-Jun
NH2-terminal mitogen-activated protein kinases. J Biol Chem, 1998. 273(9): p.
4904-8.

58.

Wu, C.J., D.M. O'Rourke, G.S. Feng, G.R. Johnson, Q. Wang, and M.I. Greene,
The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3kinase/Akt activation by growth factors. Oncogene, 2001. 20(42): p. 6018-25.

59.

Bard-Chapeau, E.A., S. Li, J. Ding, S.S. Zhang, H.H. Zhu, F. Princen, D.D. Fang,
T. Han, B. Bailly-Maitre, V. Poli, N.M. Varki, H. Wang, and G.S. Feng,
Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer
Cell, 2011. 19(5): p. 629-39.

60.

Kholodenko, B.N., J.F. Hancock, and W. Kolch, Signalling ballet in space and
time. Nat Rev Mol Cell Biol, 2010. 11(6): p. 414-26.

61.

Morimatsu, M., H. Takagi, K.G. Ota, R. Iwamoto, T. Yanagida, and Y. Sako,
Multiple-state reactions between the epidermal growth factor receptor and Grb2
as observed by using single-molecule analysis. Proc Natl Acad Sci U S A, 2007.
104(46): p. 18013-8.

62.

Barua, D., J.R. Faeder, and J.M. Haugh, Structure-based kinetic models of
modular signaling protein function: focus on Shp2. Biophys J, 2007. 92(7): p.
2290-300.

216

63.

Monast, C.S., C.M. Furcht, and M.J. Lazzara, Computational analysis of the
regulation of EGFR by protein tyrosine phosphatases. Biophys J, 2012. 102(9): p.
2012-21.

64.

Mayer, B.J., Perspective: Dynamics of receptor tyrosine kinase signaling
complexes. FEBS Lett, 2012. 586(17): p. 2575-9.

65.

Lehr, S., J. Kotzka, A. Herkner, E. Klein, C. Siethoff, B. Knebel, V. Noelle, J.C.
Bruning, H.W. Klein, H.E. Meyer, W. Krone, and D. Muller-Wieland,
Identification of tyrosine phosphorylation sites in human Gab-1 protein by EGF
receptor kinase in vitro. Biochemistry, 1999. 38(1): p. 151-9.

66.

Daub, H., C. Wallasch, A. Lankenau, A. Herrlich, and A. Ullrich, Signal
characteristics of G protein-transactivated EGF receptor. EMBO J, 1997. 16(23):
p. 7032-44.

67.

Fortian, A. and A. Sorkin, Live-cell fluorescence imaging reveals high
stoichiometry of Grb2 binding to the EGF receptor sustained during endocytosis.
J Cell Sci, 2014. 127(Pt 2): p. 432-44.

68.

Chan, R.J. and G.S. Feng, PTPN11 is the first identified proto-oncogene that
encodes a tyrosine phosphatase. Blood, 2007. 109(3): p. 862-7.

69.

Zhou, X., J. Coad, B. Ducatman, and Y.M. Agazie, SHP2 is up-regulated in
breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its
involvement in breast oncogenesis. Histopathology, 2008. 53(4): p. 389-402.

70.

Zhan, X., H. Dong, C. Sun, L. Liu, D. Wang, and Z. Wei, [Expression and
clinical significance of SHP2 in the tumor tissues of smokers with lung cancer].
Zhongguo Fei Ai Za Zhi, 2010. 13(9): p. 877-81.

217

71.

Mohi, M.G. and B.G. Neel, The role of Shp2 (PTPN11) in cancer. Curr Opin
Genet Dev, 2007. 17(1): p. 23-30.

72.

Hatakeyama, M., Oncogenic mechanisms of the Helicobacter pylori CagA
protein. Nat Rev Cancer, 2004. 4(9): p. 688-94.

73.

Zhan, Y., G.J. Counelis, and D.M. O'Rourke, The protein tyrosine phosphatase
SHP-2 is required for EGFRvIII oncogenic transformation in human
glioblastoma cells. Exp Cell Res, 2009. 315(14): p. 2343-57.

74.

Zhou, X.D. and Y.M. Agazie, Inhibition of SHP2 leads to mesenchymal to
epithelial transition in breast cancer cells. Cell Death Differ, 2008. 15(6): p. 98896.

75.

Yang, J. and R.A. Weinberg, Epithelial-mesenchymal transition: at the
crossroads of development and tumor metastasis. Dev Cell, 2008. 14(6): p. 81829.

76.

Tsuji, T., S. Ibaragi, and G.F. Hu, Epithelial-mesenchymal transition and cell
cooperativity in metastasis. Cancer Res, 2009. 69(18): p. 7135-9.

77.

Bentires-Alj, M., J.G. Paez, F.S. David, H. Keilhack, B. Halmos, K. Naoki, J.M.
Maris, A. Richardson, A. Bardelli, D.J. Sugarbaker, W.G. Richards, J. Du, L.
Girard, J.D. Minna, M.L. Loh, D.E. Fisher, V.E. Velculescu, B. Vogelstein, M.
Meyerson, W.R. Sellers, and B.G. Neel, Activating mutations of the noonan
syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute
myelogenous leukemia. Cancer Res, 2004. 64(24): p. 8816-20.

218

78.

Keilhack, H., F.S. David, M. McGregor, L.C. Cantley, and B.G. Neel, Diverse
biochemical properties of Shp2 mutants. Implications for disease phenotypes. J
Biol Chem, 2005. 280(35): p. 30984-93.

79.

Tartaglia, M., E.L. Mehler, R. Goldberg, G. Zampino, H.G. Brunner, H. Kremer,
I. van der Burgt, A.H. Crosby, A. Ion, S. Jeffery, K. Kalidas, M.A. Patton, R.S.
Kucherlapati, and B.D. Gelb, Mutations in PTPN11, encoding the protein tyrosine
phosphatase SHP-2, cause Noonan syndrome. Nat Genet, 2001. 29(4): p. 465-8.

80.

Sturla, L.M., P.O. Zinn, K. Ng, M. Nitta, D. Kozono, C.C. Chen, and E.M.
Kasper, Src homology domain-containing phosphatase 2 suppresses cellular
senescence in glioblastoma. Br J Cancer, 2011. 105(8): p. 1235-43.

81.

de la Iglesia, N., S.V. Puram, and A. Bonni, STAT3 regulation of glioblastoma
pathogenesis. Curr Mol Med, 2009. 9(5): p. 580-90.

82.

Kontaridis, M.I., K.D. Swanson, F.S. David, D. Barford, and B.G. Neel, PTPN11
(Shp2) mutations in LEOPARD syndrome have dominant negative, not activating,
effects. J Biol Chem, 2006. 281(10): p. 6785-92.

83.

Engelman, J.A., P.A. Janne, C. Mermel, J. Pearlberg, T. Mukohara, C. Fleet, K.
Cichowski, B.E. Johnson, and L.C. Cantley, ErbB-3 mediates phosphoinositide 3kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc
Natl Acad Sci U S A, 2005. 102(10): p. 3788-93.

84.

Chan, G., D. Kalaitzidis, and B.G. Neel, The tyrosine phosphatase Shp2
(PTPN11) in cancer. Cancer Metastasis Rev, 2008. 27(2): p. 179-92.

85.

Vieira, A.V., C. Lamaze, and S.L. Schmid, Control of EGF receptor signaling by
clathrin-mediated endocytosis. Science, 1996. 274(5295): p. 2086-9.

219

86.

Ventura, A., A. Meissner, C.P. Dillon, M. McManus, P.A. Sharp, L. Van Parijs,
R. Jaenisch, and T. Jacks, Cre-lox-regulated conditional RNA interference from
transgenes. Proc Natl Acad Sci U S A, 2004. 101(28): p. 10380-5.

87.

Wickrema, A., S. Uddin, A. Sharma, F. Chen, Y. Alsayed, S. Ahmad, S.T.
Sawyer, G. Krystal, T. Yi, K. Nishada, M. Hibi, T. Hirano, and L.C. Platanias,
Engagement of Gab1 and Gab2 in erythropoietin signaling. J Biol Chem, 1999.
274(35): p. 24469-74.

88.

Salvi, M., A. Stringaro, A.M. Brunati, E. Agostinelli, G. Arancia, G. Clari, and A.
Toninello, Tyrosine phosphatase activity in mitochondria: presence of Shp-2
phosphatase in mitochondria. Cell Mol Life Sci, 2004. 61(18): p. 2393-404.

89.

Maroun, C.R., M.A. Naujokas, M. Holgado-Madruga, A.J. Wong, and M. Park,
The tyrosine phosphatase SHP-2 is required for sustained activation of
extracellular signal-regulated kinase and epithelial morphogenesis downstream
from the met receptor tyrosine kinase. Mol Cell Biol, 2000. 20(22): p. 8513-25.

90.

Turke, A.B., K. Zejnullahu, Y.L. Wu, Y. Song, D. Dias-Santagata, E. Lifshits, L.
Toschi, A. Rogers, T. Mok, L. Sequist, N.I. Lindeman, C. Murphy, S.
Akhavanfard, B.Y. Yeap, Y. Xiao, M. Capelletti, A.J. Iafrate, C. Lee, J.G.
Christensen, J.A. Engelman, and P.A. Janne, Preexistence and clonal selection of
MET amplification in EGFR mutant NSCLC. Cancer Cell, 2010. 17(1): p. 77-88.

91.

Yano, S., W. Wang, Q. Li, K. Matsumoto, H. Sakurama, T. Nakamura, H. Ogino,
S. Kakiuchi, M. Hanibuchi, Y. Nishioka, H. Uehara, T. Mitsudomi, Y. Yatabe,
and S. Sone, Hepatocyte growth factor induces gefitinib resistance of lung

220

adenocarcinoma with epidermal growth factor receptor-activating mutations.
Cancer Res, 2008. 68(22): p. 9479-87.
92.

Coldren, C.D., B.A. Helfrich, S.E. Witta, M. Sugita, R. Lapadat, C. Zeng, A.
Baron, W.A. Franklin, F.R. Hirsch, M.W. Geraci, and P.A. Bunn, Jr., Baseline
gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell
lines. Mol Cancer Res, 2006. 4(8): p. 521-8.

93.

Wang, S.E., A. Narasanna, M. Perez-Torres, B. Xiang, F.Y. Wu, S. Yang, G.
Carpenter, A.F. Gazdar, S.K. Muthuswamy, and C.L. Arteaga, HER2 kinase
domain mutation results in constitutive phosphorylation and activation of HER2
and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell, 2006.
10(1): p. 25-38.

94.

Offterdinger, M. and P.I. Bastiaens, Prolonged EGFR signaling by ERBB2mediated sequestration at the plasma membrane. Traffic, 2008. 9(1): p. 147-55.

95.

Hendriks, B.S., L.K. Opresko, H.S. Wiley, and D. Lauffenburger, Coregulation of
epidermal growth factor receptor/human epidermal growth factor receptor 2
(HER2) levels and locations: quantitative analysis of HER2 overexpression
effects. Cancer Res, 2003. 63(5): p. 1130-7.

96.

Zhou, X. and Y.M. Agazie, Molecular mechanism for SHP2 in promoting HER2induced signaling and transformation. J Biol Chem, 2009. 284(18): p. 12226-34.

97.

Paulsen, C.E., T.H. Truong, F.J. Garcia, A. Homann, V. Gupta, S.E. Leonard, and
K.S. Carroll, Peroxide-dependent sulfenylation of the EGFR catalytic site
enhances kinase activity. Nat Chem Biol, 2011. 8(1): p. 57-64.

221

98.

Ren, Y., Z. Chen, L. Chen, B. Fang, H. Win-Piazza, E. Haura, J.M. Koomen, and
J. Wu, Critical role of Shp2 in tumor growth involving regulation of c-Myc. Genes
Cancer, 2010. 1(10): p. 994-1007.

99.

Sharma, S.V., D.W. Bell, J. Settleman, and D.A. Haber, Epidermal growth factor
receptor mutations in lung cancer. Nat Rev Cancer, 2007. 7(3): p. 169-81.

100.

Janes, K.A., J.G. Albeck, S. Gaudet, P.K. Sorger, D.A. Lauffenburger, and M.B.
Yaffe, A systems model of signaling identifies a molecular basis set for cytokineinduced apoptosis. Science, 2005. 310(5754): p. 1646-53.

101.

Kumar, N., A. Wolf-Yadlin, F.M. White, and D.A. Lauffenburger, Modeling
HER2 effects on cell behavior from mass spectrometry phosphotyrosine data.
PLoS Comput Biol, 2007. 3(1): p. e4.

102.

Lazzara, M.J. and D.A. Lauffenburger, Quantitative modeling perspectives on the
ErbB system of cell regulatory processes. Exp Cell Res, 2009. 315(4): p. 717-25.

103.

Wolf-Yadlin, A., N. Kumar, Y. Zhang, S. Hautaniemi, M. Zaman, H.D. Kim, V.
Grantcharova, D.A. Lauffenburger, and F.M. White, Effects of HER2
overexpression on cell signaling networks governing proliferation and migration.
Mol Syst Biol, 2006. 2: p. 54.

104.

Schmitz, J., M. Weissenbach, S. Haan, P.C. Heinrich, and F. Schaper, SOCS3
exerts its inhibitory function on interleukin-6 signal transduction through the
SHP2 recruitment site of gp130. J Biol Chem, 2000. 275(17): p. 12848-56.

105.

Bard-Chapeau, E.A., S. Li, J. Ding, S.S. Zhang, H.H. Zhu, F. Princen, D.D. Fang,
T. Han, B. Bailly-Maitre, V. Poli, N.M. Varki, H. Wang, and G.S. Feng,

222

Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer
Cell, 2012. 19(5): p. 629-39.
106.

Zhang, S.Q., W.G. Tsiaras, T. Araki, G. Wen, L. Minichiello, R. Klein, and B.G.
Neel, Receptor-specific regulation of phosphatidylinositol 3'-kinase activation by
the protein tyrosine phosphatase Shp2. Mol Cell Biol, 2002. 22(12): p. 4062-72.

107.

Cai, T., K. Nishida, T. Hirano, and P.A. Khavari, Gab1 and SHP-2 promote
Ras/MAPK regulation of epidermal growth and differentiation. J Cell Biol, 2002.
159(1): p. 103-12.

108.

Furcht, C.M., A.R. Munoz Rojas, D. Nihalani, and M.J. Lazzara, Diminished
functional role and altered localization of SHP2 in non-small cell lung cancer
cells with EGFR-activating mutations. Oncogene, 2012.

109.

Aceto, N., N. Sausgruber, H. Brinkhaus, D. Gaidatzis, G. Martiny-Baron, G.
Mazzarol, S. Confalonieri, M. Quarto, G. Hu, P.J. Balwierz, M. Pachkov, S.J.
Elledge, E. van Nimwegen, M.B. Stadler, and M. Bentires-Alj, Tyrosine
phosphatase SHP2 promotes breast cancer progression and maintains tumorinitiating cells via activation of key transcription factors and a positive feedback
signaling loop. Nat Med, 2012. 18(4): p. 529-37.

110.

Roberts, P.J. and C.J. Der, Targeting the Raf-MEK-ERK mitogen-activated
protein kinase cascade for the treatment of cancer. Oncogene, 2007. 26(22): p.
3291-310.

111.

Hodge, D.R., E.M. Hurt, and W.L. Farrar, The role of IL-6 and STAT3 in
inflammation and cancer. Eur J Cancer, 2005. 41(16): p. 2502-12.

223

112.

Zhan, Y. and D.M. O'Rourke, SHP-2-dependent mitogen-activated protein kinase
activation regulates EGFRvIII but not wild-type epidermal growth factor receptor
phosphorylation and glioblastoma cell survival. Cancer Res, 2004. 64(22): p.
8292-8.

113.

De Witt Hamer, P.C., Small molecule kinase inhibitors in glioblastoma: a
systematic review of clinical studies. Neuro Oncol, 2010. 12(3): p. 304-16.

114.

Argyriou, A.A. and H.P. Kalofonos, Molecularly targeted therapies for malignant
gliomas. Mol Med, 2009. 15(3-4): p. 115-22.

115.

Lund, K.A., L.K. Opresko, C. Starbuck, B.J. Walsh, and H.S. Wiley, Quantitative
analysis of the endocytic system involved in hormone-induced receptor
internalization. J Biol Chem, 1990. 265(26): p. 15713-23.

116.

Wiley, H.S. and D.D. Cunningham, The endocytotic rate constant. A cellular
parameter for quantitating receptor-mediated endocytosis. J Biol Chem, 1982.
257(8): p. 4222-9.

117.

Amin, A.R., V.S. Thakur, R.K. Paul, G.S. Feng, C.K. Qu, H. Mukhtar, and M.L.
Agarwal, SHP-2 tyrosine phosphatase inhibits p73-dependent apoptosis and
expression of a subset of p53 target genes induced by EGCG. Proc Natl Acad Sci
U S A, 2007. 104(13): p. 5419-24.

118.

Chung, J., E. Uchida, T.C. Grammer, and J. Blenis, STAT3 serine
phosphorylation by ERK-dependent and -independent pathways negatively
modulates its tyrosine phosphorylation. Mol Cell Biol, 1997. 17(11): p. 6508-16.

119.

Shao, H., H.Y. Cheng, R.G. Cook, and D.J. Tweardy, Identification and
characterization of signal transducer and activator of transcription 3 recruitment

224

sites within the epidermal growth factor receptor. Cancer Res, 2003. 63(14): p.
3923-30.
120.

Fan, Q.W., C.K. Cheng, W.C. Gustafson, E. Charron, P. Zipper, R.A. Wong, J.
Chen, J. Lau, C. Knobbe-Thomsen, M. Weller, N. Jura, G. Reifenberger, K.M.
Shokat, and W.A. Weiss, EGFR phosphorylates tumor-derived EGFRvIII driving
STAT3/5 and progression in glioblastoma. Cancer Cell, 2013. 24(4): p. 438-49.

121.

Agazie, Y.M. and M.J. Hayman, Development of an efficient "substrate-trapping"
mutant of Src homology phosphotyrosine phosphatase 2 and identification of the
epidermal growth factor receptor, Gab1, and three other proteins as target
substrates. J Biol Chem, 2003. 278(16): p. 13952-8.

122.

Krens, S.F., M. Corredor-Adamez, S. He, B.E. Snaar-Jagalska, and H.P. Spaink,
ERK1 and ERK2 MAPK are key regulators of distinct gene sets in zebrafish
embryogenesis. BMC Genomics, 2008. 9: p. 196.

123.

Dauer, D.J., B. Ferraro, L. Song, B. Yu, L. Mora, R. Buettner, S. Enkemann, R.
Jove, and E.B. Haura, Stat3 regulates genes common to both wound healing and
cancer. Oncogene, 2005. 24(21): p. 3397-408.

124.

Yu, H. and R. Jove, The STATs of cancer--new molecular targets come of age.
Nat Rev Cancer, 2004. 4(2): p. 97-105.

125.

Lu, Z. and S. Xu, ERK1/2 MAP kinases in cell survival and apoptosis. IUBMB
Life, 2006. 58(11): p. 621-31.

126.

Zhang, W. and H.T. Liu, MAPK signal pathways in the regulation of cell
proliferation in mammalian cells. Cell Res, 2002. 12(1): p. 9-18.

225

127.

Tykocinski, E.S., R.A. Grant, G.S. Kapoor, J. Krejza, L.E. Bohman, T.A. Gocke,
S. Chawla, C.H. Halpern, J. Lopinto, E.R. Melhem, and D.M. O'Rourke, Use of
magnetic perfusion-weighted imaging to determine epidermal growth factor
receptor variant III expression in glioblastoma. Neuro Oncol, 2012. 14(5): p.
613-23.

128.

Vivanco, I., H.I. Robins, D. Rohle, C. Campos, C. Grommes, P.L. Nghiemphu, S.
Kubek, B. Oldrini, M.G. Chheda, N. Yannuzzi, H. Tao, S. Zhu, A. Iwanami, D.
Kuga, J. Dang, A. Pedraza, C.W. Brennan, A. Heguy, L.M. Liau, F. Lieberman,
W.K. Yung, M.R. Gilbert, D.A. Reardon, J. Drappatz, P.Y. Wen, K.R. Lamborn,
S.M. Chang, M.D. Prados, H.A. Fine, S. Horvath, N. Wu, A.B. Lassman, L.M.
DeAngelis, W.H. Yong, J.G. Kuhn, P.S. Mischel, M.P. Mehta, T.F. Cloughesy,
and I.K. Mellinghoff, Differential sensitivity of glioma- versus lung cancerspecific EGFR mutations to EGFR kinase inhibitors. Cancer Discov, 2012. 2(5):
p. 458-71.

129.

Maroun, C.R., M. Holgado-Madruga, I. Royal, M.A. Naujokas, T.M. Fournier,
A.J. Wong, and M. Park, The Gab1 PH domain is required for localization of
Gab1 at sites of cell-cell contact and epithelial morphogenesis downstream from
the met receptor tyrosine kinase. Mol Cell Biol, 1999. 19(3): p. 1784-99.

130.

Maroun, C.R., M.A. Naujokas, and M. Park, Membrane targeting of Grb2associated binder-1 (Gab1) scaffolding protein through Src myristoylation
sequence substitutes for Gab1 pleckstrin homology domain and switches an
epidermal growth factor response to an invasive morphogenic program. Mol Biol
Cell, 2003. 14(4): p. 1691-708.

226

131.

Schaeper, U., N.H. Gehring, K.P. Fuchs, M. Sachs, B. Kempkes, and W.
Birchmeier, Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological
responses. J Cell Biol, 2000. 149(7): p. 1419-32.

132.

Cunnick, J.M., L. Mei, C.A. Doupnik, and J. Wu, Phosphotyrosines 627 and 659
of Gab1 constitute a bisphosphoryl tyrosine-based activation motif (BTAM)
conferring binding and activation of SHP2. J Biol Chem, 2001. 276(26): p.
24380-7.

133.

Waters, C.M., K.C. Oberg, G. Carpenter, and K.A. Overholser, Rate constants for
binding, dissociation, and internalization of EGF: effect of receptor occupancy
and ligand concentration. Biochemistry, 1990. 29(14): p. 3563-9.

134.

French, A.R., D.K. Tadaki, S.K. Niyogi, and D.A. Lauffenburger, Intracellular
trafficking of epidermal growth factor family ligands is directly influenced by the
pH sensitivity of the receptor/ligand interaction. J Biol Chem, 1995. 270(9): p.
4334-40.

135.

Zamaraeva, M.V., R.Z. Sabirov, E. Maeno, Y. Ando-Akatsuka, S.V. Bessonova,
and Y. Okada, Cells die with increased cytosolic ATP during apoptosis: a
bioluminescence study with intracellular luciferase. Cell Death Differ, 2005.
12(11): p. 1390-7.

136.

Hendriks, B.S., L.K. Opresko, H.S. Wiley, and D. Lauffenburger, Quantitative
analysis of HER2-mediated effects on HER2 and epidermal growth factor
receptor endocytosis: distribution of homo- and heterodimers depends on relative
HER2 levels. J Biol Chem, 2003. 278(26): p. 23343-51.

227

137.

Shan, Y., M.P. Eastwood, X. Zhang, E.T. Kim, A. Arkhipov, R.O. Dror, J.
Jumper, J. Kuriyan, and D.E. Shaw, Oncogenic mutations counteract intrinsic
disorder in the EGFR kinase and promote receptor dimerization. Cell, 2012.
149(4): p. 860-70.

138.

Fan, Y.X., L. Wong, T.B. Deb, and G.R. Johnson, Ligand regulates epidermal
growth factor receptor kinase specificity: activation increases preference for
GAB1 and SHC versus autophosphorylation sites. J Biol Chem, 2004. 279(37): p.
38143-50.

139.

Huang, F., D. Kirkpatrick, X. Jiang, S. Gygi, and A. Sorkin, Differential
regulation

of

EGF

receptor

internalization

and

degradation

by

multiubiquitination within the kinase domain. Mol Cell, 2006. 21(6): p. 737-48.
140.

Kiyatkin, A., E. Aksamitiene, N.I. Markevich, N.M. Borisov, J.B. Hoek, and B.N.
Kholodenko, Scaffolding protein Grb2-associated binder 1 sustains epidermal
growth factor-induced mitogenic and survival signaling by multiple positive
feedback loops. J Biol Chem, 2006. 281(29): p. 19925-38.

141.

Abram, C.L. and S.A. Courtneidge, Src family tyrosine kinases and growth factor
signaling. Exp Cell Res, 2000. 254(1): p. 1-13.

142.

Borisov, N., E. Aksamitiene, A. Kiyatkin, S. Legewie, J. Berkhout, T. Maiwald,
N.P. Kaimachnikov, J. Timmer, J.B. Hoek, and B.N. Kholodenko, Systems-level
interactions between insulin-EGF networks amplify mitogenic signaling. Mol Syst
Biol, 2009. 5: p. 256.

143.

Okada, M. and H. Nakagawa, A protein tyrosine kinase involved in regulation of
pp60c-src function. J Biol Chem, 1989. 264(35): p. 20886-93.

228

144.

Cole, P.A., P. Burn, B. Takacs, and C.T. Walsh, Evaluation of the catalytic
mechanism of recombinant human Csk (C-terminal Src kinase) using nucleotide
analogs and viscosity effects. J Biol Chem, 1994. 269(49): p. 30880-7.

145.

Schmidt, H. and M. Jirstrand, Systems Biology Toolbox for MATLAB: a
computational platform for research in systems biology. Bioinformatics, 2006.
22(4): p. 514-5.

146.

Biscardi, J.S., M.C. Maa, D.A. Tice, M.E. Cox, T.H. Leu, and S.J. Parsons, c-Srcmediated phosphorylation of the epidermal growth factor receptor on Tyr845 and
Tyr1101 is associated with modulation of receptor function. J Biol Chem, 1999.
274(12): p. 8335-43.

147.

Thomas, S.M. and J.S. Brugge, Cellular functions regulated by Src family
kinases. Annu Rev Cell Dev Biol, 1997. 13: p. 513-609.

148.

Patwardhan, P. and M.D. Resh, Myristoylation and membrane binding regulate cSrc stability and kinase activity. Mol Cell Biol, 2010. 30(17): p. 4094-107.

149.

Jiang, X., F. Huang, A. Marusyk, and A. Sorkin, Grb2 regulates internalization of
EGF receptors through clathrin-coated pits. Mol Biol Cell, 2003. 14(3): p. 85870.

150.

Sorkin, A., M. McClure, F. Huang, and R. Carter, Interaction of EGF receptor
and grb2 in living cells visualized by fluorescence resonance energy transfer
(FRET) microscopy. Curr Biol, 2000. 10(21): p. 1395-8.

151.

Lokker, N.A. and P.J. Godowski, Generation and characterization of a
competitive antagonist of human hepatocyte growth factor, HGF/NK1. J Biol
Chem, 1993. 268(23): p. 17145-50.

229

152.

Klein, P., D. Mattoon, M.A. Lemmon, and J. Schlessinger, A structure-based
model for ligand binding and dimerization of EGF receptors. Proc Natl Acad Sci
U S A, 2004. 101(4): p. 929-34.

153.

Chan, P.C., Y.L. Chen, C.H. Cheng, K.C. Yu, L.A. Cary, K.H. Shu, W.L. Ho, and
H.C. Chen, Src phosphorylates Grb2-associated binder 1 upon hepatocyte growth
factor stimulation. J Biol Chem, 2003. 278(45): p. 44075-82.

154.

Rotin, D., B. Margolis, M. Mohammadi, R.J. Daly, G. Daum, N. Li, E.H. Fischer,
W.H. Burgess, A. Ullrich, and J. Schlessinger, SH2 domains prevent tyrosine
dephosphorylation of the EGF receptor: identification of Tyr992 as the highaffinity binding site for SH2 domains of phospholipase C gamma. EMBO J, 1992.
11(2): p. 559-67.

155.

Tasaki, S., M. Nagasaki, H. Kozuka-Hata, K. Semba, N. Gotoh, S. Hattori, J.
Inoue, T. Yamamoto, S. Miyano, S. Sugano, and M. Oyama, Phosphoproteomicsbased modeling defines the regulatory mechanism underlying aberrant EGFR
signaling. PLoS One, 2010. 5(11): p. e13926.

156.

Ferrell, J.E., Jr., Tripping the switch fantastic: how a protein kinase cascade can
convert graded inputs into switch-like outputs. Trends Biochem Sci, 1996. 21(12):
p. 460-6.

157.

Huang, C.Y. and J.E. Ferrell, Jr., Ultrasensitivity in the mitogen-activated protein
kinase cascade. Proc Natl Acad Sci U S A, 1996. 93(19): p. 10078-83.

158.

Sandilands, E., V.G. Brunton, and M.C. Frame, The membrane targeting and
spatial activation of Src, Yes and Fyn is influenced by palmitoylation and distinct
RhoB/RhoD endosome requirements. J Cell Sci, 2007. 120(Pt 15): p. 2555-64.

230

159.

Sirvent, A., C. Benistant, J. Pannequin, L. Veracini, V. Simon, J.F. Bourgaux, F.
Hollande, F. Cruzalegui, and S. Roche, Src family tyrosine kinases-driven colon
cancer cell invasion is induced by Csk membrane delocalization. Oncogene,
2010. 29(9): p. 1303-15.

160.

Dittmann, K., C. Mayer, R. Kehlbach, and H.P. Rodemann, Radiation-induced
caveolin-1 associated EGFR internalization is linked with nuclear EGFR
transport and activation of DNA-PK. Mol Cancer, 2008. 7: p. 69.

161.

Kholodenko, B.N., MAP kinase cascade signaling and endocytic trafficking: a
marriage of convenience? Trends Cell Biol, 2002. 12(4): p. 173-7.

162.

Pepperkok, R., M.H. Bre, J. Davoust, and T.E. Kreis, Microtubules are stabilized
in confluent epithelial cells but not in fibroblasts. J Cell Biol, 1990. 111(6 Pt 2):
p. 3003-12.

163.

Erickson, H.P., Size and shape of protein molecules at the nanometer level
determined by sedimentation, gel filtration, and electron microscopy. Biol Proced
Online, 2009. 11: p. 32-51.

164.

Furcht, C.M., A.R. Munoz Rojas, D. Nihalani, and M.J. Lazzara, Diminished
functional role and altered localization of SHP2 in non-small cell lung cancer
cells with EGFR-activating mutations. Oncogene, 2013. 32(18): p. 2346-55, 2355
e1-10.

165.

Incoronato, M., A. D'Alessio, S. Paladino, C. Zurzolo, M.S. Carlomagno, L.
Cerchia, and V. de Franciscis, The Shp-1 and Shp-2, tyrosine phosphatases, are
recruited on cell membrane in two distinct molecular complexes including Ret
oncogenes. Cell Signal, 2004. 16(7): p. 847-56.

231

166.

Wang, Y., S. Pennock, X. Chen, and Z. Wang, Endosomal signaling of epidermal
growth factor receptor stimulates signal transduction pathways leading to cell
survival. Mol Cell Biol, 2002. 22(20): p. 7279-90.

167.

Miaczynska, M., L. Pelkmans, and M. Zerial, Not just a sink: endosomes in
control of signal transduction. Curr Opin Cell Biol, 2004. 16(4): p. 400-6.

168.

Ye, H., R. Kuruvilla, L.S. Zweifel, and D.D. Ginty, Evidence in support of
signaling endosome-based retrograde survival of sympathetic neurons. Neuron,
2003. 39(1): p. 57-68.

169.

Furcht, C.M., J.M. Buonato, N. Skuli, L.K. Mathew, A. Munoz Rojas, M.C.
Simon, and M.J. Lazzara, Multivariate signaling regulation by SHP2
differentially controls proliferation and therapeutic response in glioma cells. J
Cell Sci, 2014.

170.

Good, M.C., J.G. Zalatan, and W.A. Lim, Scaffold proteins: hubs for controlling
the flow of cellular information. Science, 2011. 332(6030): p. 680-6.

171.

Barr, A.J., Protein tyrosine phosphatases as drug targets: strategies and
challenges of inhibitor development. Future Med Chem, 2010. 2(10): p. 1563-76.

172.

Chen, L., S.S. Sung, M.L. Yip, H.R. Lawrence, Y. Ren, W.C. Guida, S.M. Sebti,
N.J. Lawrence, and J. Wu, Discovery of a novel shp2 protein tyrosine
phosphatase inhibitor. Mol Pharmacol, 2006. 70(2): p. 562-70.

173.

Zhang, X., Y. He, S. Liu, Z. Yu, Z.X. Jiang, Z. Yang, Y. Dong, S.C. Nabinger, L.
Wu, A.M. Gunawan, L. Wang, R.J. Chan, and Z.Y. Zhang, Salicylic acid based
small molecule inhibitor for the oncogenic Src homology-2 domain containing
protein tyrosine phosphatase-2 (SHP2). J Med Chem, 2010. 53(6): p. 2482-93.

232

174.

Xu, J., L.F. Zeng, W. Shen, J.J. Turchi, and Z.Y. Zhang, Targeting SHP2 for
EGFR inhibitor resistant non-small cell lung carcinoma. Biochem Biophys Res
Commun, 2013. 439(4): p. 586-90.

175.

Tang, C., D. Luo, H. Yang, Q. Wang, R. Zhang, G. Liu, and X. Zhou, Expression
of SHP2 and related markers in non-small cell lung cancer: a tissue microarray
study of 80 cases. Appl Immunohistochem Mol Morphol, 2013. 21(5): p. 386-94.

176.

Sattler, M., M.G. Mohi, Y.B. Pride, L.R. Quinnan, N.A. Malouf, K. Podar, F.
Gesbert, H. Iwasaki, S. Li, R.A. Van Etten, H. Gu, J.D. Griffin, and B.G. Neel,
Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell, 2002. 1(5): p.
479-92.

177.

Buonato, J.M. and M.J. Lazzara, ERK1/2 blockade prevents epithelialmesenchymal transition in lung cancer cells and promotes their sensitivity to
EGFR inhibition. Cancer Res, 2014. 74(1): p. 309-19.

178.

Thomson, S., E. Buck, F. Petti, G. Griffin, E. Brown, N. Ramnarine, K.K. Iwata,
N. Gibson, and J.D. Haley, Epithelial to mesenchymal transition is a determinant
of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to
epidermal growth factor receptor inhibition. Cancer Res, 2005. 65(20): p. 945562.

179.

Thiery, J.P., Epithelial-mesenchymal transitions in tumour progression. Nat Rev
Cancer, 2002. 2(6): p. 442-54.

180.

Johnson, G.L. and R. Lapadat, Mitogen-activated protein kinase pathways
mediated by ERK, JNK, and p38 protein kinases. Science, 2002. 298(5600): p.
1911-2.

233

181.

Lu, W., D. Gong, D. Bar-Sagi, and P.A. Cole, Site-specific incorporation of a
phosphotyrosine mimetic reveals a role for tyrosine phosphorylation of SHP-2 in
cell signaling. Mol Cell, 2001. 8(4): p. 759-69.

182.

Sun, J., S. Lu, M. Ouyang, L.J. Lin, Y. Zhuo, B. Liu, S. Chien, B.G. Neel, and Y.
Wang, Antagonism between binding site affinity and conformational dynamics
tunes alternative cis-interactions within Shp2. Nat Commun, 2013. 4: p. 2037.

183.

Hanke, J.H., J.P. Gardner, R.L. Dow, P.S. Changelian, W.H. Brissette, E.J.
Weringer, B.A. Pollok, and P.A. Connelly, Discovery of a novel, potent, and Src
family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T
cell activation. J Biol Chem, 1996. 271(2): p. 695-701.

184.

Klinghoffer, R.A., C. Sachsenmaier, J.A. Cooper, and P. Soriano, Src family
kinases are required for integrin but not PDGFR signal transduction. EMBO J,
1999. 18(9): p. 2459-71.

185.

Donepudi, M. and M.D. Resh, c-Src trafficking and co-localization with the EGF
receptor promotes EGF ligand-independent EGF receptor activation and
signaling. Cell Signal, 2008. 20(7): p. 1359-67.

186.

Sekar, R.B. and A. Periasamy, Fluorescence resonance energy transfer (FRET)
microscopy imaging of live cell protein localizations. J Cell Biol, 2003. 160(5): p.
629-33.

187.

Wallrabe, H. and A. Periasamy, Imaging protein molecules using FRET and
FLIM microscopy. Curr Opin Biotechnol, 2005. 16(1): p. 19-27.

234

